

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2014254262 B2**

(54) Title
Fungicidal carboxamides

(51) International Patent Classification(s)
C07D 403/12 (2006.01) **C07D 231/14** (2006.01)
A01N 43/56 (2006.01) **C07D 401/14** (2006.01)
A01N 43/707 (2006.01) **C07D 405/12** (2006.01)
A01N 43/78 (2006.01) **C07D 409/12** (2006.01)
A61K 31/4155 (2006.01) **C07D 417/12** (2006.01)
A61K 31/4427 (2006.01)

(21) Application No: **2014254262** (22) Date of Filing: **2014.04.11**

(87) WIPO No: **WO14/172191**

(30) Priority Data

(31) Number	(32) Date	(33) Country
61/811,919	2013.04.15	US

(43) Publication Date: **2014.10.23**

(44) Accepted Journal Date: **2018.08.23**

(71) Applicant(s)
E. I. du Pont de Nemours and Company

(72) Inventor(s)
Bereznak, James Francis;Taggi, Andrew Edmund;Marcus, Kimberly Katherine;Reddy, Ravisekhara P.

(74) Agent / Attorney
Houlihan² Pty Ltd, PO Box 611, BALWYN NORTH, VIC, 3104, AU

(56) Related Art
WO 2009016220 A1
WO 2006120224 A1
WO 2013156559 A1
WO 2012052490 A1



(51) International Patent Classification:

C07D 403/12 (2006.01) A61K 31/4155 (2006.01)
 C07D 401/14 (2006.01) A61K 31/4427 (2006.01)
 C07D 231/14 (2006.01) A01N 43/56 (2006.01)
 C07D 405/12 (2006.01) A01N 43/707 (2006.01)
 C07D 409/12 (2006.01) A01N 43/78 (2006.01)
 C07D 417/12 (2006.01)

(21) International Application Number:

PCT/US2014/033766

(22) International Filing Date:

11 April 2014 (11.04.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/811,919 15 April 2013 (15.04.2013) US

(71) Applicant: E. I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, Delaware 19898 (US).

(72) Inventors: BEREZNAK, James, Francis; 3231 Saw Mill Road, Newtown Square, Pennsylvania 19073 (US). TAGGI, Andrew, Edmund; 21 Tremont Court, Newark, Delaware 19711 (US). MARCUS, Kimberly, Katherine; 406 Gayley Street, Media, Pennsylvania 19063 (US). REDDY, Ravisekhara, P.; 502 Saibrundavan Apt, DLR Enclave, Madhavapuri Colony, Sainikpuri, Secunderabad, Andhra Pradesh 500094 (IN).

(74) Agent: COATS, Reed, A.; E. I. du Pont de Nemours and Company, Legal Patent Records Center, Chestnut Run Plaza 721/2340, 974 Centre Road, PO Box 2915 Wilmington, Delaware 19805 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: FUNGICIDAL CARBOXAMIDES



(57) Abstract: Disclosed are compounds of Formula 1, including all stereoisomers, *N*-oxides, and salts thereof, wherein G is phenyl, pyridinyl, pyridazinyl or pyrazinyl substituted with *Q meta or para to the* -C(R^{2a})R^{2b}- radical, and optionally substituted with up to 3 substituents selected from R³; and A, Z, R¹, R^{2a}, R^{2b}, R³ and Q are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal plant pathogen comprising applying an effective amount of a compound or a composition of the invention.

FUNGICIDAL CARBOXAMIDES

FIELD OF THE INVENTION


This invention relates to certain fungicidal amides, their *N*-oxides, salts and compositions, and methods of their use as fungicides.

BACKGROUND OF THE INVENTION

The control of plant diseases caused by fungal plant pathogens is extremely important in achieving high crop efficiency. Plant disease damage to ornamental, vegetable, field, cereal, and fruit crops can cause significant reduction in productivity and thereby result in increased costs to the consumer. Many products are commercially available for these purposes, but the need continues for new compounds which are more effective, less costly, less toxic, environmentally safer or have different sites of action.


SUMMARY OF THE INVENTION

This invention is directed to compounds of Formula 1 (including all stereoisomers), *N*-oxides, and salts thereof, agricultural compositions containing them and their use as fungicides:



wherein

A is a radical selected from the group consisting of



Z is O or S;

R¹ is C₃–C₅ cycloalkyl; or a 4- to 6-membered ring containing ring members selected from carbon atoms, 1 O atom and 1 S atom;

R^{2a} and R^{2b} are each independently H, halogen, C₁–C₂ alkyl or C₁–C₂ haloalkyl; or

R^{2a} and R^{2b} are taken together as C₂–C₅ alkanediyl;

G is phenyl, pyridinyl, pyridazinyl or pyrazinyl substituted with Q *meta* or *para* to the -C(R^{2a})R^{2b}- radical, and optionally substituted with up to 3 substituents selected from R³;

R³ is halogen, nitro, cyano, C₁-C₅ cyanoalkoxy, C₂-C₅ alkynyloxy, C₂-C₅ alkenyl, C₁-C₅ alkyl, C₁-C₅ haloalkyl, C₁-C₅ alkoxy, C₁-C₅ haloalkoxy, C₂-C₅ alkoxyalkyl, C₃-C₅ cycloalkyl, C₂-C₅ alkoxycarbonyl or C₃-C₁₂ trialkylsilyl;

R⁴ is halogen, C₁-C₃ alkyl or C₁-C₃ haloalkyl;

5 R⁵ is H, halogen, C₁-C₃ alkyl or C₁-C₃ haloalkyl;

R⁶ is C₁-C₂ alkyl;

R⁷ is halogen, C₁-C₃ alkyl or C₁-C₃ haloalkyl;

R⁸ is H, C₁-C₂ alkyl or C₁-C₂ haloalkyl;

R⁹ is halogen, C₁-C₃ alkyl or C₁-C₃ haloalkyl;

10 R¹⁰ is halogen, C₁-C₃ alkyl or C₁-C₃ haloalkyl;

R¹¹ is halogen, C₁-C₃ alkyl or C₁-C₃ haloalkyl;

m is 0, 1 or 2;

Q is a 5-membered unsaturated or partially unsaturated heterocyclic ring containing ring members selected from carbon atoms and up to 4 heteroatoms independently selected from up to 1 O, up to 1 S and up to 4 N atoms, wherein up to 2 carbon atom ring members are independently selected from C(=O), the ring optionally substituted with one substituent on a ring member distal relative to the ring member connecting the heteroaromatic ring to the remainder of Formula 1, said optional substituent selected from R^{12c} on carbon atom ring members and from R¹²ⁿ on nitrogen atom ring members, the heterocyclic ring further optionally substituted with substituents selected from R^{13c} on carbon atom ring members and R¹³ⁿ on nitrogen atom ring members;

each R^{12c} is independently halogen, cyano, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ alkoxy, C₁-C₃ haloalkoxy or C₂-C₃ alkoxycarbonyl; or a phenyl ring optionally substituted with up to 5 substituents independently selected from R¹⁴; or a heteroaromatic ring optionally substituted with up to 4 substituents independently selected from R^{15c} on carbon atom ring members and from R¹⁵ⁿ on nitrogen atom ring members; or

two R^{12c} bonded to adjacent carbon atoms are taken together with carbon atom ring members to form a 5- or 6-membered carbocyclic or partially aromatic ring;


each R¹²ⁿ is independently C₁-C₃ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkoxy; or a phenyl ring optionally substituted with up to 5 substituents independently selected from R¹⁶; or a heteroaromatic ring optionally substituted with up to 4 substituents independently selected from R^{17c} on carbon atom ring members and from R¹⁷ⁿ on nitrogen atom ring members;

each R^{13c} is independently halogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkoxy;

each R¹³ⁿ is independently C₁-C₃ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkoxy;


each R^{14} , R^{15c} , R^{16} and R^{17c} is independently halogen, cyano, C_1 - C_2 alkyl, C_1 - C_2 haloalkyl, C_1 - C_2 alkoxy or C_1 - C_2 haloalkoxy; and
 each R^{15n} and R^{17n} is independently C_1 - C_2 alkyl, C_1 - C_2 haloalkyl or C_1 - C_2 alkoxy.

This invention also relates to a compound selected from Formula 1, *N*-oxides and salts thereof,



wherein

A is a radical selected from the group consisting of



Z is O or S;

R^1 is C_3 - C_5 cycloalkyl; or a 4- to 6-membered ring containing carbon ring members and heteroatom ring members selected from 1 O atom and 1 S atom;

R^{2a} and R^{2b} are each independently H, halogen, C_1 - C_2 alkyl or C_1 - C_2 haloalkyl; or R^{2a} and R^{2b} are taken together as C_2 - C_5 alkanediyl;

G is phenyl, pyridinyl, pyridazinyl or pyrazinyl substituted with Q *meta* or *para* to the $-C(R^{2a})R^{2b}$ - radical, and optionally substituted with up to 3 substituents selected from R^3 ;

R^3 is halogen, nitro, cyano, C_1 - C_5 alkyl, C_1 - C_5 haloalkyl, C_1 - C_5 alkoxy, C_1 - C_5 haloalkoxy, C_2 - C_5 alkoxyalkyl, C_3 - C_5 cycloalkyl, C_2 - C_5 alkoxycarbonyl or C_3 - C_{12} trialkylsilyl; or R^3 is C_1 - C_5 cyanoalkoxy, C_2 - C_5 alkynyloxy or C_2 - C_5 alkenyl;

R^4 is halogen, C_1 - C_3 alkyl or C_1 - C_3 haloalkyl;

R^5 is H, halogen, C_1 - C_3 alkyl or C_1 - C_3 haloalkyl;

R^6 is C_1 - C_2 alkyl;

R^7 is halogen, C_1 - C_3 alkyl or C_1 - C_3 haloalkyl;

R^8 is H, C_1 - C_2 alkyl or C_1 - C_2 haloalkyl;


R^9 is halogen, C_1 - C_3 alkyl or C_1 - C_3 haloalkyl;

R^{10} is halogen, C_1 - C_3 alkyl or C_1 - C_3 haloalkyl; R^{11} is halogen, C_1 - C_3 alkyl or C_1 - C_3 haloalkyl;

m is 0, 1 or 2;

Q is a 5-membered unsaturated or partially unsaturated heterocyclic ring containing ring members selected from carbon atoms and up to 4 heteroatoms independently selected from up to 1 O, up to 1 S and up to 4 N atoms, wherein up to 2 carbon

- atom ring members are independently selected from C(=O), the ring optionally substituted with one substituent on a ring member distal relative to the ring member connecting the heteroaromatic ring to the remainder of Formula 1, said optional substituent selected from R^{12c} on carbon atom ring members and from R^{12n} on nitrogen atom ring members, the heterocyclic ring further optionally substituted with substituents selected from R^{13c} on carbon atom ring members and R^{13n} on nitrogen atom ring members;
- each R^{12c} is independently halogen, cyano, C_1 - C_3 alkyl, C_1 - C_3 haloalkyl, C_1 - C_3 alkoxy, C_1 - C_3 haloalkoxy or C_2 - C_3 alkoxycarbonyl; or a phenyl ring optionally substituted with up to 5 substituents independently selected from R^{14} ; or a heteroaromatic ring optionally substituted with up to 4 substituents independently selected from R^{15c} on carbon atom ring members and from R^{15n} on nitrogen atom ring members; or
- two R^{12c} bonded to adjacent carbon atoms are taken together with carbon atom ring members to form a 5- or 6-membered carbocyclic or partially aromatic ring;
- each R^{12n} is independently C_1 - C_3 alkyl, C_1 - C_3 haloalkyl or C_1 - C_3 alkoxy; or a phenyl ring optionally substituted with up to 5 substituents independently selected from R^{16} ; or a heteroaromatic ring optionally substituted with up to 4 substituents independently selected from R^{17c} on carbon atom ring members and from R^{17n} on nitrogen atom ring members;
- each R^{13c} is independently halogen, C_1 - C_3 alkyl, C_1 - C_3 haloalkyl or C_1 - C_3 alkoxy;
- each R^{13n} is independently C_1 - C_3 alkyl, C_1 - C_3 haloalkyl or C_1 - C_3 alkoxy;
- each R^{14} , R^{15c} , R^{16} and R^{17c} is independently halogen, cyano, C_1 - C_2 alkyl, C_1 - C_2 haloalkyl, C_1 - C_2 alkoxy or C_1 - C_2 haloalkoxy;
- each R^{15n} and R^{17n} is independently C_1 - C_2 alkyl, C_1 - C_2 haloalkyl or C_1 - C_2 alkoxy;
- and wherein the compound is not




wherein R^9 , R^{2a} , G, $(R^3)_n$ and Q are defined as follows:





R^9	R^{2a}	G	$(R^3)_n$	Q
CH ₃	H	G-1b	H	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl.

This invention also relates to a compound of Formula 1A

3b



wherein R^5 , R^{2a} , G , $(R^3)_n$ and Q are defined as follows:



R^5	R^{2a}	G	$(R^3)_n$	Q
H	CH ₃	G-2a	H	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl
H	H	G-2a	H	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl
F	H	G-1b	H	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl
H	H	G-2b	H	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl
H	H	G-2b	H	3-Cl-1 <i>H</i> -pyrazol-1-yl
H	H	G-2b	H	4-Cl-1 <i>H</i> -pyrazol-1-yl
H	H	G-2b	H	1 <i>H</i> -pyrazol-1-yl
H	H	G-2b	H	3-phenyl-1 <i>H</i> -pyrazol-1-yl
H	H	G-1b	H	3-CF ₃ -1 <i>H</i> pyrazol-1-yl
H	H	G-1a	2-Cl	4-Br-1 <i>H</i> -pyrazol-1-yl
H	H	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl
F	H	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl.

More particularly, this invention pertains to a compound of Formula 1 (including all stereoisomers), an *N*-oxide or a salt thereof.

This invention also relates to a fungicidal composition comprising (a) a compound of the invention (i.e. in a fungicidally effective amount); and (b) at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents.

This invention also relates to a fungicidal composition comprising (a) a compound of the invention; and (b) at least one other fungicide (e.g., at least one other fungicide having a different site of action).

This invention further relates to a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant

seed, a fungicidally effective amount of a compound of the invention (e.g., as a composition described herein).

DETAILS OF THE INVENTION

As used herein, the terms “comprises,” “comprising,” “includes,” “including,” “has,” “having,” “contains,” “containing,” “characterized by” or any other variation thereof, are intended to cover a non-exclusive inclusion, subject to any limitation explicitly indicated. For example, a composition, mixture, process, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, mixture, process, method, article, or apparatus.

The transitional phrase “consisting of” excludes any element, step, or ingredient not specified. If in the claim, such would close the claim to the inclusion of materials other than those recited except for impurities ordinarily associated therewith. When the phrase “consisting of” appears in a clause of the body of a claim, rather than immediately following the preamble, it limits only the element set forth in that clause; other elements are not excluded from the claim as a whole.

The transitional phrase “consisting essentially of” is used to define a composition, method or apparatus that includes materials, steps, features, components, or elements, in addition to those literally disclosed, provided that these additional materials, steps, features, components, or elements do not materially affect the basic and novel characteristic(s) of the claimed invention. The term “consisting essentially of” occupies a middle ground between “comprising” and “consisting of”.

Where applicants have defined an invention or a portion thereof with an open-ended term such as “comprising,” it should be readily understood that (unless otherwise stated) the description should be interpreted to also describe such an invention using the terms “consisting essentially of” or “consisting of.”

Further, unless expressly stated to the contrary, “or” refers to an inclusive or and not to an exclusive or. For example, a condition A or B is satisfied by any one of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present).

Also, the indefinite articles “a” and “an” preceding an element or component of the invention are intended to be nonrestrictive regarding the number of instances (i.e. occurrences) of the element or component. Therefore “a” or “an” should be read to include one or at least one, and the singular word form of the element or component also includes the plural unless the number is obviously meant to be singular.

As referred to in the present disclosure and claims, “plant” includes members of Kingdom Plantae, particularly seed plants (Spermatopsida), at all life stages, including young plants (e.g., germinating seeds developing into seedlings) and mature, reproductive stages (e.g., plants producing flowers and seeds). Portions of plants include geotropic members typically growing beneath the surface of the growing medium (e.g., soil), such as roots, tubers, bulbs and corms, and also members growing above the growing medium, such as foliage (including stems and leaves), flowers, fruits and seeds. As referred to herein, the term “seedling”, used either alone or in a combination of words means a young plant developing from the embryo of a seed. In the context of this disclosure, plant disease control refers to protecting plants preventatively and/or curatively from diseases caused by pathogens. As referred to in this disclosure, the terms “fungal pathogen” and “fungal plant pathogen” include pathogens in the Ascomycota, Basidiomycota and Zygomycota phyla, and the fungal-like Oomycota class that are the causal agents of a broad spectrum of plant diseases of economic importance, affecting ornamental, turf, vegetable, field, cereal and fruit crops. In the context of this disclosure, “protecting a plant from disease” or “control of a plant disease” includes preventative action (interruption of the fungal cycle of infection, colonization, symptom development and spore production) and/or curative action (inhibition of colonization of plant host tissues).

As referred to in this disclosure, the term mode of action (MOA) is as defined broadly by the Fungicide Resistance Action Committee (FRAC), and is used to distinguish fungicide groups according to their biochemical mode of action in the biosynthetic pathways of plant pathogens. These FRAC-defined MOAs are (A) nucleic acid synthesis, (B) mitosis and cell division, (C) respiration, (D) amino acid and protein synthesis, (E) signal transduction, (F) lipid synthesis and membrane integrity, (G) sterol biosynthesis in membranes, (H) cell wall biosynthesis in membranes, (I) melanin synthesis in cell wall, (P) host plant defense

induction, multi-site contact activity and unknown mode of action. Each MOA class consists of one or more groups based either on individual validated target sites of action, or in cases where the precise target site is unknown, based on cross resistance profiles within a group or in relation to other groups. Each of these groupings within a FRAC-defined MOA, whether the target site is known or unknown, is designated by a FRAC code. Additional information on target sites and FRAC codes can be obtained from publicly available databases maintained, for example, by FRAC.

As referred to in this disclosure, the term “cross resistance” refers to a phenomenon wherein a pathogen evolves resistance to one fungicide and in addition acquires resistance to others. These additional fungicides are typically, but not always, in the same chemical class or have the same target site of action, or can be detoxified by the same mechanism.

In the above recitations, the term “alkyl”, used either alone or in compound words such as “alkylthio” or “haloalkyl” includes straight-chain or branched alkyl such as methyl, ethyl, *n*-propyl, *i*-propyl, or the different butyl, pentyl or hexyl isomers. “Alkenyl” includes straight-chain or branched alkenes such as ethenyl, 1-propenyl, 2-propenyl, and the different butenyl, pentenyl and hexenyl isomers. “Alkenyl” also includes polyenes such as 1,2-propadienyl and 2,4-hexadienyl. “Alkynyl” includes straight-chain or branched alkynes such as ethynyl, 1-propynyl, 2-propynyl and the different butynyl, pentynyl and hexynyl isomers. “Alkynyl” also includes moieties comprised of multiple triple bonds such as 2,5-hexadiynyl. “Alkanediyl” denotes a straight-chain or branched alkylene. Examples of “alkanediyl” include CH₂, CH₂CH₂, CH(CH₃), CH₂CH₂CH₂, CH₂CH(CH₃), and the different butylene isomers. “Trialkylsilyl” includes 3 branched and/or straight-chain alkyl radicals attached to and linked through a silicon atom, such as trimethylsilyl, triethylsilyl and *tert*-butyldimethylsilyl. “Alkoxy” includes, for example, methoxy, ethoxy, *n*-propyloxy, isopropyloxy and the different butoxy, pentoxy and hexyloxy isomers. “Alkoxyalkyl” denotes alkoxy substitution on alkyl. Examples of “alkoxyalkyl” include CH₃OCH₂, CH₃OCH₂CH₂, CH₃CH₂OCH₂, CH₃CH₂CH₂CH₂OCH₂ and CH₃CH₂OCH₂CH₂. “Alkoxyalkoxy” denotes alkoxy substitution on alkoxy. “Alkenyloxy” includes straight-chain or branched alkenyloxy moieties. Examples of “alkenyloxy” include H₂C=CHCH₂O, (CH₃)₂C=CHCH₂O, (CH₃)CH=CHCH₂O, (CH₃)CH=C(CH₃)CH₂O and CH₂=CHCH₂CH₂O. “Alkynyloxy” includes straight-chain or branched alkynyloxy moieties. Examples of “alkynyloxy” include HC≡CCH₂O, CH₃C≡CCH₂O and CH₃C≡CCH₂CH₂O. “Alkylthio” includes branched or straight-chain alkylthio moieties such as methylthio, ethylthio, and the different propylthio, butylthio, pentylthio and hexylthio isomers. “Alkylsulfinyl” includes both enantiomers of an alkylsulfinyl group. Examples of “alkylsulfinyl” include CH₃S(O)-, CH₃CH₂S(O)-, CH₃CH₂CH₂S(O)-, (CH₃)₂CHS(O)- and the different butylsulfinyl, pentylsulfinyl and hexylsulfinyl isomers. Examples of “alkylsulfonyl” include CH₃S(O)₂-, CH₃CH₂S(O)₂-, CH₃CH₂CH₂S(O)₂-,

(CH₃)₂CHS(O)₂-, and the different butylsulfonyl, pentylsulfonyl and hexylsulfonyl isomers. “Alkylthioalkyl” denotes alkylthio substitution on alkyl. Examples of “alkylthioalkyl” include CH₃SCH₂, CH₃SCH₂CH₂, CH₃CH₂SCH₂, CH₃CH₂CH₂CH₂SCH₂ and CH₃CH₂SCH₂CH₂. “Alkylthioalkoxy” denotes alkylthio substitution on alkoxy. “Alkyldithio” denotes branched or straight-chain alkyldithio moieties. Examples of “alkyldithio” include CH₃SS-, CH₃CH₂SS-, CH₃CH₂CH₂SS-, (CH₃)₂CHSS- and the different butyldithio and pentyldithio isomers. “Cyanoalkyl” denotes an alkyl group substituted with one cyano group. Examples of “cyanoalkyl” include NCCH₂, NCCH₂CH₂ and CH₃CH(CN)CH₂. “Cyanoalkoxy”, “dialkylamino”, “alkenylthio”, “alkenylsulfinyl”, “alkenylsulfonyl”, “alkynylthio”, “alkynylsulfinyl”, “alkynylsulfonyl”, and the like, are defined analogously to the above examples. Examples of “cyanoalkoxy” include CNCH₂O and CNCH₂CH₂O.

“Cycloalkyl” includes, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term “alkylcycloalkyl” denotes alkyl substitution on a cycloalkyl moiety and includes, for example, ethylcyclopropyl, *i*-propylcyclobutyl, 3-methylcyclopentyl and 4-methylcyclohexyl. The term “cycloalkylalkyl” denotes cycloalkyl substitution on an alkyl moiety. Examples of “cycloalkylalkyl” include cyclopropylmethyl, cyclopentylethyl, and other cycloalkyl moieties bonded to straight-chain or branched alkyl groups. The term “cycloalkoxy” denotes cycloalkyl linked through an oxygen atom such as cyclopentyloxy and cyclohexyloxy. “Cycloalkylalkoxy” denotes cycloalkylalkyl linked through an oxygen atom attached to the alkyl chain. Examples of “cycloalkylalkoxy” include cyclopropylmethoxy, cyclopentylethoxy, and other cycloalkyl moieties bonded to straight-chain or branched alkoxy groups.

The term “halogen”, either alone or in compound words such as “haloalkyl”, includes fluorine, chlorine, bromine or iodine. “Haloalkoxy”, is defined analogously to the term “haloalkyl”.

The total number of carbon atoms in a substituent group is indicated by the “C_i-C_j” prefix where *i* and *j* are numbers from 1 to 5. For example, C₁-C₃ alkoxy designates CH₃O-, CH₃CH₂O-, CH₃CH₂CH₂O- and (CH₃)₂CHO-.

“Aromatic” indicates that each of the ring atoms is essentially in the same plane and has a *p*-orbital perpendicular to the ring plane, and that (4*n* + 2) π electrons, where *n* is a positive integer, are associated with the ring to comply with Hückel’s rule. When a fully unsaturated carbocyclic ring satisfies Hückel’s rule, then said ring is also called an “aromatic ring. When a fully unsaturated heterocyclic ring satisfies Hückel’s rule, then said ring is also called a “heteroaromatic ring.” The term “nonaromatic heterocyclic ring ” denotes a heterocyclic ring system in which no ring in the ring system is aromatic.

The term “optionally substituted” in connection with the heterocyclic rings refers to groups which are unsubstituted or have at least one non-hydrogen substituent that does not

extinguish the biological activity possessed by the unsubstituted analog. As used herein, the following definitions shall apply unless otherwise indicated. The term “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted” or with the term “(un)substituted.” Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is independent of the other.

When a compound is substituted with a substituent bearing a subscript that indicates the number of said substituents can exceed 1, said substituents (when they exceed 1) are independently selected from the group of defined substituents, e.g., $(R^3)_n$, n is 0, 1, 2 or 3.

When a group contains a substituent which can be hydrogen, for example R^{2a} , then when this substituent is taken as hydrogen, it is recognized that this is equivalent to said group being unsubstituted. When a variable group is shown to be optionally attached to a position, for example $(R^3)_n$, wherein n may be 0, then hydrogen may be at the position even if not recited in the variable group definition. When one or more positions on a group are said to be “not substituted” or “unsubstituted”, then hydrogen atoms are attached to take up any free valency.


As referred to by the present disclosure and claims, an “unsaturated heterocyclic ring” is a heterocyclic ring wherein at least two ring member atoms are linked together by a double bond. Unless otherwise stated, an “unsaturated or partially unsaturated heterocyclic ring” (e.g., substituent Q) may be partially unsaturated or fully unsaturated. The expression “fully unsaturated heterocyclic ring” means a heterocyclic ring of atoms in which the bonds between carbon and/or nitrogen atoms in the ring are single or double bonds according to valence bond theory and furthermore the bonds between carbon and/or nitrogen atoms in the ring include as many double bonds as possible without double bonds being cumulative (i.e. no $C=C=C$, $N=C=C$, etc.). The term “partially unsaturated heterocyclic ring” denotes a heterocyclic ring comprising at least one ring member bonded to an adjacent ring member through a double bond and which conceptually potentially accommodates a number of non-cumulated double bonds between adjacent ring members (i.e. in its fully unsaturated counterpart form) greater than the number of double bonds present (i.e. in its partially unsaturated form). In the Summary of the Invention R^1 can be *inter alia* a 4- to 6-membered ring containing ring members selected from carbon atoms, 1 O atom and 1 S atom. This ring is understood to be a carbocyclic ring and includes a non-carbon ring member selected from 1 O atom or 1 S atom. Examples of a 4-membered ring containing ring members selected from carbon atoms, 1 O atom and 1 S atom include an oxetane ring (i.e. 2-oxetanyl or 3-oxetanyl) or a thietane ring (i.e. 2-thietanyl or 3-thietanyl). Examples of a 5-membered ring containing ring members selected from carbon atoms, 1 O atom and 1 S atom include the various regioisomers or tetrahydrofuran or tetrahydrothiophene. Examples of a 6-membered ring containing ring members selected from carbon atoms, 1 O atom and 1 S

atom include the various regioisomers of pyran and thiopyran. Note that the attachment point of these rings to the remainder of a Formula 1 can be through any available carbon atom with free valency.

In the Summary of the Invention the unsaturated heterocyclic ring of Q is specified to be 5-membered, with ring members selected from carbon atoms and up to 4 heteroatoms independently selected from up to 1 O, up to 1 S and up to 4 N atoms, wherein up to 2 carbon atoms are independently selected from C(=O). The heterocyclic ring is optionally substituted with one substituent on a ring member distal relative to the ring member connecting the heteroaromatic ring to the remainder of Formula 1. As depicted in Exhibit 1, the five-membered heterocyclic ring of Q, a ring member distal relative to the ring member connecting the ring to the remainder of Formula 1 is linked through two ring bonds to connecting ring member. The heterocyclic ring of Q is further optionally substituted with substituents selected from R^{12c} on carbon atom ring members and R¹²ⁿ on nitrogen atom ring members.

Exhibit 1

Optional R^{12c} substitution on Q ring of Formula 1




Certain heterocycles forming Q may have two distal ring members available for substitution. In this situation, only one of the distal ring members may be substituted with R^{12c} or R¹²ⁿ; the other distal ring member may be substituted with R^{13c} or R¹³ⁿ. If neither of the distal ring members of a heterocycle forming Q are available for substitution, then any additional substituents on the heterocycle are selected from R^{13c} or R¹³ⁿ. If a distal ring member can have two substituents, one substituent may be selected from R^{12c} or R¹²ⁿ and the other substituent may be selected from R^{13c} or R¹³ⁿ. In other words, the Q ring is limited to one R^{12c} or R¹²ⁿ substituent and this substituent must be bonded to a distal ring member; the Q ring can otherwise be further substituted with R^{13c} or R¹³ⁿ on any available ring member.

If an attachment point on a group (e.g., ring) is depicted as floating (e.g., as illustrated by the 5-membered unsaturated or partially saturated heterocyclic rings Q-1 through Q-21 in Exhibit 3), the group can be attached to the remainder of Formula 1 through any available

carbon or nitrogen of the group by replacement of a hydrogen atom. If the attachment point of a substituent on a group (e.g., ring) is depicted as floating (e.g., as illustrated for R¹² and R¹³ on the 5-membered unsaturated heterocyclic rings Q-1 through Q-21 in Exhibit 3 of Embodiment 54), the substituent can be attached to any available carbon or nitrogen atom by replacing a hydrogen atom.

In the Summary of the Invention G can be phenyl, pyridinyl, pyridazinyl or pyrazinyl substituted with Q *meta* or *para* to the -C(R^{2a})R^{2b}- radical, and optionally substituted with up to 3 substituents selected from R³. Examples of phenyl, pyridinyl, pyridazinyl or pyrazinyl are shown in Exhibit 2.

Exhibit 2




n = 0, 1, 2 or 3.

A wide variety of synthetic methods are known in the art to enable preparation of aromatic and nonaromatic heterocyclic rings and ring systems; for extensive reviews see the eight volume set of *Comprehensive Heterocyclic Chemistry*, A. R. Katritzky and C. W. Rees editors-in-chief, Pergamon Press, Oxford, 1984 and the twelve volume set of *Comprehensive Heterocyclic Chemistry II*, A. R. Katritzky, C. W. Rees and E. F. V. Scriven editors-in-chief, Pergamon Press, Oxford, 1996.

Compounds of this invention can exist as one or more stereoisomers. Stereoisomers are isomers of identical constitution but differing in the arrangement of their atoms in space and include enantiomers, diastereomers, cis-trans isomers (also known as geometric isomers) and atropisomers. Atropisomers result from restricted rotation about single bonds where the rotational barrier is high enough to permit isolation of the isomeric species. One skilled in the art will appreciate that one stereoisomer may be more active and/or may exhibit beneficial effects when enriched relative to the other stereoisomer(s) or when separated from the other stereoisomer(s). Additionally, the skilled artisan knows how to separate, enrich, and/or to selectively prepare said stereoisomers. For a comprehensive discussion of all aspects of stereoisomerism, see Ernest L. Eliel and Samuel H. Wilen, *Stereochemistry of Organic Compounds*, John Wiley & Sons, 1994.

This invention comprises all stereoisomers, conformational isomers and mixtures thereof in all proportions as well as isotopic forms such as deuterated compounds.

The compounds of the invention may be present as a mixture of stereoisomers, or individual stereoisomers. For example, when R^{2a} and R^{2b} not the same, then Formula 1 possesses a chiral center at the carbon atom to which R^{2a} and R^{2b} are bonded. The two enantiomers are depicted as Formula 1' and Formula 1'' with the chiral center identified with an asterisk (*).



Molecular depictions drawn herein follow standard conventions for depicting stereochemistry. To indicate stereoconfiguration, bonds rising from the plane of the drawing and towards the viewer are denoted by solid wedges wherein the broad end of the wedge is attached to the atom rising from the plane of the drawing towards the viewer. Bonds going below the plane of the drawing and away from the viewer are denoted by dashed wedges wherein the narrow end of the wedge is attached to the atom further away from the viewer. Constant width lines indicate bonds with a direction opposite or neutral relative to bonds shown with solid or dashed wedges; constant width lines also depict bonds in molecules or parts of molecules in which no particular stereoconfiguration is intended to be specified.

This invention comprises racemic mixtures, for example, equal amounts of the enantiomers of Formulae 1' and 1''. In addition, this invention includes compounds that are enriched compared to the racemic mixture in an enantiomer of Formula 1. Also included are the essentially pure enantiomers of compounds of Formula 1, for example, Formula 1' and Formula 1''.

When enantiomerically enriched, one enantiomer is present in greater amounts than the other, and the extent of enrichment can be defined by an expression of enantiomeric excess ("ee"), which is defined as $(2x-1) \cdot 100\%$, where x is the mole fraction of the dominant enantiomer in the mixture (e.g., an ee of 20 % corresponds to a 60:40 ratio of enantiomers).

Preferably the compositions of this invention have at least a 50 % enantiomeric excess; more preferably at least a 75 % enantiomeric excess; still more preferably at least a 90 % enantiomeric excess; and the most preferably at least a 94 % enantiomeric excess of the more active isomer. Of particular note are enantiomerically pure embodiments of the more active isomer.

Compounds of Formula 1 can comprise additional chiral centers. For example, substituents and other molecular constituents such as R^1 may themselves contain chiral

centers. This invention comprises racemic mixtures as well as enriched and essentially pure stereoconfigurations at these additional chiral centers.

Compounds of this invention can exist as one or more conformational isomers due to restricted rotation about the amide bond (e.g., AC(=Z)-N) in Formula 1. This invention
5 comprises mixtures of conformational isomers. In addition, this invention includes compounds that are enriched in one conformer relative to others.

One skilled in the art will appreciate that not all nitrogen containing heterocycles can form *N*-oxides since the nitrogen requires an available lone pair for oxidation to the oxide; one skilled in the art will recognize those nitrogen-containing heterocycles which can form
10 *N*-oxides. One skilled in the art will also recognize that tertiary amines can form *N*-oxides. Synthetic methods for the preparation of *N*-oxides of heterocycles and tertiary amines are very well known by one skilled in the art including the oxidation of heterocycles and tertiary amines with peroxy acids such as peracetic and *m*-chloroperbenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as *t*-butyl hydroperoxide, sodium perborate,
15 and dioxiranes such as dimethyldioxirane. These methods for the preparation of *N*-oxides have been extensively described and reviewed in the literature, see for example: T. L. Gilchrist in *Comprehensive Organic Synthesis*, vol. 7, pp 748–750, S. V. Ley, Ed., Pergamon Press; M. Tisler and B. Stanovnik in *Comprehensive Heterocyclic Chemistry*, vol. 3, pp 18–20, A. J. Boulton and A. McKillop, Eds., Pergamon Press; M. R. Grimmett and
20 B. R. T. Keene in *Advances in Heterocyclic Chemistry*, vol. 43, pp 149–161, A. R. Katritzky, Ed., Academic Press; M. Tisler and B. Stanovnik in *Advances in Heterocyclic Chemistry*, vol. 9, pp 285–291, A. R. Katritzky and A. J. Boulton, Eds., Academic Press; and G. W. H. Cheeseman and E. S. G. Werstiuk in *Advances in Heterocyclic Chemistry*, vol. 22, pp 390–392, A. R. Katritzky and A. J. Boulton, Eds., Academic Press.

One skilled in the art recognizes that because in the environment and under physiological conditions salts of chemical compounds are in equilibrium with their corresponding nonsalt forms, salts share the biological utility of the nonsalt forms. Thus a wide variety of salts of the compounds of Formula 1 are useful for control of plant diseases caused by fungal plant pathogens (i.e. are agriculturally suitable). The salts of the
30 compounds of Formula 1 include acid-addition salts with inorganic or organic acids such as hydrobromic, hydrochloric, nitric, phosphoric, sulfuric, acetic, butyric, fumaric, lactic, maleic, malonic, oxalic, propionic, salicylic, tartaric, 4-toluenesulfonic or valeric acids. When a compound of Formula 1 contains an acidic moiety such as a carboxylic acid or phenol, salts also include those formed with organic or inorganic bases such as pyridine,
35 triethylamine or ammonia, or amides, hydrides, hydroxides or carbonates of sodium, potassium, lithium, calcium, magnesium or barium. Accordingly, the present invention comprises compounds selected from Formula 1, *N*-oxides and agriculturally suitable salts thereof.

Compounds selected from Formula 1, stereoisomers, tautomers, *N*-oxides, and salts thereof, typically exist in more than one form, and Formula 1 thus includes all crystalline and non-crystalline forms of the compounds that Formula 1 represents. Non-crystalline forms include embodiments which are solids such as waxes and gums as well as
5 embodiments which are liquids such as solutions and melts. Crystalline forms include embodiments which represent essentially a single crystal type and embodiments which represent a mixture of polymorphs (i.e. different crystalline types). The term “polymorph” refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and/or conformations of the
10 molecules in the crystal lattice. Although polymorphs can have the same chemical composition, they can also differ in composition due to the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice. Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility,
15 dissolution rate and biological availability. One skilled in the art will appreciate that a polymorph of a compound represented by Formula 1 can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs of the same compound represented by Formula 1. Preparation and isolation of a particular polymorph of a compound represented
20 by Formula 1 can be achieved by methods known to those skilled in the art including, for example, crystallization using selected solvents and temperatures. For a comprehensive discussion of polymorphism see R. Hilfiker, Ed., *Polymorphism in the Pharmaceutical Industry*, Wiley-VCH, Weinheim, 2006.

Embodiments of the present invention as described in the Summary of the Invention
25 include (where Formula 1 as used in the following Embodiments includes *N*-oxides and salts thereof):

Embodiment 1. A compound of Formula 1 wherein A is selected from the group consisting of A-1, A-2, A-3 and A-4.

Embodiment 2. A compound of Formula 1 or Embodiment 1 wherein A is selected from
30 the group consisting of A-1, A-2 and A-3.

Embodiment 3. A compound of Formula 1 or any one of Embodiments 1 and 2 wherein A is selected from the group consisting of A-1 and A-2.

Embodiment 4. A compound of Formula 1 or any one of Embodiments 1 through 3 wherein A is A-2.

Embodiment 5. A compound of Formula 1 or any one of Embodiments 1 through 3
35 wherein A is A-1.

Embodiment 6. A compound of Formula 1 or any one of Embodiments 1 through 5 wherein Z is O.

Embodiment 7. A compound of Formula **1** or any one of Embodiments 1 through 6 wherein G is phenyl or pyridinyl substituted with Q *meta* or *para* to the -C(R^{2a})R^{2b}- radical, and optionally substituted with up to 2 substituents selected from R³.

Embodiment 8. A compound of Embodiment 7 wherein G is phenyl or pyridinyl substituted with Q *meta* or *para* to the -C(R^{2a})R^{2b}- radical, and optionally substituted with 1 substituent selected from R³.

Embodiment 9. A compound of Embodiment 8 wherein G is phenyl substituted with Q *meta* or *para* to the -C(R^{2a})R^{2b}- radical, and optionally substituted with 1 substituent selected from R³.

Embodiment 10. A compound of Embodiment 9 wherein G is phenyl substituted with Q *para* to the -C(R^{2a})R^{2b}- radical (i.e. unsubstituted with R³).

Embodiment 10a. A compound of Embodiment 9 wherein G is phenyl substituted with Q *para* to the -C(R^{2a})R^{2b}- radical, and unsubstituted with R³.

Embodiment 11. A compound of Embodiment 8 wherein G is pyridinyl substituted with Q *meta* or *para* to the -C(R^{2a})R^{2b}- radical, and optionally substituted with 1 substituent selected from R³.

Embodiment 12. A compound of Embodiment 11 wherein G is pyridinyl substituted with Q *para* to the -C(R^{2a})R^{2b}- radical (i.e. unsubstituted with R³).

Embodiment 13. A compound of Formula **1** or any one of Embodiments 1 through 12 wherein R¹ is C₃–C₄ cycloalkyl; or a 4- to 5-membered ring containing ring members selected from carbon atoms, 1 O atom and 1 S atom.

Embodiment 14. A compound of Embodiment 13 wherein R¹ is cyclopropyl; or a 4-membered ring containing ring members selected from carbon atoms, 1 O atom and 1 S atom.

Embodiment 15. A compound of Embodiment 14 wherein R¹ is cyclopropyl, 3-oxetanyl or 3-thietanyl.

Embodiment 16. A compound of Embodiment 15 wherein R¹ is cyclopropyl.

Embodiment 17. A compound of Formula **1** or any one of Embodiments 1 through 16 wherein R^{2a} is H, CH₃, CF₃ or CHF₂.

Embodiment 18. A compound of Embodiment 17 wherein R^{2a} is H, F or CH₃.

Embodiment 19. A compound of Embodiment 18 wherein R^{2a} is H.

Embodiment 20. A compound of Embodiment 18 wherein R^{2a} is F.

Embodiment 21. A compound of Embodiment 18 wherein R^{2a} is CH₃.

Embodiment 22. A compound of Formula **1** or any one of Embodiments 1 through 21 wherein R^{2b} is H or CH₃.

Embodiment 23. A compound of Embodiment 22 wherein R^{2b} is H.

Embodiment 24. A compound of Formula **1** or any one of Embodiments 1 through 16 wherein when R^{2a} and R^{2b} are taken together, they are taken together as C₂ or C₃ alkanediyl.

Embodiment 25. A compound of Embodiment 24 wherein R^{2a} and R^{2b} are taken together as C₂ alkanediyl (i.e. R^{2a} and R^{2b} are taken together along with the carbon to which they are attached to form a cyclopropyl ring).

Embodiment 26. A compound of Formula **1** or any one of Embodiments 1 through 9, 11 or 13 through 25 wherein R³ is halogen, cyano, C₁–C₅ alkyl, C₁–C₅ haloalkyl, C₁–C₅ alkoxy, C₁–C₅ haloalkoxy, C₂–C₅ alkoxyalkyl or C₃–C₅ cycloalkyl.

Embodiment 27. A compound of Embodiment 26 wherein R³ is halogen, CH₃, CF₃, CHF₂, OCH₃, OCF₃, CH₂CH₂OCH₃ or cyclopropyl.

Embodiment 28. A compound of Embodiment 27 wherein R³ is Cl, Br, CH₃, CF₃, CHF₂, OCH₃ or cyclopropyl.

Embodiment 29. A compound of Embodiment 28 wherein R³ is Cl.

Embodiment 30. A compound of Formula **1** or any one of Embodiments 1 through 3 or 5 through 29 wherein R⁴ is halogen, C₁–C₂ alkyl or C₁–C₂ haloalkyl.

Embodiment 31. A compound of Embodiment 30 wherein R⁴ is halogen, CH₃ or C₁ haloalkyl.

Embodiment 32. A compound of Embodiment 31 wherein R⁴ is F, Cl, Br, CH₃, CHF₂ or CF₃.

Embodiment 33. A compound of Embodiment 32 wherein R⁴ is CHF₂.

Embodiment 34. A compound of Formula **1** or any one of Embodiments 1 through 3 or 5 through 33 wherein R⁵ is H, halogen, C₁–C₂ alkyl or C₁–C₂ haloalkyl.

Embodiment 35. A compound of Embodiment 34 wherein R⁵ is H, halogen, CH₃ or C₁ haloalkyl.

Embodiment 36. A compound of Embodiment 35 wherein R⁵ is H, F, Cl, Br, CH₃, CHF₂ or CF₃.

Embodiment 37. A compound of Embodiment 36 wherein R⁵ is F or Cl.

Embodiment 38. A compound of Formula **1** or any one of Embodiments 1 through 3 or 5 through 37 wherein R⁶ is CH₃.

Embodiment 39. A compound of Formula **1** or any one of Embodiments 1 through 4 or 6 through 29 wherein R⁷ is halogen, C₁–C₂ alkyl or C₁–C₂ haloalkyl.

Embodiment 40. A compound of Embodiment 39 wherein R⁷ is halogen, CH₃ or C₁ haloalkyl.

Embodiment 41. A compound of Embodiment 40 wherein R⁷ is F, Cl, Br, CH₃, CHF₂ or CF₃.

Embodiment 42. A compound of Formula **1** or any one of Embodiments 1 through 4 or 6 through 29 or 39 through 41 wherein R⁸ is H or CH₃.

Embodiment 43. A compound of Formula 1 or any one of Embodiments 1, 2 or 6 through 29 wherein R^9 is halogen, C_1-C_2 alkyl or C_1-C_2 haloalkyl.

Embodiment 44. A compound of Embodiment 43 wherein R^9 is halogen, CH_3 or C_1 haloalkyl.

5 Embodiment 45. A compound of Embodiment 44 wherein R^9 is F, Cl, Br, CHF_2 or CF_3 .

Embodiment 46. A compound of Formula 1 or Embodiment 1 wherein R^{10} is F, Cl, Br, CH_3 , CHF_2 or CF_3 .

Embodiment 47. A compound of Formula 1 wherein R^{11} is F, Cl, Br, CH_3 , CHF_2 or CF_3 .

10 Embodiment 48. A compound of Formula 1 or Embodiment 47 wherein m is 0 or 2.

Embodiment 49. A compound of Formula 1 or any one of Embodiments 1 through 48 wherein the heterocyclic ring Q contains at least one nitrogen atom ring member.

Embodiment 50. A compound of Embodiment 49 wherein the heterocyclic ring Q contains two nitrogen atom ring members.


15 Embodiment 51. A compound of Formula 1 or any one of Embodiments 1 through 50 wherein the heterocyclic ring Q is fully unsaturated (i.e. is heteroaromatic).


Embodiment 52. A compound of Formula 1 or any one of Embodiments 1 through 51 wherein the heterocyclic ring Q is selected from furan, thiophene, pyrrole, oxazole, thiazole, imidazole, isoxazole, isothiazole, pyrazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole, 1,3,4-oxadiazole, 1,2,4-thiadiazole, 1,2,5-thiadiazole, 1,3,4-thiadiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, 4,5-dihydroisoxazole and 4,5-dihydropyrazole.

Embodiment 53. A compound of Embodiment 52 wherein the heterocyclic ring Q is selected from pyrazole.

25 Embodiment 54. A compound of Embodiment 51 wherein Q is selected from Q-1 through Q-21 depicted in Exhibit 3.

Exhibit 3





wherein

R^{12} is bonded to a ring member distal relative to the ring member connecting the Q ring to the remainder of Formula 1, and independently selected from R^{12c} on carbon atom ring members and R^{12n} on nitrogen atom ring members;

5 each R^{13} is independently selected from R^{13c} on carbon atom ring members and R^{13n} on nitrogen atom ring members;


each x is independently 0 or 1;

each y is independently 0, 1 or 2; and

each z is independently 0, 1, 2 or 3.

10 Embodiment 55. A compound of Embodiment 54 wherein Q is selected from Q-1 through Q-19.

Embodiment 56. A compound of Embodiment 55 wherein Q is selected from



Embodiment 57. A compound of Embodiment 56 wherein Q is selected from Q-9A and Q-9B.

Embodiment 58. A compound of Embodiment 57 wherein Q is Q-9A.

Embodiment 59. A compound of any one of Embodiments 56 through 58 wherein y is 0 or 1.

Embodiment 60. A compound of Formula 1 or any one of Embodiments 1 through 59 wherein each R^{12c} is independently halogen, cyano, C₁–C₂ alkyl, C₁–C₂ haloalkyl, C₁–C₂ alkoxy or C₁–C₂ haloalkoxy.

Embodiment 61. A compound of Embodiment 60 wherein each R^{12c} is independently halogen, CH₃ or C₁ haloalkyl.

Embodiment 62. A compound of Embodiment 61 wherein each R^{12c} is independently F, Cl, Br, CH₃, CHF₂ or CF₃.

Embodiment 63. A compound of Embodiment 62 wherein each R^{12c} is independently CF₃.

Embodiment 64. A compound of Formula 1 or any one of Embodiments 1 through 63 wherein each R¹²ⁿ is independently C₁–C₂ alkyl or C₁–C₂ haloalkyl.

Embodiment 65. A compound of Embodiment 64 wherein each R¹²ⁿ is C₁–C₂ alkyl.

Embodiment 66. A compound of Embodiment 65 wherein each R¹²ⁿ is CH₃.

Embodiment 67. A compound of Formula 1 or any one of Embodiments 1 through 66 wherein each R^{13c} is independently halogen, C₁–C₂ alkyl, C₁–C₂ haloalkyl or C₁–C₂ alkoxy.

Embodiment 68. A compound of Embodiment 67 wherein each R^{13c} is independently halogen, CH₃ or C₁ haloalkyl.

Embodiment 69. A compound of Embodiment 68 wherein each R^{13c} is independently F, Cl, Br, CH₃, CHF₂ or CF₃.

Embodiment 70. A compound of Formula 1 or any one of Embodiments 1 through 69 wherein each R¹³ⁿ is independently C₁–C₂ alkyl or C₁–C₂ haloalkyl.

Embodiment 71. A compound of Embodiment 70 wherein each R¹³ⁿ is C₁–C₂ alkyl.

Embodiment 72. A compound of Embodiment 71 wherein each R¹³ⁿ is CH₃.

Embodiment 73. A compound of Formula 1 or any one of Embodiments 1 through 72 wherein each R¹⁴, R^{15c}, R¹⁶ and R^{17c} is independently halogen, C₁–C₂ alkyl, C₁–C₂ haloalkyl or C₁–C₂ alkoxy.

Embodiment 74. A compound of Embodiment 73 wherein each R¹⁴, R^{15c}, R¹⁶ and R^{17c} is independently halogen, CH₃ or C₁ haloalkyl.

Embodiment 75. A compound of Embodiment 74 wherein each R¹⁴, R^{15c}, R¹⁶ and R^{17c} is independently F, Cl, Br, CH₃, CHF₂ or CF₃.

Embodiment 76. A compound of Formula 1 or any one of Embodiments 1 through 75 wherein each R¹⁵ⁿ and R¹⁷ⁿ is independently C₁–C₂ alkyl or C₁–C₂ haloalkyl.

Embodiment 77. A compound of Embodiment 76 wherein each R¹⁵ⁿ and R¹⁷ⁿ is independently C₁–C₂ alkyl.

Embodiment 78. A compound of Embodiment 77 wherein each R^{15n} and R^{17n} is CH_3 .

Embodiments of this invention, including Embodiments 1–78 above as well as any other embodiments described herein, can be combined in any manner, and the descriptions of variables in the embodiments pertain not only to the compounds of Formula 1 but also to the starting compounds and intermediate compounds useful for preparing the compounds of Formula 1. In addition, embodiments of this invention, including Embodiments 1–78 above as well as any other embodiments described herein, and any combination thereof, pertain to the compositions and methods of the present invention.

Combinations of Embodiments 1–78 are illustrated by:

Embodiment A. A compound of Formula 1 wherein

Z is O;

R^1 is C_3 – C_4 cycloalkyl; or a 4- to 5-membered ring containing ring members selected from carbon atoms, 1 O atom and 1 S atom;

R^{2a} is H, CH_3 , CF_3 or CHF_2 ;

R^{2b} is H or CH_3 ; or

R^{2a} and R^{2b} are taken together as C_2 or C_3 alkanediyl;

G is phenyl or pyridinyl substituted with Q *meta* or *para* to the $-C(R^{2a})R^{2b}$ - radical, and optionally substituted with up to 2 substituents selected from R^3 ;

R^3 halogen, cyano, C_1 – C_5 alkyl, C_1 – C_5 haloalkyl, C_1 – C_5 alkoxy, C_1 – C_5 haloalkoxy, C_2 – C_5 alkoxyalkyl, C_3 – C_5 cycloalkyl;

R^4 is halogen, C_1 – C_2 alkyl or C_1 – C_2 haloalkyl;

R^5 is H, halogen, C_1 – C_2 alkyl or C_1 – C_2 haloalkyl;

R^6 is CH_3 ;

R^7 is halogen, C_1 – C_2 alkyl or C_1 – C_2 haloalkyl;

R^8 is H or CH_3 ;

R^9 is halogen, C_1 – C_2 alkyl or C_1 – C_2 haloalkyl;

R^{10} is F, Cl, Br, CH_3 , CHF_2 or CF_3 ;

R^{11} is F, Cl, Br, CH_3 , CHF_2 or CF_3 ;

Q is selected from Q-1 through Q-21 (as depicted in Embodiment 54);

each R^{12c} is independently halogen, cyano, C_1 – C_2 alkyl, C_1 – C_2 haloalkyl, C_1 – C_2 alkoxy or C_1 – C_2 haloalkoxy;

each R^{12n} is independently C_1 – C_2 alkyl or C_1 – C_2 haloalkyl;

each R^{13c} is independently halogen, C_1 – C_2 alkyl, C_1 – C_2 haloalkyl or C_1 – C_2 alkoxy;

each R^{13n} is independently C_1 – C_2 alkyl or C_1 – C_2 haloalkyl;

each R^{14} , R^{15c} , R^{16} and R^{17c} is independently halogen, CH_3 or C_1 haloalkyl; and

R^{15n} and R^{17n} is independently C_1 – C_2 alkyl or C_1 – C_2 haloalkyl.

Embodiment B. A compound of Embodiment A wherein

A is selected from the group consisting of A-1, A-2, A-3 and A-4;

R¹ is cyclopropyl; or a 4-membered ring containing ring members selected from carbon atoms, 1 O atom and 1 S atom;

R^{2b} is H; or

R^{2a} and R^{2b} are taken together as C₂ alkanediyl;

G is phenyl or pyridinyl substituted with Q *meta* or *para* to the -C(R^{2a})R^{2b}- radical, and optionally substituted with 1 substituent selected from R³;

R³ is halogen, CH₃, CF₃, CHF₂, OCH₃, OCF₃, CH₂CH₂OCH₃ or cyclopropyl;

R⁴ is halogen, CH₃ or C₁ haloalkyl;

R⁵ is H, F, Cl, Br, CH₃, CHF₂ or CF₃;

R⁷ is halogen, CH₃ or C₁ haloalkyl;

R⁹ is F, Cl, Br, CHF₂ or CF₃;

Q is selected from Q-1 through Q-19;

R^{12c} is independently halogen, CH₃ or C₁ haloalkyl;

R¹²ⁿ is C₁-C₂ alkyl;

each R^{13c} is independently halogen, CH₃ or C₁ haloalkyl;

each R¹³ⁿ is C₁-C₂ alkyl;

each R¹⁴, R^{15c}, R¹⁶ and R^{17c} is independently F, Cl, Br, CH₃, CHF₂ or CF₃; and

each R¹⁵ⁿ and R¹⁷ⁿ is independently C₁-C₂ alkyl.

Embodiment C. A compound of Embodiment B wherein

A is selected from the group consisting of A-1, A-2 and A-3;

R¹ is cyclopropyl, 3-oxetanyl or 3-thietanyl;

G is phenyl substituted with Q *meta* or *para* to the -C(R^{2a})R^{2b}- radical, and optionally substituted with 1 substituent selected from R³;

R³ is Cl, Br, CH₃, CF₃, CHF₂, OCH₃ or cyclopropyl;

R⁴ is F, Cl, Br, CH₃, CHF₂ or CF₃;

R⁵ is F or Cl;

R⁷ is F, Cl, Br, CH₃, CHF₂ or CF₃;

R⁹ is F, Cl, Br, CHF₂ or CF₃;

Q is selected from Q-9A, Q-9B and Q-9C (as depicted in Embodiment 56);

each R^{12c} is independently F, Cl, Br, CH₃, CHF₂ or CF₃;

each R¹²ⁿ is CH₃;

each R^{13c} is independently F, Cl, Br, CH₃, CHF₂ or CF₃;

each R¹³ⁿ is CH₃; and

each R¹⁵ⁿ and R¹⁷ⁿ is CH₃.

Embodiment D. A compound of Embodiment A wherein


A is selected from the group consisting of A-1 and A-2;

R^1 is cyclopropyl;


G is phenyl substituted with Q *para* to the $-C(R^{2a})R^{2b}$ - radical, and unsubstituted with R^3 ;

R^4 is CHF_2 ;

Q is selected from



Q-9A



Q-9B

R^{12c} is CF_3 .

Embodiment E. A compound of Embodiment B wherein

A is A-1;

R^1 is cyclopropyl;

G is pyridinyl substituted with Q *meta* or *para* to the $-C(R^{2a})R^{2b}$ - radical, and optionally substituted with 1 substituent selected from R^3 ;

R^3 is Cl;

R^4 is CHF_2 ;

Q is



Q-9A

R^{12c} is CF_3 .

Specific embodiments include compounds of Formula 1 selected from the group consisting of:

N-[[2-chloro-4-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]phenyl]methyl]-*N*-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1*H*-pyrazole-4-carboxamide (Compound 12); and
N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-*N*-[[3-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]phenyl]methyl]-1*H*-pyrazole-4-carboxamide (Compound 3).

This invention also includes a compound of Formula 1 wherein R^3 is halogen, nitro, cyano, C_1 - C_5 alkyl, C_1 - C_5 haloalkyl, C_1 - C_5 alkoxy, C_1 - C_5 haloalkoxy, C_2 - C_5 alkoxyalkyl, C_3 - C_5 cycloalkyl, C_2 - C_5 alkoxycarbonyl or C_3 - C_{12} trialkylsilyl. This invention provides a fungicidal composition comprising a compound of Formula 1 (including all stereoisomers, *N*-oxides, and salts thereof), and at least one other fungicide. Of note as embodiments of such compositions are compositions comprising a compound corresponding to any of the compound embodiments described above.

This invention provides a fungicidal composition comprising a compound of Formula 1 (including all stereoisomers, *N*-oxides, and salts thereof) (i.e. in a fungicidally effective amount), and at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents. Of note as embodiments of such compositions are compositions comprising a compound corresponding to any of the compound embodiments described above.


This invention provides a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of Formula 1 (including all stereoisomers,

N-oxides, and salts thereof). Of note as embodiment of such methods are methods comprising applying a fungicidally effective amount of a compound corresponding to any of the compound embodiments describe above. Of particular notes are embodiments where the compounds are applied as compositions of this invention.

One or more of the following methods and variations as described in Schemes 1-11 can be used to prepare the compounds of Formula 1. The definitions of A, R¹, R^{2a}, R^{2b}, G, Q, and Z in the compounds of Formulae 1–21 below are as defined above in the Summary of the Invention unless otherwise noted. Compounds of Formulae 1a–1c are various subsets of a compound of Formula 1, and all substituents for Formulae 1a–1c are as defined above for a compound of Formula 1. Compounds of Formulae 2a–2b are various subsets of a compound of Formula 2, and all substituents for Formulae 2a–2b are as defined herein for a compound of Formula 2. Compounds of Formulae 7a–7c are various subsets of a compound of Formula 7, and all substituents for Formulae 7a–7c are as defined herein for a compound of Formula 7. Compounds of Formulae 9a–9b are various subsets of a compound of Formula 9, and all substituents for Formulae 9a–9b are as defined hererin for a compound of Formula 9.

As shown in Scheme 1, a compound of Formula 1b (i.e. Formula 1 wherein Z is sulfur) may be prepared from a compound of Formula 1a (i.e. Formula 1 wherein Z is oxygen) by treatment with Lawesson's reagent, P₂S₅, or P₄S₁₀. Thioamide formation reactions of this type are typically conducted in an aprotic solvent such as toluene or *p*-dioxane at elevated temperatures between 40 °C and the boiling point of the solvent. Reactions of this type are well known in the literature; see, for example, March and Smith, *March's Advanced Organic Chemistry*, 5th ed., John Wiley & Sons, Inc., New York, 2001, Chapter 16.

Scheme 1



25

As shown in Scheme 2, a compound of Formula 1c (i.e. a compound of Formula 1 wherein Z is oxygen; and Q is a nitrogen-linked heterocycle denoted by Q^N positioned *meta* or *para* to the -C(R^{2a})R^{2b}- radical on the G ring) may be prepared by nucleophilic aromatic substitution by reaction of a compound of Formula 2a (i.e. a compound of Formula 2 wherein L is a phenyl, pyridinyl, pyridazinyl or pyrazinyl group) with a heterocycle of Formula 3 wherein a hydrogen atom is bonded to a ring nitrogen. These substitution reactions are typically conducted in a polar aprotic solvent such as *N,N*-dimethylformamide or dimethylsulfoxide in the presence of an inorganic base such as potassium or cesium carbonate at temperatures between ambient and the boiling point of the solvent. These types


30

of reactions are well documented in the literature (see, for example, March and Smith, *March's Advanced Organic Chemistry*, 5th ed., John Wiley & Sons, Inc., New York, 2001, Chapter 13). Heterocycles of Formula **3** are commercially available or may be prepared by methods well known in the art.

5 As also shown in Scheme 2, a compound of Formula **1c** may be prepared by copper-catalyzed Buchwald-Hartwig coupling of a compound of Formula **2b** with a heterocycle of Formula **3** wherein a ring nitrogen is bonded to a hydrogen atom. These coupling reactions are typically conducted in an aprotic solvent such as *p*-dioxane, 1,2-diethoxyethane or toluene in the presence of a suitable ligand, a copper(I) salt such as CuI or CuBr, and a base
10 such as sodium or potassium carbonate. Typical ligands are *trans*-*N,N*-dimethyl-1,2-diaminocyclohexane and phenanthroline, and typical reaction temperatures range from ambient temperature to reflux. Conditions for this reaction are well known in the literature (see *Chemical Science* **2010**, *1*, 13-31, *Chemical Reviews* **2008**, *108*(8), 3054-3131, and references cited therein).

15 As also shown in Scheme 2, a compound of Formula **1d** (i.e. Formula **1** wherein Z is oxygen; and Q is a carbon-linked heterocycle denoted by Q^C positioned *meta* or *para* to the -C(R^{2a})R^{2b}- radical on the G ring) can be prepared by Suzuki coupling reaction. A compound of Formula **2b** (i.e. a compound of Formula **2** wherein L is a phenyl, pyridinyl, pyridazinyl, or pyrazinyl group) may be coupled with a boronic acid or ester of Formula **4**,
20 wherein a ring carbon is bonded to boron, in the presence of Pd(0) or Pd(II) salts, a suitable ligand, and a base. Suitable bases for this transformation are potassium carbonate or cesium carbonate. Pd(II) salts such as Pd(OAc)₂ or PdCl₂ are used in conjunction with ligands such as triphenylphosphine or 1,1'-bis(diphenylphosphino)ferrocene (dppf). Conditions for Suzuki couplings are well documented in the literature (see, for example, *Angewandte Chemie, Int. Ed.* **2006**, *45*, 3484). A boronic acid or ester of Formula **4** is commercially
25 available or may be prepared from the corresponding halides or trifluoromethanesulfonates by methods known in the literature (see, for example, *J. Org. Chem.* **1995**, *60*, 7508).

23




Alternatively, as shown in Scheme 3, a compound of Formula **1c** may be prepared from a boron intermediate of Formula **5** using Chan-Lam conditions by coupling with a nitrogen heterocycle of Formula **3** in the presence of a Cu(II) salt, oxygen, and a base at temperatures ranging from ambient to the reflux temperature of the solvent. Examples of Cu(II) salts which may be used are $\text{Cu}(\text{OAc})_2$, CuBr_2 , and CuI_2 . Suitable bases for this reaction type include pyridine, quinoline, and triethylamine, and suitable solvents include dichloromethane, chloroform, diethyl ether, and tetrahydrofuran. For representative conditions see *Tetrahedron Letters* **1998**, 39, 2941, *Angewandte Chemie, Int. Ed.* **2003**, 42, 5400, and references therein.


As also shown in Scheme 3, a compound of Formula **1d** may be prepared via Suzuki reaction by coupling of a boronic acid or ester of Formula **5** with a heterocycle of Formula **6** wherein X^2 is bonded to a ring carbon. Conditions for carrying out such couplings are analogous to the Suzuki conditions described in Scheme 2. A compound of Formula **6** is commercially available or may readily be prepared by methods described in the literature.

A compound of Formula **5** may be prepared from a compound of Formula **2b** using the methods cited for the preparation of a compound of Formula **4** in Scheme 2.

24




As shown in Scheme 4, a compound of Formula 2 may be prepared by the acylation of amine derivatives of a compound of Formula 7 with a compound of Formula 8. These types of acylations are well documented in the literature (see, for example, March and Smith, *March's Advanced Organic Chemistry*, 5th ed., John Wiley & Sons, Inc., New York, 2001, Chapter 10).




As shown in Scheme 5, a compound of Formula 7a (i.e. a compound of Formula 7 wherein R^1 is cyclopropyl) may be prepared by the reaction of a primary amine derivative of Formula 9 with commercially available cyclopropanone ethyl trimethylsilyl acetal 10 in acetic acid/methanol in the presence of sodium cyanoborohydride (see, for example, PCT Patent Publication WO2012/22265). A compound of Formula 9 is commercially available or may readily be prepared by methods described in the literature.

Scheme 5



As shown in Scheme 6, a compound of Formula 7b (i.e. a compound of Formula 7 wherein R¹ is cyclobutyl, cyclopentyl, or a 4- to 6-membered ring containing ring members selected from carbon atoms, 1 O atom and 1 S atom) may be prepared by condensation of a primary amine of Formula 9 with a ketone of Formula 11 followed by treatment with a reducing agent such as sodium borohydride, sodium cyanoborohydride, or sodium triacetoxyborohydride. For representative conditions, see *J. Med. Chem.* **2005**, 48(4), 1169 and PCT Patent Publication WO 2012/66070.

Scheme 6




R⁵¹ is C₁-C₂ alkylene, O, S, -CH₂O-, -CH₂S-, -CH₂OCH₂-, -CH₂-S-CH₂-, -OCH₂CH₂- or -SCH₂CH₂-

As shown in Scheme 7, an amine of Formula 7 or Formula 7c (i.e. a compound of Formula 7 wherein R^{2b} is H) may be prepared from a ketone of Formula 12. Condensation of an amine of Formula 13 with a ketone of Formula 12 results in the formation of imines of Formula 14. Condensation reactions of this type are well known in the literature (see March and Smith, *March's Advanced Organic Chemistry*, 5th ed., John Wiley & Sons, Inc., New York, 2001, Chapter 16). Treatment of an imine of Formula 14 with a reducing agent provides amines of Formula 7c. Typical reducing agents used in these reactions include sodium borohydride, sodium cyanoborohydride, and sodium triacetoxyborohydride, and typical solvents are methanol, ethanol, acetonitrile, or tetrahydrofuran. The transformation of a compound of Formula 12 to a compound of Formula 7c is often done in a single reaction pot. For representative conditions, see US Patent Publications US2005/58301 and US2008/275085. A dialkylated or haloalkylated compound of Formula 7 may be obtained by treatment of an imine of Formula 14 with an alkyl- or haloalkyl-metal species of Formula


15. Typical reaction temperatures for this alkylation reaction range from $-78\text{ }^{\circ}\text{C}$ to $60\text{ }^{\circ}\text{C}$ and typical solvents include tetrahydrofuran, acetonitrile and diethyl ether. For representative conditions, see US2012/59162 and *Tetrahedron* **2011**, 67(14), 2670. A ketone of Formula **12**, an amine of Formula **13**, and a metal reagent of Formula **15** are commercially available or may readily be prepared by methods described in the literature.

Scheme 7




As shown in Scheme 8, a compound of Formula **9a** (i.e. a compound of Formula **9** wherein R^{2a} and R^{2b} are both H) may be prepared by the reduction of a corresponding nitrile compound of Formula **16**. The nitrile reduction may be performed via a number of methods, including the use of hydrogen/palladium on carbon, nickel(II) chloride/sodium borohydride or borane, which are well documented in the literature. See, for example, Smith, M. B., *Organic Synthesis*, 2nd ed., McGraw-Hill Companies, Inc., 2002, Chapter 4, and references cited therein. A compound of Formula **16** is commercially available or may readily be prepared by methods described in the literature.

Scheme 8




A compound of Formula **9b** (i.e. a compound of Formula **9** wherein R^{2a} is F and R^{2b} is F or H) may be prepared as shown in Scheme 9. Treatment of a bromide of Formula **17** with silver nitrite in a solvent such as diethyl ether at temperatures from about $0\text{ }^{\circ}\text{C}$ to ambient temperature may provide a nitro compound of Formula **18**. For representative conditions, see US2012/165343. A compound of Formula **19** may be prepared by treatment of a compound of Formula **18** with a base such as potassium hydroxide, tetrabutylammonium hydroxide, sodium hydride or ammonium acetate and an electrophilic fluorinating reagent such as SelectfluorTM (1-chloromethyl-4-fluoro-1,4-diazoniabicyclo-[2.2.2]octane


bis(tetrafluoroborate)) in solvents such as *N,N*-dimethylformamide, acetonitrile, dichloromethane or methanol at temperatures around 0 °C to ambient temperature. One skilled in the art will recognize that these conditions may be modulated to obtain the mono-fluorinated product (i.e. a compound of Formula **19** wherein R⁵³ is H) or the di-fluorinated product (i.e. a compound of Formula **19** wherein R⁵³ is F). In cases where product mixtures are produced, the desired product may be isolated using separation techniques well known in the art. For representative conditions see *Tetrahedron Letters* **2005**, 46, 4905 and *Tetrahedron Letters* **2006**, 47, 4519. An amino compound of Formula **9b** may be prepared via the reduction of a nitro compound of Formula **19** using Fe, Zn, or tin(II) chloride in aqueous acidic media at temperatures ranging from ambient temperature to reflux. Alcohol co-solvents such as methanol, ethanol, and isopropanol may also be employed. Acids such as hydrochloric, hydrobromic, and acetic, or ammonium chloride, are typically employed. Conditions for such reductions may be found in *J. Med. Chem.* **2012**, 55(3), 1021. Alternatively, hydrogenation conditions such as the use of Raney nickel under an atmosphere of hydrogen may be utilized to prepare a compound of Formula **9b**. This type of hydrogenation is typically conducted in a solvent such as ethanol. For representative conditions, see US2012/259111. A compound of Formula **17** is commercially available or may readily be prepared by methods described in the literature.



As shown in Scheme 10, a compound of Formula **1a** can be prepared by coupling of an amine of Formula **20** with an acid derivative of Formula **8** according to the methods described for the preparation of a compound of Formula **2** in Scheme 4.



As shown in Scheme 11, a compound of Formula **20** may be prepared either from a compound of Formula **7** using the coupling methods described in Scheme 2 with reagents of compounds of Formulae **3** or **4**, or from a boron derivative of Formula **21** using the coupling methods described in Scheme 3 with a compound of Formulae **3** or **6**. A compound of Formula **21** can be prepared from a compound of Formula **7** using methods cited for the preparation of **4** in Scheme 2.



It is recognized that some reagents and reaction conditions described above for preparing a compound of Formula **1** may not be compatible with certain functionalities present in the intermediates. In these instances, the incorporation of protection/deprotection sequences or functional group interconversions into the synthesis will aid in obtaining the desired products. The use and choice of the protecting groups will be apparent to one skilled in chemical synthesis (see, for example, Greene, T. W.; Wuts, P. G. M. *Protective Groups in Organic Synthesis*, 2nd ed.; Wiley: New York, 1991). One skilled in the art will recognize that, in some cases, after the introduction of a given reagent as it is depicted in any individual scheme, it may be necessary to perform additional routine synthetic steps not described in detail to complete the synthesis of compounds of Formula **1**. One skilled in the art will also recognize that it may be necessary to perform a combination of the steps illustrated in the above schemes in an order other than that implied by the particular sequence presented to prepare the compounds of Formula **1**.

One skilled in the art will also recognize that compounds of Formula **1** and the intermediates described herein can be subjected to various electrophilic, nucleophilic, radical, organometallic, oxidation, and reduction reactions to add substituents or modify existing substituents.

Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following Examples are, therefore, to be construed as merely illustrative, and not limiting of the disclosure in any way whatsoever. Steps in the following Examples illustrate a procedure for each step in an overall synthetic transformation, and the starting material for each step may not have necessarily been prepared by a particular preparative run whose procedure is described in other Examples or Steps. Percentages are by weight except for chromatographic solvent mixtures or where otherwise indicated. Parts and percentages for chromatographic solvent mixtures are by volume unless otherwise indicated. 1H NMR spectra are reported in ppm

downfield from tetramethylsilane in CDCl₃ unless otherwise noted; “s” means singlet, “d” means doublet, “t” means triplet, “m” means multiplet, “dd” means doublet of doublets, “dt” means doublet of triplets, “br s” means broad singlet.

EXAMPLE 1

- 5 Preparation of *N*-cyclopropyl-3-(difluoromethyl)-1-methyl-*N*-[1-[6-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]-3-pyridinyl]ethyl]-1*H*-pyrazole-4-carboxamide (Compound 1)

Step A: Preparation of 6-chloro-*N*-cyclopropyl- α -methyl-3-pyridinemethanamine

A stirred mixture of cyclopropylamine (2.1 g, 37.0 mmol) and 2 Å molecular sieves (2.0 g) in methanol (25 mL) was cooled to 0 °C and treated successively with glacial acetic acid (2.75 mL) and 1-(6-chloro-3-pyridinyl)ethanone (2.88 g, 18.5 mmol). External cooling was removed and the mixture was heated to reflux for 3 h and then allowed to cool to ambient temperature. A solution of sodium cyanoborohydride (1.73 g, 46.3 mmol) in methanol (5 mL) was added dropwise, and the reaction mixture was heated to reflux for an additional 3 h. The cooled reaction mixture was concentrated under reduced pressure, and the resulting residue purified by silica gel chromatography eluting with 20 to 50% ethyl acetate in hexanes to yield the title compound (1.61 g).

¹H NMR δ 8.32 (m, 1H), 7.65 (m, 1H), 7.28 (d, 1H), 3.91 (m, 1H), 1.96 (m, 1H), 1.74 (br s, 1H), 1.36 (d, 3H), 0.38 (m, 3H), 0.20 (m, 1H).

- Step B: Preparation of *N*-[1-(6-chloro-3-pyridinyl)ethyl]-*N*-cyclopropyl-3-(difluoromethyl)-1-methyl-1*H*-pyrazole-4-carboxamide
-

A mixture of 3-(difluoromethyl)-1-methyl-1*H*-pyrazole-4-carboxylic acid (0.25 g, 1.42 mmol) and thionyl chloride (5 mL) was heated to reflux for 1 h. The cooled reaction mixture was concentrated under reduced pressure and the resulting residue was twice diluted with toluene and concentrated under reduced pressure. The residual 3-(difluoromethyl)-1-methyl-1*H*-pyrazole-4-carbonyl chloride was taken up in dichloromethane (5 mL) and treated dropwise at room temperature with a mixture of 6-chloro-*N*-cyclopropyl- α -methyl-3-pyridinemethanamine (i.e. the product of Step A, 0.23 g, 1.18 mmol) and triethylamine (0.12 g, 1.18 mmol) in dichloromethane. The reaction mixture was stirred overnight at ambient temperature, and then partitioned between 1N hydrochloric acid and dichloromethane. The organic phase was separated and the aqueous phase extracted again with dichloromethane. The combined organic phases were dried (MgSO₄) and concentrated under reduced pressure. The residue was chromatographed on silica gel eluting with 30 to 100% ethyl acetate in hexanes to yield the title compound (0.27 g).

¹H NMR δ 8.39 (m, 1H), 7.65 (m, 2H), 7.28 (d, 1H), 7.01 (t, 1H), 5.68 (m, 1H), 3.96 (s, 3H), 2.62 (m, 1H), 1.79 (d, 3H), 0.64 (m, 2H), 0.52 (m, 1H), 0.35 (m, 1H).

Step C: Preparation of *N*-cyclopropyl-3-(difluoromethyl)-1-methyl-*N*-[1-[6-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]-3-pyridinyl]ethyl]-1*H*-pyrazole-4-carboxamide

A mixture of *N*-[1-(6-chloro-3-pyridinyl)ethyl]-*N*-cyclopropyl-3-(difluoromethyl)-1-methyl-1*H*-pyrazole-4-carboxamide (i.e. the product of Step B, 0.08 g, 0.23 mmol), 3-(trifluoromethyl)-1*H*-pyrazole (0.02 g, 0.15 mmol), *trans*-*N,N*-dimethyl-1,2-diaminocyclohexane (0.01 g, 0.07 mmol), copper(I) iodide (0.01 g, 0.05 mmol), and potassium carbonate (0.07 g, 0.51 mmol) in dioxanes (2 mL) was heated to 200 °C for 20 min in a microwave reactor. Upon cooling to room temperature, an aliquot was analyzed by liquid chromatography/mass spectrometry (LCMS) and found to contain the desired product. A second portion of *N*-[1-(6-chloro-3-pyridinyl)ethyl]-*N*-cyclopropyl-3-(difluoromethyl)-1-methyl-1*H*-pyrazole-4-carboxamide (0.12 g, 0.33 mmol) was reacted as described above, and the two crude reaction mixtures were combined and concentrated under reduced pressure. The residue was chromatographed on silica gel eluting with 80 to 100% ethyl acetate in hexanes to provide the title compound (0.23 g), a compound of the invention, as a brown oil.

¹H NMR δ 8.61 (m, 1H), 8.43 (m, 1H), 8.00 (m, 1H), 7.85 (m, 1H), 7.64 (s, 1H), 7.03 (t, 1H), 7.72 (m, 1H), 5.79 (m, 1H), 3.96 (s, 3H), 2.63 (m, 1H), 1.83 (d, 3H), 0.65 (m, 2H), 0.55 (m, 1H), 0.35 (m, 1H).

EXAMPLE 2

Preparation of *N*-cyclopropyl-3-(difluoromethyl)-1-methyl-*N*-[[3-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]phenyl]methyl]-1*H*-pyrazole-4-carboxamide (Compound 9)

Step A: Preparation of 3-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]benzaldehyde

3-Bromobenzaldehyde (1.0 g, 5.4 mmol, 1.0 eq.), 3-(trifluoromethyl)-pyrazole (730 mg, 1.0 eq.), Cu(I) iodide (210 mg, 0.20 eq.), and cesium carbonate (3.5 g, 2.0 eq.) were placed in a reaction vial. The vial was purged with nitrogen and *N,N*-dimethylformamide (10 mL) was added. The reaction was heated at 120 °C overnight and then cooled to ambient temperature. The resulting solids were removed by filtration and washed with diethyl ether. Water was added to the filtrate, the layers were separated and the aqueous phase was extracted twice with diethyl ether. The combined organic extracts were washed with water (4X), brine, dried (MgSO₄) and concentrated under reduced pressure. The resulting residue was purified by medium pressure liquid chromatography on silica gel eluting with 10 to 40% ethyl acetate in hexanes to yield the title compound (200 mg) as a white solid.

¹H NMR δ 10.10 (s, 1H), 8.19–8.24 (m, 1H), 8.03–8.09 (m, 2H), 7.89 (dt, 1H), 7.69 (t, 1H), 6.78 (d, 1H).

Step B: Preparation of *N*-cyclopropyl-3-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]benzenemethanamine

To a solution of 3-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]benzaldehyde (i.e. the product of Step A, 200 mg) in methanol (5 mL) was added cyclopropylamine (1 mL), and the resulting mixture was stirred at ambient temperature for 1 h. Excess sodium borohydride was then added, and the reaction mixture was stirred at room temperature for 1 h. The reaction was quenched by the addition of water. The layers were separated and the aqueous layer was extracted with dichloromethane (4X). The combined organic layers were dried (MgSO₄) and concentrated under reduced pressure. The resulting residue was purified by medium pressure liquid chromatography on silica gel eluting with 10 to 60% ethyl acetate in hexanes to yield the title compound (100 mg).

¹H NMR δ 7.95 (dd, 1H), 7.69 (t, 1H), 7.54–7.59 (m, 1H), 7.43 (t, 1H), 7.32 (d, 1H), 6.71 (d, 1H), 3.92 (s, 2H), 2.10–2.25 (m, 1H), 0.42–0.48 (m, 2H), 0.38–0.42 (m, 2H).

Step C: Preparation of *N*-cyclopropyl-3-(difluoromethyl)-1-methyl-*N*-[[3-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]phenyl]methyl]-1*H*-pyrazole-4-carboxamide

3-(Difluoromethyl)-1-methyl-1*H*-pyrazole-4-carboxylic acid (30 mg, 0.17 mmol, 1 eq.) was dissolved in thionyl chloride (1 mL) and the resulting solution was heated to reflux for 3 h. The reaction mixture was allowed to cool to room temperature and then concentrated under reduced pressure. To this material was added a solution of *N*-cyclopropyl-3-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]benzenemethanamine (i.e. the product of Step B, 46 mg, 1.0 eq.) and triethylamine (3.5 eq.) in dichloromethane (4 mL). The reaction mixture was stirred overnight at ambient temperature. The reaction was then quenched with water and extracted with dichloromethane. The organic phase was dried (MgSO₄) and concentrated under reduced pressure. The resulting residue was purified by medium pressure liquid chromatography on silica gel eluting with 20 to 80% ethyl acetate in hexanes followed by a second purification by medium pressure liquid chromatography on silica gel eluting with 1 to 10% acetone in chloroform to yield the title compound (35 mg), a compound of the invention, as a colorless oil.

¹H NMR δ 7.95 (dd, 1H), 7.67 (d, 2H), 7.62 (dd, 1H), 7.43–7.47 (m, 1H), 7.28–7.33 (m, 1H), 6.92–7.20 (m, 1H), 6.72 (d, 1H), 4.80 (s, 2H), 3.96 (s, 3H), 2.69–2.79 (m, 1H), 0.67–0.80 (m, 4H).

EXAMPLE 3

Preparation of *N*-[[2-chloro-4-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]phenyl]methyl]-*N*-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1*H*-pyrazole-4-carboxamide (Compound

Step A: Preparation of 2-chloro-4-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]benzaldehyde

A mixture of 2-chloro-4-fluorobenzaldehyde (7.0 g, 44.3 mmol), 3-(trifluoromethyl)-1*H*-pyrazole (9.03 g, 66.45 mmol) and potassium carbonate (12.2 g, 88.6 mmol) in anhydrous *N,N*-dimethylformamide (70 mL) was stirred for 2 h at 110 °C. The reaction mixture was cooled to 0 °C, poured into ice water (800 mL) and stirred for 15 min. The precipitate formed was filtered and dried under reduced pressure to afford the title compound (10.2 g), which was used without further purification.

¹H NMR δ 10.4 (s, 1H), 8.00 (m, 2H), 7.85 (d, 1H), 7.77 (m, 1H), 6.70 (d, 1H).

Step B: Preparation of 2-chloro-*N*-cyclopropyl-4-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]benzenemethanamine

To a solution of 2-chloro-4-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]benzaldehyde (i.e. the product of Step A, 1.0 g, 3.6 mmol) in anhydrous tetrahydrofuran (10 mL) was added cyclopropylamine (0.2 g, 4 mmol) and titanium(IV) isopropoxide (5.2 g, 18.2 mmol) at 0 °C. The resulting solution was stirred at ambient temperature for 4 h. Sodium borohydride (0.34 g, 9.0 mmol) was then added, and the mixture was stirred at room temperature for 6 h. The reaction mixture was poured into ice water and extracted with ethyl acetate (20 mL). The aqueous layer was extracted with ethyl acetate (2 X 25 mL), and the combined organic layers were washed with brine (50 mL), dried (Na₂SO₄) and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with 50% ethyl acetate in hexanes to afford the title compound (0.6 g).

Step C: Preparation *N*-[[2-chloro-4-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]phenyl]methyl]-*N*-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1*H*-pyrazole-4-carboxamide

To a solution of 2-chloro-*N*-cyclopropyl-4-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]benzenemethanamine (i.e. the product of Step B, 150 mg, 0.47 mmol), *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide (137 mg, 0.71 mmol), 1-hydroxybenzotriazole (77 mg, 0.57 mmol) and *N,N*-diisopropylethylamine (0.25 mL, 1.43 mmol) in dichloromethane (5 mL) was added 3-difluoromethyl-5-fluoro-1-methyl-1*H*-pyrazole-4-carboxylic acid (92 mg, 0.47 mmol; prepared as described in PCT Patent Publication WO 2010/130767), was stirred for 12 h. The reaction mixture was washed with water, brine, dried (Na₂SO₄) and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluting with 50% ethyl acetate in hexanes to afford the title compound (100 mg), a compound of the invention, as an off-white solid.

¹H NMR δ 7.94 (s, 1H), 7.82 (d, 1H), 7.58 (dd, 1H), 7.40 (d, 1H), 6.80 (t, 1H), 6.70 (d, 1H), 4.84 (s, 2H), 3.80 (s, 3H), 2.78 (m, 1H), 0.70 (m, 4H).

By the procedures described herein together with methods known in the art, the following compounds of Tables 1 to 1539 can be prepared. The following abbreviations are

used in the Tables which follow: Me means methyl, Et means ethyl, Pr means propyl, *i*-Pr means isopropyl, *c*-Pr means cyclopropyl, OMe means methoxy, TMS means trimethylsilyl, Ph means phenyl, MeOC(=O) means methoxycarbonyl and CN means cyano. “(R³)_n is H” means that n is 0 and the ring comprising G is not substituted with R³. The structures of individual “A” substituents in the Tables are depicted in Exhibit 4.

Exhibit 4





TABLE 1



A is A-1a and (R³)_n is H.

Q	Q	Q
3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	3-Me-1 <i>H</i> -pyrazol-1-yl	3-F-1 <i>H</i> -pyrazol-1-yl
3-Br-1 <i>H</i> -pyrazol-1-yl	4-CF ₃ -1 <i>H</i> -pyrazol-1-yl	4-Me-1 <i>H</i> -pyrazol-1-yl
4-F-1 <i>H</i> -pyrazol-1-yl	4-Br-1 <i>H</i> -pyrazol-1-yl	5-CF ₃ -1 <i>H</i> -pyrazol-1-yl
5-Me-1 <i>H</i> -pyrazol-1-yl	5-F-1 <i>H</i> -pyrazol-1-yl	5-Br-1 <i>H</i> -pyrazol-1-yl
3-CHF ₂ -1 <i>H</i> -pyrazol-1-yl	3-Et-1 <i>H</i> -pyrazol-1-yl	3-Cl-1 <i>H</i> -pyrazol-1-yl
3-I-1 <i>H</i> -pyrazol-1-yl	4-CHF ₂ -1 <i>H</i> -pyrazol-1-yl	4-Et-1 <i>H</i> -pyrazol-1-yl
4-Cl-1 <i>H</i> -pyrazol-1-yl	4-I-1 <i>H</i> -pyrazol-1-yl	5-CHF ₂ -1 <i>H</i> -pyrazol-1-yl
5-Et-1 <i>H</i> -pyrazol-1-yl	5-Cl-1 <i>H</i> -pyrazol-1-yl	3-I-1 <i>H</i> -pyrazol-1-yl
3-OMe-1 <i>H</i> -pyrazol-1-yl	3-CN-1 <i>H</i> -pyrazol-1-yl	3-OCF ₃ -1 <i>H</i> -pyrazol-1-yl
3-OCHF ₂ -1 <i>H</i> -pyrazol-1-yl	4-OMe-1 <i>H</i> -pyrazol-1-yl	4-CN-1 <i>H</i> -pyrazol-1-yl
4-OCF ₃ -1 <i>H</i> -pyrazol-1-yl	4-OCHF ₂ -1 <i>H</i> -pyrazol-1-yl	5-OCF ₃ -1 <i>H</i> -pyrazol-1-yl

5-CN-1 <i>H</i> -pyrazol-1-yl	5-OCF ₃ -1 <i>H</i> -pyrazol-1-yl	5-OCHF ₂ -1 <i>H</i> -pyrazol-1-yl
3-MeOC(=O)-1 <i>H</i> -pyrazol-1-yl	3-Ph-1 <i>H</i> -pyrazol-1-yl	3,5-di-Me-1 <i>H</i> -pyrazol-1-yl
3,5-di-F-1 <i>H</i> -pyrazol-1-yl	4-MeOC(=O)-1 <i>H</i> -pyrazol-1-yl	4-Ph-1 <i>H</i> -pyrazol-1-yl
3,5-di-CF ₃ -1 <i>H</i> -pyrazol-1-yl	3,5-di-Cl-1 <i>H</i> -pyrazol-1-yl	5-MeOC(=O)-1 <i>H</i> -pyrazol-1-yl
5-Ph-1 <i>H</i> -pyrazol-1-yl	3,5-di-CHF ₂ -1 <i>H</i> -pyrazol-1-yl	3,5-di-Br-1 <i>H</i> -pyrazol-1-yl
3-CF ₃ -5-Me-1 <i>H</i> -pyrazol-1-yl	3,4-di-Me-1 <i>H</i> -pyrazol-1-yl	3,4-di-CF ₃ -1 <i>H</i> -pyrazol-1-yl
3,4-di-Br-1 <i>H</i> -pyrazol-1-yl	3,4-di-Cl-1 <i>H</i> -pyrazol-1-yl	1 <i>H</i> -pyrazol-1-yl
3-Me-1 <i>H</i> -[1,2,4]triazol-1-yl	3-CF ₃ -1 <i>H</i> -[1,2,4]triazol-1-yl	3-CHF ₂ -1 <i>H</i> -[1,2,4]triazol-1-yl
3-F-1 <i>H</i> -[1,2,4]triazol-1-yl	3-Cl-1 <i>H</i> -[1,2,4]triazol-1-yl	3-Br-1 <i>H</i> -[1,2,4]triazol-1-yl
3,5-di-Cl-1 <i>H</i> -[1,2,4]triazol-1-yl	3,5-di-Br-1 <i>H</i> -[1,2,4]triazol-1-yl	3-Ph-1 <i>H</i> -[1,2,4]triazol-1-yl
1 <i>H</i> -[1,2,4]triazol-1-yl	4-Me-2 <i>H</i> -[1,2,3]triazol-2-yl	4-CF ₃ -2 <i>H</i> -[1,2,3]triazol-2-yl
4-CHF ₂ -2 <i>H</i> -[1,2,3]triazol-2-yl	4-F-2 <i>H</i> -[1,2,3]triazol-2-yl	4-Cl-2 <i>H</i> -[1,2,3]triazol-2-yl
4-Br-2 <i>H</i> -[1,2,3]triazol-2-yl	4-Ph-2 <i>H</i> -[1,2,3]triazol-2-yl	4,5-di-Me-2 <i>H</i> -[1,2,3]triazol-2-yl
4,5-di-CF ₃ -2 <i>H</i> -[1,2,3]triazol-2-yl	4,5-di-Cl-2 <i>H</i> -[1,2,3]triazol-2-yl	4,5-di-Br-2 <i>H</i> -[1,2,3]triazol-2-yl
2 <i>H</i> -[1,2,3]triazol-2-yl	4-Me-1 <i>H</i> -[1,2,3]triazol-1-yl	4-CF ₃ -1 <i>H</i> -[1,2,3]triazol-1-yl
4-CHF ₂ -1 <i>H</i> -[1,2,3]triazol-1-yl	4-F-1 <i>H</i> -[1,2,3]triazol-1-yl	4-Cl-1 <i>H</i> -[1,2,3]triazol-1-yl
4-Br-1 <i>H</i> -[1,2,3]triazol-1-yl	4-Ph-1 <i>H</i> -[1,2,3]triazol-1-yl	1 <i>H</i> -[1,2,3]triazol-1-yl
3-Me-1 <i>H</i> -pyrrol-1-yl	3-CF ₃ -1 <i>H</i> -pyrrol-1-yl	3-CHF ₂ -1 <i>H</i> -pyrrol-1-yl
3,4-di-Me-1 <i>H</i> -pyrrol-1-yl	2,4-di-Me-1 <i>H</i> -pyrrol-1-yl	3,4-di-CF ₃ -1 <i>H</i> -pyrrol-1-yl
2,4-di-CF ₃ -1 <i>H</i> -pyrrol-1-yl	3,4-di-Br-1 <i>H</i> -pyrrol-1-yl	3,4-di-Cl-1 <i>H</i> -pyrrol-1-yl
1 <i>H</i> -pyrrol-1-yl	1-Me-1 <i>H</i> -pyrazol-3-yl	1-CF ₃ -1 <i>H</i> -pyrazol-3-yl
1-Et-1 <i>H</i> -pyrazol-3-yl	1- <i>i</i> -Pr-1 <i>H</i> -pyrazol-3-yl	1-(F ₃ CCH ₂)-1 <i>H</i> -pyrazol-3-yl
1-Ph-1 <i>H</i> -pyrazol-3-yl	1,4-di-Me-1 <i>H</i> -pyrazol-3-yl	1-Me-4-CF ₃ -1 <i>H</i> -pyrazol-3-yl
1-Me-1 <i>H</i> -pyrazol-4-yl	1-CF ₃ -1 <i>H</i> -pyrazol-4-yl	1-Et-1 <i>H</i> -pyrazol-4-yl
1- <i>i</i> -Pr-1 <i>H</i> -pyrazol-4-yl	1-(F ₃ CCH ₂)-1 <i>H</i> -pyrazol-4-yl	1-Ph-1 <i>H</i> -pyrazol-4-yl
1,3-di-Me-1 <i>H</i> -pyrazol-4-yl	1-Me-3-CF ₃ -1 <i>H</i> -pyrazol-4-yl	3-Me-1-CF ₃ -1 <i>H</i> -pyrazol-4-yl
1-Me-1 <i>H</i> -[1,2,4]triazol-3-yl	1-CF ₃ -1 <i>H</i> -[1,2,4]triazol-3-yl	1-Et-1 <i>H</i> -[1,2,4]triazol-3-yl
1- <i>i</i> -Pr-1 <i>H</i> -[1,2,4]triazol-3-yl	1-Ph-1 <i>H</i> -[1,2,4]triazol-3-yl	5-Ph-4,5-dihydro-isoxazol-3-yl
3,5-di-Me-1 <i>H</i> -[1,2,4]triazol-1-yl	3,5-di-CF ₃ -1 <i>H</i> -[1,2,4]triazol-1-yl	3,5-di-CHF ₂ -1 <i>H</i> -[1,2,4]triazol-
5-CF ₃ -2,4-dihydro-3-oxopyrazol-	5-Me-2,4-dihydro-3-oxopyrazol-	1-yl
1-yl	1-yl	

The present disclosure also includes Tables 2 through 769, each of which is constructed the same as Table 1 above, except that the row heading in Table 1 (i.e. “A is A-1a and R³ is H.”) is replaced with the respective row heading shown below. For example, in Table 2 the row heading is “A is A-1a and R³ is 2-F and Q is as defined in Table 1 above.

5 Thus, the first entry in Table 2 specifically discloses *N*-[[2-fluoro-4-(3-trifluoromethyl-1*H*-

pyrazol-1-yl)phenyl]methyl]-*N*-cyclopropyl-3-(trifluoromethyl)-1-methyl-1*H*-pyrazole-4-carboxamide. Tables 3 through 769 are constructed similarly.

TABLES 2–761

Table	Row Heading	Table	Row Heading
2	A is A-1a and (R ³) _n is 2-F.	386	A is A-1j and (R ³) _n is 2,5-di-TMS.
3	A is A-1a and (R ³) _n is 2,3-di-F.	387	A is A-1j and (R ³) _n is 3,5-di-TMS.
4	A is A-1a and (R ³) _n is 2,6-di-F.	388	A is A-1j and (R ³) _n is 2-Cl-6-Me.
5	A is A-1a and (R ³) _n is 2-Cl.	389	A is A-1j and (R ³) _n is 2-Cl-5-Me.
6	A is A-1a and (R ³) _n is 2,3-di-Cl.	390	A is A-1a and (R ³) _n is 3-F.
7	A is A-1a and (R ³) _n is 2,6-di-Cl.	391	A is A-1a and (R ³) _n is 2,5-di-F.
8	A is A-1a and (R ³) _n is 2-Br.	392	A is A-1a and (R ³) _n is 3,5-di-F.
9	A is A-1a and (R ³) _n is 2,3-di-Br.	393	A is A-1a and (R ³) _n is 3-Cl.
10	A is A-1a and (R ³) _n is 2,6-di-Br.	394	A is A-1a and (R ³) _n is 2,5-di-Cl.
11	A is A-1a and (R ³) _n is 2-I.	395	A is A-1a and (R ³) _n is 3,5-di-Cl.
12	A is A-1a and (R ³) _n is 2,3-di-I.	396	A is A-1a and (R ³) _n is 3-Br.
13	A is A-1a and (R ³) _n is 2,6-di-I.	397	A is A-1a and (R ³) _n is 2,5-di-Br.
14	A is A-1a and (R ³) _n is 2-Me.	398	A is A-1a and (R ³) _n is 3,5-di-Br.
15	A is A-1a and (R ³) _n is 2,3-di-Me.	399	A is A-1a and (R ³) _n is 3-I.
16	A is A-1a and (R ³) _n is 2,6-di-Me.	400	A is A-1a and (R ³) _n is 2,5-di-I.
17	A is A-1a and (R ³) _n is 2-Et.	401	A is A-1a and (R ³) _n is 3,5-di-I.
18	A is A-1a and (R ³) _n is 2,3-di-Et.	402	A is A-1a and (R ³) _n is 3-Me.
19	A is A-1a and (R ³) _n is 2,6-di-Et.	403	A is A-1a and (R ³) _n is 2,5-di-Me.
20	A is A-1a and (R ³) _n is 2- <i>i</i> -Pr.	404	A is A-1a and (R ³) _n is 3,5-di-Me.
21	A is A-1a and (R ³) _n is 2,3-di- <i>i</i> -Pr.	405	A is A-1a and (R ³) _n is 3-Et.
22	A is A-1a and (R ³) _n is 2,6-di- <i>i</i> -Pr.	406	A is A-1a and (R ³) _n is 2,5-di-Et.
23	A is A-1a and (R ³) _n is 2- <i>c</i> -Pr.	407	A is A-1a and (R ³) _n is 3,5-di-Et.
24	A is A-1a and (R ³) _n is 2,3-di- <i>c</i> -Pr.	408	A is A-1a and (R ³) _n is 3- <i>i</i> -Pr.
25	A is A-1a and (R ³) _n is 2,6-di- <i>c</i> -Pr.	409	A is A-1a and (R ³) _n is 2,5-di- <i>i</i> -Pr.
26	A is A-1a and (R ³) _n is 2-CF ₃ .	410	A is A-1a and (R ³) _n is 3,5-di- <i>i</i> -Pr.
27	A is A-1a and (R ³) _n is 2,3-di-CF ₃ .	411	A is A-1a and (R ³) _n is 3- <i>c</i> -Pr.
28	A is A-1a and (R ³) _n is 2,6-di-CF ₃ .	412	A is A-1a and (R ³) _n is 2,5-di- <i>c</i> -Pr.
29	A is A-1a and (R ³) _n is 2-OMe.	413	A is A-1a and (R ³) _n is 3,5-di- <i>c</i> -Pr.
30	A is A-1a and (R ³) _n is 2,3-di-OMe.	414	A is A-1a and (R ³) _n is 3-CF ₃ .
31	A is A-1a and (R ³) _n is 2,6-di-OMe.	415	A is A-1a and (R ³) _n is 2,5-di-CF ₃ .
32	A is A-1a and (R ³) _n is 2-OCF ₃ .	416	A is A-1a and (R ³) _n is 3,5-di-CF ₃ .
33	A is A-1a and (R ³) _n is 2,3-di-OCF ₃ .	417	A is A-1a and (R ³) _n is 3-OMe.
34	A is A-1a and (R ³) _n is 2,6-di-OCF ₃ .	418	A is A-1a and (R ³) _n is 2,5-di-OMe.

Table	Row Heading	Table	Row Heading
35	A is A-1a and (R ³) _n is 2-TMS.	419	A is A-1a and (R ³) _n is 3,5-di-OMe.
36	A is A-1a and (R ³) _n is 2,3-di-TMS.	420	A is A-1a and (R ³) _n is 3-OCF ₃ .
37	A is A-1a and (R ³) _n is 2,6-di-TMS.	421	A is A-1a and (R ³) _n is 2,5-di-OCF ₃ .
38	A is A-1a and (R ³) _n is 2-Cl-6-F.	422	A is A-1a and (R ³) _n is 3,5-di-OCF ₃ .
39	A is A-1a and (R ³) _n is 2-Cl-5-F.	423	A is A-1a and (R ³) _n is 3-TMS.
40	A is A-1b and (R ³) _n is H.	424	A is A-1a and (R ³) _n is 2,5-di-TMS.
41	A is A-1b and (R ³) _n is 2-F.	425	A is A-1a and (R ³) _n is 3,5-di-TMS.
42	A is A-1b and (R ³) _n is 2,3-di-F.	426	A is A-1a and (R ³) _n is 2-Cl-6-Me.
43	A is A-1b and (R ³) _n is 2,6-di-F.	427	A is A-1a and (R ³) _n is 2-Cl-5-Me.
44	A is A-1b and (R ³) _n is 2-Cl.	428	A is A-1b and (R ³) _n is 3-F.
45	A is A-1b and (R ³) _n is 2,3-di-Cl.	429	A is A-1b and (R ³) _n is 2,5-di-F.
46	A is A-1b and (R ³) _n is 2,6-di-Cl.	430	A is A-1b and (R ³) _n is 3,5-di-F.
47	A is A-1b and (R ³) _n is 2-Br.	431	A is A-1b and (R ³) _n is 3-Cl.
48	A is A-1b and (R ³) _n is 2,3-di-Br.	432	A is A-1b and (R ³) _n is 2,5-di-Cl.
49	A is A-1b and (R ³) _n is 2,6-di-Br.	433	A is A-1b and (R ³) _n is 3,5-di-Cl.
50	A is A-1b and (R ³) _n is 2-I.	434	A is A-1b and (R ³) _n is 3-Br.
51	A is A-1b and (R ³) _n is 2,3-di-I.	435	A is A-1b and (R ³) _n is 2,5-di-Br.
52	A is A-1b and (R ³) _n is 2,6-di-I.	436	A is A-1b and (R ³) _n is 3,5-di-Br.
53	A is A-1b and (R ³) _n is 2-Me.	437	A is A-1b and (R ³) _n is 3-I.
54	A is A-1b and (R ³) _n is 2,3-di-Me.	438	A is A-1b and (R ³) _n is 2,5-di-I.
55	A is A-1b and (R ³) _n is 2,6-di-Me.	439	A is A-1b and (R ³) _n is 3,5-di-I.
56	A is A-1b and (R ³) _n is 2-Et.	440	A is A-1b and (R ³) _n is 3-Me.
57	A is A-1b and (R ³) _n is 2,3-di-Et.	441	A is A-1b and (R ³) _n is 2,5-di-Me.
58	A is A-1b and (R ³) _n is 2,6-di-Et.	442	A is A-1b and (R ³) _n is 3,5-di-Me.
59	A is A-1b and (R ³) _n is 2- <i>i</i> -Pr.	443	A is A-1b and (R ³) _n is 3-Et.
60	A is A-1b and (R ³) _n is 2,3-di- <i>i</i> -Pr.	444	A is A-1b and (R ³) _n is 2,5-di-Et.
61	A is A-1b and (R ³) _n is 2,6-di- <i>i</i> -Pr.	445	A is A-1b and (R ³) _n is 3,5-di-Et.
62	A is A-1b and (R ³) _n is 2- <i>c</i> -Pr.	446	A is A-1b and (R ³) _n is 3- <i>i</i> -Pr.
63	A is A-1b and (R ³) _n is 2,3-di- <i>c</i> -Pr.	447	A is A-1b and (R ³) _n is 2,5-di- <i>i</i> -Pr.
64	A is A-1b and (R ³) _n is 2,6-di- <i>c</i> -Pr.	448	A is A-1b and (R ³) _n is 3,5-di- <i>i</i> -Pr.
65	A is A-1b and (R ³) _n is 2-CF ₃ .	449	A is A-1b and (R ³) _n is 3- <i>c</i> -Pr.
66	A is A-1b and (R ³) _n is 2,3-di-CF ₃ .	450	A is A-1b and (R ³) _n is 2,5-di- <i>c</i> -Pr.
67	A is A-1b and (R ³) _n is 2,6-di-CF ₃ .	451	A is A-1b and (R ³) _n is 3,5-di- <i>c</i> -Pr.
68	A is A-1b and (R ³) _n is 2-OMe.	452	A is A-1b and (R ³) _n is 3-CF ₃ .
69	A is A-1b and (R ³) _n is 2,3-di-OMe.	453	A is A-1b and (R ³) _n is 2,5-di-CF ₃ .
70	A is A-1b and (R ³) _n is 2,6-di-OMe.	454	A is A-1b and (R ³) _n is 3,5-di-CF ₃ .
71	A is A-1b and (R ³) _n is 2-OCF ₃ .	455	A is A-1b and (R ³) _n is 3-OMe.

Table	Row Heading	Table	Row Heading
72	A is A-1b and (R ³) _n is 2,3-di-OCF ₃ .	456	A is A-1b and (R ³) _n is 2,5-di-OMe.
73	A is A-1b and (R ³) _n is 2,6-di-OCF ₃ .	457	A is A-1b and (R ³) _n is 3,5-di-OMe.
74	A is A-1b and (R ³) _n is 2-TMS.	458	A is A-1b and (R ³) _n is 3-OCF ₃ .
75	A is A-1b and (R ³) _n is 2,3-di-TMS.	459	A is A-1b and (R ³) _n is 2,5-di-OCF ₃ .
76	A is A-1b and (R ³) _n is 2,6-di-TMS.	460	A is A-1b and (R ³) _n is 3,5-di-OCF ₃ .
77	A is A-1b and (R ³) _n is 2-Cl-6-F.	461	A is A-1b and (R ³) _n is 3-TMS.
78	A is A-1b and (R ³) _n is 2-Cl-5-F.	462	A is A-1b and (R ³) _n is 2,5-di-TMS.
78	A is A-1c and (R ³) _n is H.	463	A is A-1b and (R ³) _n is 3,5-di-TMS.
79	A is A-1c and (R ³) _n is 2-F.	464	A is A-1b and (R ³) _n is 2-Cl-6-Me.
80	A is A-1c and (R ³) _n is 2,3-di-F.	465	A is A-1b and (R ³) _n is 2-Cl-5-Me.
81	A is A-1c and (R ³) _n is 2,6-di-F.	466	A is A-1c and (R ³) _n is 3-F.
82	A is A-1c and (R ³) _n is 2-Cl.	467	A is A-1c and (R ³) _n is 2,5-di-F.
83	A is A-1c and (R ³) _n is 2,3-di-Cl.	468	A is A-1c and (R ³) _n is 3,5-di-F.
84	A is A-1c and (R ³) _n is 2,6-di-Cl.	469	A is A-1c and (R ³) _n is 3-Cl.
85	A is A-1c and (R ³) _n is 2-Br.	470	A is A-1c and (R ³) _n is 2,5-di-Cl.
86	A is A-1c and (R ³) _n is 2,3-di-Br.	471	A is A-1c and (R ³) _n is 3,5-di-Cl.
87	A is A-1c and (R ³) _n is 2,6-di-Br.	472	A is A-1c and (R ³) _n is 3-Br.
88	A is A-1c and (R ³) _n is 2-I.	473	A is A-1c and (R ³) _n is 2,5-di-Br.
89	A is A-1c and (R ³) _n is 2,3-di-I.	474	A is A-1c and (R ³) _n is 3,5-di-Br.
90	A is A-1c and (R ³) _n is 2,6-di-I.	475	A is A-1c and (R ³) _n is 3-I.
91	A is A-1c and (R ³) _n is 2-Me.	476	A is A-1c and (R ³) _n is 2,5-di-I.
92	A is A-1c and (R ³) _n is 2,3-di-Me.	477	A is A-1c and (R ³) _n is 3,5-di-I.
93	A is A-1c and (R ³) _n is 2,6-di-Me.	478	A is A-1c and (R ³) _n is 3-Me.
94	A is A-1c and (R ³) _n is 2-Et.	479	A is A-1c and (R ³) _n is 2,5-di-Me.
95	A is A-1c and (R ³) _n is 2,3-di-Et.	480	A is A-1c and (R ³) _n is 3,5-di-Me.
96	A is A-1c and (R ³) _n is 2,6-di-Et.	481	A is A-1c and (R ³) _n is 3-Et.
97	A is A-1c and (R ³) _n is 2- <i>i</i> -Pr.	482	A is A-1c and (R ³) _n is 2,5-di-Et.
98	A is A-1c and (R ³) _n is 2,3-di- <i>i</i> -Pr.	483	A is A-1c and (R ³) _n is 3,5-di-Et.
99	A is A-1c and (R ³) _n is 2,6-di- <i>i</i> -Pr.	484	A is A-1c and (R ³) _n is 3- <i>i</i> -Pr.
100	A is A-1c and (R ³) _n is 2- <i>c</i> -Pr.	485	A is A-1c and (R ³) _n is 2,5-di- <i>i</i> -Pr.
101	A is A-1c and (R ³) _n is 2,3-di- <i>c</i> -Pr.	486	A is A-1c and (R ³) _n is 3,5-di- <i>i</i> -Pr.
102	A is A-1c and (R ³) _n is 2,6-di- <i>c</i> -Pr.	487	A is A-1c and (R ³) _n is 3- <i>c</i> -Pr.
103	A is A-1c and (R ³) _n is 2-CF ₃ .	488	A is A-1c and (R ³) _n is 2,5-di- <i>c</i> -Pr.
104	A is A-1c and (R ³) _n is 2,3-di-CF ₃ .	489	A is A-1c and (R ³) _n is 3,5-di- <i>c</i> -Pr.
105	A is A-1c and (R ³) _n is 2,6-di-CF ₃ .	490	A is A-1c and (R ³) _n is 3-CF ₃ .
106	A is A-1c and (R ³) _n is 2-OMe.	491	A is A-1c and (R ³) _n is 2,5-di-CF ₃ .
107	A is A-1c and (R ³) _n is 2,3-di-OMe.	492	A is A-1c and (R ³) _n is 3,5-di-CF ₃ .

Table	Row Heading	Table	Row Heading
108	A is A-1c and (R ³) _n is 2,6-di-OMe.	493	A is A-1c and (R ³) _n is 3-OMe.
109	A is A-1c and (R ³) _n is 2-OCF ₃ .	494	A is A-1c and (R ³) _n is 2,5-di-OMe.
110	A is A-1c and (R ³) _n is 2,3-di-OCF ₃ .	495	A is A-1c and (R ³) _n is 3,5-di-OMe.
111	A is A-1c and (R ³) _n is 2,6-di-OCF ₃ .	496	A is A-1c and (R ³) _n is 3-OCF ₃ .
112	A is A-1c and (R ³) _n is 2-TMS.	497	A is A-1c and (R ³) _n is 2,5-di-OCF ₃ .
113	A is A-1c and (R ³) _n is 2,3-di-TMS.	498	A is A-1c and (R ³) _n is 3,5-di-OCF ₃ .
114	A is A-1c and (R ³) _n is 2,6-di-TMS.	499	A is A-1c and (R ³) _n is 3-TMS.
115	A is A-1c and (R ³) _n is 2-Cl-6-F.	500	A is A-1c and (R ³) _n is 2,5-di-TMS.
116	A is A-1c and (R ³) _n is 2-Cl-5-F.	501	A is A-1c and (R ³) _n is 3,5-di-TMS.
117	A is A-1d and (R ³) _n is H.	502	A is A-1c and (R ³) _n is 2-Cl-6-Me.
118	A is A-1d and (R ³) _n is 2-F.	503	A is A-1c and (R ³) _n is 2-Cl-5-Me.
119	A is A-1d and (R ³) _n is 2,3-di-F.	504	A is A-1d and (R ³) _n is 3-F.
120	A is A-1d and (R ³) _n is 2,6-di-F.	505	A is A-1d and (R ³) _n is 2,5-di-F.
121	A is A-1d and (R ³) _n is 2-Cl.	506	A is A-1d and (R ³) _n is 3,5-di-F.
122	A is A-1d and (R ³) _n is 2,3-di-Cl.	507	A is A-1d and (R ³) _n is 3-Cl.
123	A is A-1d and (R ³) _n is 2,6-di-Cl.	508	A is A-1d and (R ³) _n is 2,5-di-Cl.
124	A is A-1d and (R ³) _n is 2-Br.	509	A is A-1d and (R ³) _n is 3,5-di-Cl.
125	A is A-1d and (R ³) _n is 2,3-di-Br.	510	A is A-1d and (R ³) _n is 3-Br.
126	A is A-1d and (R ³) _n is 2,6-di-Br.	511	A is A-1d and (R ³) _n is 2,5-di-Br.
127	A is A-1d and (R ³) _n is 2-I.	512	A is A-1d and (R ³) _n is 3,5-di-Br.
128	A is A-1d and (R ³) _n is 2,3-di-I.	513	A is A-1d and (R ³) _n is 3-I.
129	A is A-1d and (R ³) _n is 2,6-di-I.	514	A is A-1d and (R ³) _n is 2,5-di-I.
130	A is A-1d and (R ³) _n is 2-Me.	515	A is A-1d and (R ³) _n is 3,5-di-I.
131	A is A-1d and (R ³) _n is 2,3-di-Me.	516	A is A-1d and (R ³) _n is 3-Me.
132	A is A-1d and (R ³) _n is 2,6-di-Me.	517	A is A-1d and (R ³) _n is 2,5-di-Me.
133	A is A-1d and (R ³) _n is 2-Et.	518	A is A-1d and (R ³) _n is 3,5-di-Me.
134	A is A-1d and (R ³) _n is 2,3-di-Et.	519	A is A-1d and (R ³) _n is 3-Et.
135	A is A-1d and (R ³) _n is 2,6-di-Et.	520	A is A-1d and (R ³) _n is 2,5-di-Et.
136	A is A-1d and (R ³) _n is 2- <i>i</i> -Pr.	521	A is A-1d and (R ³) _n is 3,5-di-Et.
137	A is A-1d and (R ³) _n is 2,3-di- <i>i</i> -Pr.	522	A is A-1d and (R ³) _n is 3- <i>i</i> -Pr.
138	A is A-1d and (R ³) _n is 2,6-di- <i>i</i> -Pr.	523	A is A-1d and (R ³) _n is 2,5-di- <i>i</i> -Pr.
139	A is A-1d and (R ³) _n is 2- <i>c</i> -Pr.	524	A is A-1d and (R ³) _n is 3,5-di- <i>i</i> -Pr.
140	A is A-1d and (R ³) _n is 2,3-di- <i>c</i> -Pr.	525	A is A-1d and (R ³) _n is 3- <i>c</i> -Pr.
141	A is A-1d and (R ³) _n is 2,6-di- <i>c</i> -Pr.	526	A is A-1d and (R ³) _n is 2,5-di- <i>c</i> -Pr.
142	A is A-1d and (R ³) _n is 2-CF ₃ .	527	A is A-1d and (R ³) _n is 3,5-di- <i>c</i> -Pr.
143	A is A-1d and (R ³) _n is 2,3-di-CF ₃ .	528	A is A-1d and (R ³) _n is 3-CF ₃ .
144	A is A-1d and (R ³) _n is 2,6-di-CF ₃ .	529	A is A-1d and (R ³) _n is 2,5-di-CF ₃ .

Table	Row Heading	Table	Row Heading
145	A is A-1d and (R ³) _n is 2-OMe.	530	A is A-1d and (R ³) _n is 3,5-di-CF ₃ .
146	A is A-1d and (R ³) _n is 2,3-di-OMe.	531	A is A-1d and (R ³) _n is 3-OMe.
147	A is A-1d and (R ³) _n is 2,6-di-OMe.	532	A is A-1d and (R ³) _n is 2,5-di-OMe.
148	A is A-1d and (R ³) _n is 2-OCF ₃ .	533	A is A-1d and (R ³) _n is 3,5-di-OMe.
149	A is A-1d and (R ³) _n is 2,3-di-OCF ₃ .	534	A is A-1d and (R ³) _n is 3-OCF ₃ .
150	A is A-1d and (R ³) _n is 2,6-di-OCF ₃ .	535	A is A-1d and (R ³) _n is 2,5-di-OCF ₃ .
151	A is A-1d and (R ³) _n is 2-TMS.	536	A is A-1d and (R ³) _n is 3,5-di-OCF ₃ .
152	A is A-1d and (R ³) _n is 2,3-di-TMS.	537	A is A-1d and (R ³) _n is 3-TMS.
153	A is A-1d and (R ³) _n is 2,6-di-TMS.	538	A is A-1d and (R ³) _n is 2,5-di-TMS.
154	A is A-1d and (R ³) _n is 2-Cl-6-F.	539	A is A-1d and (R ³) _n is 3,5-di-TMS.
155	A is A-1d and (R ³) _n is 2-Cl-5-F.	540	A is A-1d and (R ³) _n is 2-Cl-6-Me.
156	A is A-1e and (R ³) _n is H.	541	A is A-1d and (R ³) _n is 2-Cl-5-Me.
157	A is A-1e and (R ³) _n is 2-F.	542	A is A-1e and (R ³) _n is 3-F.
158	A is A-1e and (R ³) _n is 2,3-di-F.	543	A is A-1e and (R ³) _n is 2,5-di-F.
159	A is A-1e and (R ³) _n is 2,6-di-F.	544	A is A-1e and (R ³) _n is 3,5-di-F.
160	A is A-1e and (R ³) _n is 2-Cl.	545	A is A-1e and (R ³) _n is 3-Cl.
161	A is A-1e and (R ³) _n is 2,3-di-Cl.	546	A is A-1e and (R ³) _n is 2,5-di-Cl.
162	A is A-1e and (R ³) _n is 2,6-di-Cl.	547	A is A-1e and (R ³) _n is 3,5-di-Cl.
163	A is A-1e and (R ³) _n is 2-Br.	548	A is A-1e and (R ³) _n is 3-Br.
164	A is A-1e and (R ³) _n is 2,3-di-Br.	549	A is A-1e and (R ³) _n is 2,5-di-Br.
165	A is A-1e and (R ³) _n is 2,6-di-Br.	550	A is A-1e and (R ³) _n is 3,5-di-Br.
166	A is A-1e and (R ³) _n is 2-I.	551	A is A-1e and (R ³) _n is 3-I.
167	A is A-1e and (R ³) _n is 2,3-di-I.	552	A is A-1e and (R ³) _n is 2,5-di-I.
168	A is A-1e and (R ³) _n is 2,6-di-I.	553	A is A-1e and (R ³) _n is 3,5-di-I.
169	A is A-1e and (R ³) _n is 2-Me.	554	A is A-1e and (R ³) _n is 3-Me.
170	A is A-1e and (R ³) _n is 2,3-di-Me.	555	A is A-1e and (R ³) _n is 2,5-di-Me.
171	A is A-1e and (R ³) _n is 2,6-di-Me.	556	A is A-1e and (R ³) _n is 3,5-di-Me.
172	A is A-1e and (R ³) _n is 2-Et.	557	A is A-1e and (R ³) _n is 3-Et.
173	A is A-1e and (R ³) _n is 2,3-di-Et.	558	A is A-1e and (R ³) _n is 2,5-di-Et.
174	A is A-1e and (R ³) _n is 2,6-di-Et.	559	A is A-1e and (R ³) _n is 3,5-di-Et.
175	A is A-1e and (R ³) _n is 2- <i>i</i> -Pr.	560	A is A-1e and (R ³) _n is 3- <i>i</i> -Pr.
176	A is A-1e and (R ³) _n is 2,3-di- <i>i</i> -Pr.	561	A is A-1e and (R ³) _n is 2,5-di- <i>i</i> -Pr.
177	A is A-1e and (R ³) _n is 2,6-di- <i>i</i> -Pr.	562	A is A-1e and (R ³) _n is 3,5-di- <i>i</i> -Pr.
178	A is A-1e and (R ³) _n is 2- <i>c</i> -Pr.	563	A is A-1e and (R ³) _n is 3- <i>c</i> -Pr.
179	A is A-1e and (R ³) _n is 2,3-di- <i>c</i> -Pr.	564	A is A-1e and (R ³) _n is 2,5-di- <i>c</i> -Pr.
180	A is A-1e and (R ³) _n is 2,6-di- <i>c</i> -Pr.	565	A is A-1e and (R ³) _n is 3,5-di- <i>c</i> -Pr.
181	A is A-1e and (R ³) _n is 2-CF ₃ .	566	A is A-1e and (R ³) _n is 3-CF ₃ .

Table	Row Heading	Table	Row Heading
182	A is A-1e and (R ³) _n is 2,3-di-CF ₃ .	567	A is A-1e and (R ³) _n is 2,5-di-CF ₃ .
183	A is A-1e and (R ³) _n is 2,6-di-CF ₃ .	568	A is A-1e and (R ³) _n is 3,5-di-CF ₃ .
184	A is A-1e and (R ³) _n is 2-OMe.	569	A is A-1e and (R ³) _n is 3-OMe.
185	A is A-1e and (R ³) _n is 2,3-di-OMe.	570	A is A-1e and (R ³) _n is 2,5-di-OMe.
186	A is A-1e and (R ³) _n is 2,6-di-OMe.	571	A is A-1e and (R ³) _n is 3,5-di-OMe.
187	A is A-1e and (R ³) _n is 2-OCF ₃ .	572	A is A-1e and (R ³) _n is 3-OCF ₃ .
188	A is A-1e and (R ³) _n is 2,3-di-OCF ₃ .	573	A is A-1e and (R ³) _n is 2,5-di-OCF ₃ .
189	A is A-1e and (R ³) _n is 2,6-di-OCF ₃ .	574	A is A-1e and (R ³) _n is 3,5-di-OCF ₃ .
190	A is A-1e and (R ³) _n is 2-TMS.	575	A is A-1e and (R ³) _n is 3-TMS.
191	A is A-1e and (R ³) _n is 2,3-di-TMS.	576	A is A-1e and (R ³) _n is 2,5-di-TMS.
192	A is A-1e and (R ³) _n is 2,6-di-TMS.	577	A is A-1e and (R ³) _n is 3,5-di-TMS.
193	A is A-1e and (R ³) _n is 2-Cl-6-F.	578	A is A-1e and (R ³) _n is 2-Cl-6-Me.
194	A is A-1e and (R ³) _n is 2-Cl-5-F.	579	A is A-1e and (R ³) _n is 2-Cl-5-Me.
195	A is A-1f and (R ³) _n is H.	580	A is A-1f and (R ³) _n is 3-F.
196	A is A-1f and (R ³) _n is 2-F.	581	A is A-1f and (R ³) _n is 2,5-di-F.
197	A is A-1f and (R ³) _n is 2,3-di-F.	582	A is A-1f and (R ³) _n is 3,5-di-F.
198	A is A-1f and (R ³) _n is 2,6-di-F.	583	A is A-1f and (R ³) _n is 3-Cl.
199	A is A-1f and (R ³) _n is 2-Cl.	584	A is A-1f and (R ³) _n is 2,5-di-Cl.
200	A is A-1f and (R ³) _n is 2,3-di-Cl.	585	A is A-1f and (R ³) _n is 3,5-di-Cl.
201	A is A-1f and (R ³) _n is 2,6-di-Cl.	586	A is A-1f and (R ³) _n is 3-Br.
202	A is A-1f and (R ³) _n is 2-Br.	587	A is A-1f and (R ³) _n is 2,5-di-Br.
203	A is A-1f and (R ³) _n is 2,3-di-Br.	588	A is A-1f and (R ³) _n is 3,5-di-Br.
204	A is A-1f and (R ³) _n is 2,6-di-Br.	589	A is A-1f and (R ³) _n is 3-I.
205	A is A-1f and (R ³) _n is 2-I.	590	A is A-1f and (R ³) _n is 2,5-di-I.
206	A is A-1f and (R ³) _n is 2,3-di-I.	591	A is A-1f and (R ³) _n is 3,5-di-I.
207	A is A-1f and (R ³) _n is 2,6-di-I.	592	A is A-1f and (R ³) _n is 3-Me.
208	A is A-1f and (R ³) _n is 2-Me.	593	A is A-1f and (R ³) _n is 2,5-di-Me.
209	A is A-1f and (R ³) _n is 2,3-di-Me.	594	A is A-1f and (R ³) _n is 3,5-di-Me.
210	A is A-1f and (R ³) _n is 2,6-di-Me.	595	A is A-1f and (R ³) _n is 2-Et.
211	A is A-1f and (R ³) _n is 3-Et.	596	A is A-1f and (R ³) _n is 2,3-di-Et.
212	A is A-1f and (R ³) _n is 2,5-di-Et.	597	A is A-1f and (R ³) _n is 2,6-di-Et.
213	A is A-1f and (R ³) _n is 3,5-di-Et.	598	A is A-1f and (R ³) _n is 2- <i>i</i> -Pr.
214	A is A-1f and (R ³) _n is 3- <i>i</i> -Pr.	599	A is A-1f and (R ³) _n is 2,3-di- <i>i</i> -Pr.
215	A is A-1f and (R ³) _n is 2,5-di- <i>i</i> -Pr.	600	A is A-1f and (R ³) _n is 2,6-di- <i>i</i> -Pr.
216	A is A-1f and (R ³) _n is 3,5-di- <i>i</i> -Pr.	601	A is A-1f and (R ³) _n is 2- <i>c</i> -Pr.
217	A is A-1f and (R ³) _n is 3- <i>c</i> -Pr.	602	A is A-1f and (R ³) _n is 2,3-di- <i>c</i> -Pr.
218	A is A-1f and (R ³) _n is 2,5-di- <i>c</i> -Pr.	603	A is A-1f and (R ³) _n is 2,6-di- <i>c</i> -Pr.

Table	Row Heading	Table	Row Heading
219	A is A-1f and (R ³) _n is 3,5-di- <i>c</i> -Pr.	604	A is A-1f and (R ³) _n is 2-CF ₃ .
220	A is A-1f and (R ³) _n is 3-CF ₃ .	605	A is A-1f and (R ³) _n is 2,3-di-CF ₃ .
221	A is A-1f and (R ³) _n is 2,5-di-CF ₃ .	606	A is A-1f and (R ³) _n is 2,6-di-CF ₃ .
222	A is A-1f and (R ³) _n is 3,5-di-CF ₃ .	607	A is A-1f and (R ³) _n is 2-OMe.
223	A is A-1f and (R ³) _n is 3-OMe.	608	A is A-1f and (R ³) _n is 2,3-di-OMe.
224	A is A-1f and (R ³) _n is 2,5-di-OMe.	609	A is A-1f and (R ³) _n is 2,6-di-OMe.
225	A is A-1f and (R ³) _n is 3,5-di-OMe.	610	A is A-1f and (R ³) _n is 2-OCF ₃ .
226	A is A-1f and (R ³) _n is 3-OCF ₃ .	611	A is A-1f and (R ³) _n is 2,3-di-OCF ₃ .
227	A is A-1f and (R ³) _n is 2,5-di-OCF ₃ .	612	A is A-1f and (R ³) _n is 2,6-di-OCF ₃ .
228	A is A-1f and (R ³) _n is 3,5-di-OCF ₃ .	613	A is A-1f and (R ³) _n is 2-TMS.
229	A is A-1f and (R ³) _n is 3-TMS.	614	A is A-1f and (R ³) _n is 2,3-di-TMS.
230	A is A-1f and (R ³) _n is 2,5-di-TMS.	615	A is A-1f and (R ³) _n is 2,6-di-TMS.
231	A is A-1f and (R ³) _n is 3,5-di-TMS.	616	A is A-1f and (R ³) _n is 2-Cl-6-F.
232	A is A-1f and (R ³) _n is 2-Cl-6-Me.	617	A is A-1f and (R ³) _n is 2-Cl-5-F.
233	A is A-1f and (R ³) _n is 2-Cl-5-Me.	618	A is A-1g and (R ³) _n is 2-F.
234	A is A-1g and (R ³) _n is H.	619	A is A-1g and (R ³) _n is 2,3-di-F.
235	A is A-1g and (R ³) _n is 3-F.	620	A is A-1g and (R ³) _n is 2,6-di-F.
236	A is A-1g and (R ³) _n is 2,5-di-F.	621	A is A-1g and (R ³) _n is 2-Cl.
237	A is A-1g and (R ³) _n is 3,5-di-F.	622	A is A-1g and (R ³) _n is 2,3-di-Cl.
238	A is A-1g and (R ³) _n is 3-Cl.	623	A is A-1g and (R ³) _n is 2,6-di-Cl.
239	A is A-1g and (R ³) _n is 2,5-di-Cl.	624	A is A-1g and (R ³) _n is 2-Br.
240	A is A-1g and (R ³) _n is 3,5-di-Cl.	625	A is A-1g and (R ³) _n is 2,3-di-Br.
241	A is A-1g and (R ³) _n is 3-Br.	626	A is A-1g and (R ³) _n is 2,6-di-Br.
242	A is A-1g and (R ³) _n is 2,5-di-Br.	627	A is A-1g and (R ³) _n is 2-I.
243	A is A-1g and (R ³) _n is 3,5-di-Br.	628	A is A-1g and (R ³) _n is 2,3-di-I.
244	A is A-1g and (R ³) _n is 3-I.	629	A is A-1g and (R ³) _n is 2,6-di-I.
245	A is A-1g and (R ³) _n is 2,5-di-I.	630	A is A-1g and (R ³) _n is 2-Me.
246	A is A-1g and (R ³) _n is 3,5-di-I.	631	A is A-1g and (R ³) _n is 2,3-di-Me.
247	A is A-1g and (R ³) _n is 3-Me.	632	A is A-1g and (R ³) _n is 2,6-di-Me.
248	A is A-1g and (R ³) _n is 2,5-di-Me.	633	A is A-1g and (R ³) _n is 2-Et.
249	A is A-1g and (R ³) _n is 3,5-di-Me.	634	A is A-1g and (R ³) _n is 2,3-di-Et.
250	A is A-1g and (R ³) _n is 3-Et.	635	A is A-1g and (R ³) _n is 2,6-di-Et.
251	A is A-1g and (R ³) _n is 2,5-di-Et.	636	A is A-1g and (R ³) _n is 2- <i>i</i> -Pr.
252	A is A-1g and (R ³) _n is 3,5-di-Et.	637	A is A-1g and (R ³) _n is 2,3-di- <i>i</i> -Pr.
253	A is A-1g and (R ³) _n is 3- <i>i</i> -Pr.	638	A is A-1g and (R ³) _n is 2,6-di- <i>i</i> -Pr.
254	A is A-1g and (R ³) _n is 2,5-di- <i>i</i> -Pr.	639	A is A-1g and (R ³) _n is 2- <i>c</i> -Pr.
255	A is A-1g and (R ³) _n is 3,5-di- <i>i</i> -Pr.	640	A is A-1g and (R ³) _n is 2,3-di- <i>c</i> -Pr.


Table	Row Heading	Table	Row Heading
256	A is A-1g and (R ³) _n is 3- <i>c</i> -Pr.	641	A is A-1g and (R ³) _n is 2,6-di- <i>c</i> -Pr.
257	A is A-1g and (R ³) _n is 2,5-di- <i>c</i> -Pr.	642	A is A-1g and (R ³) _n is 2-CF ₃ .
258	A is A-1g and (R ³) _n is 3,5-di- <i>c</i> -Pr.	643	A is A-1g and (R ³) _n is 2,3-di-CF ₃ .
259	A is A-1g and (R ³) _n is 3-CF ₃ .	644	A is A-1g and (R ³) _n is 2,6-di-CF ₃ .
260	A is A-1g and (R ³) _n is 2,5-di-CF ₃ .	645	A is A-1g and (R ³) _n is 2-OMe.
261	A is A-1g and (R ³) _n is 3,5-di-CF ₃ .	646	A is A-1g and (R ³) _n is 2,3-di-OMe.
262	A is A-1g and (R ³) _n is 3-OMe.	647	A is A-1g and (R ³) _n is 2,6-di-OMe.
263	A is A-1g and (R ³) _n is 2,5-di-OMe.	648	A is A-1g and (R ³) _n is 2-OCF ₃ .
264	A is A-1g and (R ³) _n is 3,5-di-OMe.	649	A is A-1g and (R ³) _n is 2,3-di-OCF ₃ .
265	A is A-1g and (R ³) _n is 3-OCF ₃ .	650	A is A-1g and (R ³) _n is 2,6-di-OCF ₃ .
266	A is A-1g and (R ³) _n is 2,5-di-OCF ₃ .	651	A is A-1g and (R ³) _n is 2-TMS.
267	A is A-1g and (R ³) _n is 3,5-di-OCF ₃ .	652	A is A-1g and (R ³) _n is 2,3-di-TMS.
268	A is A-1g and (R ³) _n is 3-TMS.	653	A is A-1g and (R ³) _n is 2,6-di-TMS.
269	A is A-1g and (R ³) _n is 2,5-di-TMS.	654	A is A-1g and (R ³) _n is 2-Cl-6-F.
270	A is A-1g and (R ³) _n is 3,5-di-TMS.	655	A is A-1g and (R ³) _n is 2-Cl-5-F.
271	A is A-1g and (R ³) _n is 2-Cl-6-Me.	656	A is A-1h and (R ³) _n is 2-F.
272	A is A-1g and (R ³) _n is 2-Cl-5-Me.	657	A is A-1h and (R ³) _n is 2,3-di-F.
273	A is A-1h and (R ³) _n is H.	658	A is A-1h and (R ³) _n is 2,6-di-F.
274	A is A-1h and (R ³) _n is 3-F.	659	A is A-1h and (R ³) _n is 2-Cl.
275	A is A-1h and (R ³) _n is 2,5-di-F.	660	A is A-1h and (R ³) _n is 2,3-di-Cl.
276	A is A-1h and (R ³) _n is 3,5-di-F.	661	A is A-1h and (R ³) _n is 2,6-di-Cl.
277	A is A-1h and (R ³) _n is 3-Cl.	662	A is A-1h and (R ³) _n is 2-Br.
278	A is A-1h and (R ³) _n is 2,5-di-Cl.	663	A is A-1h and (R ³) _n is 2,3-di-Br.
279	A is A-1h and (R ³) _n is 3,5-di-Cl.	664	A is A-1h and (R ³) _n is 2,6-di-Br.
280	A is A-1h and (R ³) _n is 3-Br.	665	A is A-1h and (R ³) _n is 2-I.
281	A is A-1h and (R ³) _n is 2,5-di-Br.	666	A is A-1h and (R ³) _n is 2,3-di-I.
282	A is A-1h and (R ³) _n is 3,5-di-Br.	667	A is A-1h and (R ³) _n is 2,6-di-I.
283	A is A-1h and (R ³) _n is 3-I.	668	A is A-1h and (R ³) _n is 2-Me.
284	A is A-1h and (R ³) _n is 2,5-di-I.	669	A is A-1h and (R ³) _n is 2,3-di-Me.
285	A is A-1h and (R ³) _n is 3,5-di-I.	670	A is A-1h and (R ³) _n is 2,6-di-Me.
286	A is A-1h and (R ³) _n is 3-Me.	671	A is A-1h and (R ³) _n is 2-Et.
287	A is A-1h and (R ³) _n is 2,5-di-Me.	672	A is A-1h and (R ³) _n is 2,3-di-Et.
288	A is A-1h and (R ³) _n is 3,5-di-Me.	673	A is A-1h and (R ³) _n is 2,6-di-Et.
289	A is A-1h and (R ³) _n is 3-Et.	674	A is A-1h and (R ³) _n is 2- <i>i</i> -Pr.
290	A is A-1h and (R ³) _n is 2,5-di-Et.	675	A is A-1h and (R ³) _n is 2,3-di- <i>i</i> -Pr.
291	A is A-1h and (R ³) _n is 3,5-di-Et.	676	A is A-1h and (R ³) _n is 2,6-di- <i>i</i> -Pr.
292	A is A-1h and (R ³) _n is 3- <i>i</i> -Pr.	677	A is A-1h and (R ³) _n is 2- <i>c</i> -Pr.

Table	Row Heading	Table	Row Heading
293	A is A-1h and (R ³) _n is 2,5-di- <i>i</i> -Pr.	678	A is A-1h and (R ³) _n is 2,3-di- <i>c</i> -Pr.
294	A is A-1h and (R ³) _n is 3,5-di- <i>i</i> -Pr.	679	A is A-1h and (R ³) _n is 2,6-di- <i>c</i> -Pr.
295	A is A-1h and (R ³) _n is 3- <i>c</i> -Pr.	680	A is A-1h and (R ³) _n is 2-CF ₃ .
296	A is A-1h and (R ³) _n is 2,5-di- <i>c</i> -Pr.	681	A is A-1h and (R ³) _n is 2,3-di-CF ₃ .
297	A is A-1h and (R ³) _n is 3,5-di- <i>c</i> -Pr.	682	A is A-1h and (R ³) _n is 2,6-di-CF ₃ .
298	A is A-1h and (R ³) _n is 3-CF ₃ .	683	A is A-1h and (R ³) _n is 2-OMe.
299	A is A-1h and (R ³) _n is 2,5-di-CF ₃ .	684	A is A-1h and (R ³) _n is 2,3-di-OMe.
300	A is A-1h and (R ³) _n is 3,5-di-CF ₃ .	685	A is A-1h and (R ³) _n is 2,6-di-OMe.
301	A is A-1h and (R ³) _n is 3-OMe.	686	A is A-1h and (R ³) _n is 2-OCF ₃ .
302	A is A-1h and (R ³) _n is 2,5-di-OMe.	687	A is A-1h and (R ³) _n is 2,3-di-OCF ₃ .
303	A is A-1h and (R ³) _n is 3,5-di-OMe.	688	A is A-1h and (R ³) _n is 2,6-di-OCF ₃ .
304	A is A-1h and (R ³) _n is 3-OCF ₃ .	689	A is A-1h and (R ³) _n is 2-TMS.
305	A is A-1h and (R ³) _n is 2,5-di-OCF ₃ .	690	A is A-1h and (R ³) _n is 2,3-di-TMS.
306	A is A-1h and (R ³) _n is 3,5-di-OCF ₃ .	691	A is A-1h and (R ³) _n is 2,6-di-TMS.
307	A is A-1h and (R ³) _n is 3-TMS.	692	A is A-1h and (R ³) _n is 2-Cl-6-F.
308	A is A-1h and (R ³) _n is 2,5-di-TMS.	693	A is A-1h and (R ³) _n is 2-Cl-5-F.
309	A is A-1h and (R ³) _n is 3,5-di-TMS.	694	A is A-1i and (R ³) _n is 2-F.
310	A is A-1h and (R ³) _n is 2-Cl-6-Me.	695	A is A-1i and (R ³) _n is 2,3-di-F.
311	A is A-1h and (R ³) _n is 2-Cl-5-Me.	696	A is A-1i and (R ³) _n is 2,6-di-F.
312	A is A-1i and (R ³) _n is H.	697	A is A-1i and (R ³) _n is 2-Cl.
313	A is A-1i and (R ³) _n is 3-F.	698	A is A-1i and (R ³) _n is 2,3-di-Cl.
314	A is A-1i and (R ³) _n is 2,5-di-F.	699	A is A-1i and (R ³) _n is 2,6-di-Cl.
315	A is A-1i and (R ³) _n is 3,5-di-F.	700	A is A-1i and (R ³) _n is 2-Br.
316	A is A-1i and (R ³) _n is 3-Cl.	701	A is A-1i and (R ³) _n is 2,3-di-Br.
317	A is A-1i and (R ³) _n is 2,5-di-Cl.	702	A is A-1i and (R ³) _n is 2,6-di-Br.
318	A is A-1i and (R ³) _n is 3,5-di-Cl.	703	A is A-1i and (R ³) _n is 2-I.
319	A is A-1i and (R ³) _n is 3-Br.	704	A is A-1i and (R ³) _n is 2,3-di-I.
320	A is A-1i and (R ³) _n is 2,5-di-Br.	705	A is A-1i and (R ³) _n is 2,6-di-I.
321	A is A-1i and (R ³) _n is 3,5-di-Br.	706	A is A-1i and (R ³) _n is 2-Me.
322	A is A-1i and (R ³) _n is 3-I.	707	A is A-1i and (R ³) _n is 2,3-di-Me.
323	A is A-1i and (R ³) _n is 2,5-di-I.	708	A is A-1i and (R ³) _n is 2,6-di-Me.
324	A is A-1i and (R ³) _n is 3,5-di-I.	709	A is A-1i and (R ³) _n is 2-Et.
325	A is A-1i and (R ³) _n is 3-Me.	710	A is A-1i and (R ³) _n is 2,3-di-Et.
326	A is A-1i and (R ³) _n is 2,5-di-Me.	711	A is A-1i and (R ³) _n is 2,6-di-Et.
327	A is A-1i and (R ³) _n is 3,5-di-Me.	712	A is A-1i and (R ³) _n is 2- <i>i</i> -Pr.
328	A is A-1i and (R ³) _n is 3-Et.	713	A is A-1i and (R ³) _n is 2,3-di- <i>i</i> -Pr.
329	A is A-1i and (R ³) _n is 2,5-di-Et.	714	A is A-1i and (R ³) _n is 2,6-di- <i>i</i> -Pr.

Table	Row Heading	Table	Row Heading
330	A is A-1i and (R ³) _n is 3,5-di-Et.	715	A is A-1i and (R ³) _n is 2- <i>c</i> -Pr.
331	A is A-1i and (R ³) _n is 3- <i>i</i> -Pr.	716	A is A-1i and (R ³) _n is 2,3-di- <i>c</i> -Pr.
332	A is A-1i and (R ³) _n is 2,5-di- <i>i</i> -Pr.	717	A is A-1i and (R ³) _n is 2,6-di- <i>c</i> -Pr.
333	A is A-1i and (R ³) _n is 3,5-di- <i>i</i> -Pr.	718	A is A-1i and (R ³) _n is 2-CF ₃ .
334	A is A-1i and (R ³) _n is 3- <i>c</i> -Pr.	719	A is A-1i and (R ³) _n is 2,3-di-CF ₃ .
335	A is A-1i and (R ³) _n is 2,5-di- <i>c</i> -Pr.	720	A is A-1i and (R ³) _n is 2,6-di-CF ₃ .
336	A is A-1i and (R ³) _n is 3,5-di- <i>c</i> -Pr.	721	A is A-1i and (R ³) _n is 2-OMe.
337	A is A-1i and (R ³) _n is 3-CF ₃ .	722	A is A-1i and (R ³) _n is 2,3-di-OMe.
338	A is A-1i and (R ³) _n is 2,5-di-CF ₃ .	723	A is A-1i and (R ³) _n is 2,6-di-OMe.
339	A is A-1i and (R ³) _n is 3,5-di-CF ₃ .	724	A is A-1i and (R ³) _n is 2-OCF ₃ .
340	A is A-1i and (R ³) _n is 3-OMe.	725	A is A-1i and (R ³) _n is 2,3-di-OCF ₃ .
341	A is A-1i and (R ³) _n is 2,5-di-OMe.	726	A is A-1i and (R ³) _n is 2,6-di-OCF ₃ .
342	A is A-1i and (R ³) _n is 3,5-di-OMe.	727	A is A-1i and (R ³) _n is 2-TMS.
343	A is A-1i and (R ³) _n is 3-OCF ₃ .	728	A is A-1i and (R ³) _n is 2,3-di-TMS.
344	A is A-1i and (R ³) _n is 2,5-di-OCF ₃ .	729	A is A-1i and (R ³) _n is 2,6-di-TMS.
345	A is A-1i and (R ³) _n is 3,5-di-OCF ₃ .	730	A is A-1i and (R ³) _n is 2-Cl-6-F.
346	A is A-1i and (R ³) _n is 3-TMS.	731	A is A-1i and (R ³) _n is 2-Cl-5-F.
347	A is A-1i and (R ³) _n is 2,5-di-TMS.	732	A is A-1j and (R ³) _n is 2-F.
348	A is A-1i and (R ³) _n is 3,5-di-TMS.	733	A is A-1j and (R ³) _n is 2,3-di-F.
349	A is A-1i and (R ³) _n is 2-Cl-6-Me.	734	A is A-1j and (R ³) _n is 2,6-di-F.
350	A is A-1i and (R ³) _n is 2-Cl-5-Me.	735	A is A-1j and (R ³) _n is 2-Cl.
351	A is A-1j and (R ³) _n is H.	736	A is A-1j and (R ³) _n is 2,3-di-Cl.
352	A is A-1j and (R ³) _n is 3-F.	737	A is A-1j and (R ³) _n is 2,6-di-Cl.
353	A is A-1j and (R ³) _n is 2,5-di-F.	738	A is A-1j and (R ³) _n is 2-Br.
354	A is A-1j and (R ³) _n is 3,5-di-F.	739	A is A-1j and (R ³) _n is 2,3-di-Br.
355	A is A-1j and (R ³) _n is 3-Cl.	740	A is A-1j and (R ³) _n is 2,6-di-Br.
356	A is A-1j and (R ³) _n is 2,5-di-Cl.	741	A is A-1j and (R ³) _n is 2-I.
357	A is A-1j and (R ³) _n is 3,5-di-Cl.	742	A is A-1j and (R ³) _n is 2,3-di-I.
358	A is A-1j and (R ³) _n is 3-Br.	743	A is A-1j and (R ³) _n is 2,6-di-I.
359	A is A-1j and (R ³) _n is 2,5-di-Br.	744	A is A-1j and (R ³) _n is 2-Me.
360	A is A-1j and (R ³) _n is 3,5-di-Br.	745	A is A-1j and (R ³) _n is 2,3-di-Me.
361	A is A-1j and (R ³) _n is 3-I.	746	A is A-1j and (R ³) _n is 2,6-di-Me.
362	A is A-1j and (R ³) _n is 2,5-di-I.	747	A is A-1j and (R ³) _n is 2-Et.
363	A is A-1j and (R ³) _n is 3,5-di-I.	748	A is A-1j and (R ³) _n is 2,3-di-Et.
364	A is A-1j and (R ³) _n is 3-Me.	749	A is A-1j and (R ³) _n is 2,6-di-Et.
365	A is A-1j and (R ³) _n is 2,5-di-Me.	750	A is A-1j and (R ³) _n is 2- <i>i</i> -Pr.
366	A is A-1j and (R ³) _n is 3,5-di-Me.	751	A is A-1j and (R ³) _n is 2,3-di- <i>i</i> -Pr.

Table	Row Heading	Table	Row Heading
367	A is A-1j and (R ³) _n is 3-Et.	752	A is A-1j and (R ³) _n is 2,6-di- <i>i</i> -Pr.
368	A is A-1j and (R ³) _n is 2,5-di-Et.	753	A is A-1j and (R ³) _n is 2- <i>c</i> -Pr.
369	A is A-1j and (R ³) _n is 3,5-di-Et.	754	A is A-1j and (R ³) _n is 2,3-di- <i>c</i> -Pr.
370	A is A-1j and (R ³) _n is 3- <i>i</i> -Pr.	755	A is A-1j and (R ³) _n is 2,6-di- <i>c</i> -Pr.
371	A is A-1j and (R ³) _n is 2,5-di- <i>i</i> -Pr.	756	A is A-1j and (R ³) _n is 2-CF ₃ .
372	A is A-1j and (R ³) _n is 3,5-di- <i>i</i> -Pr.	757	A is A-1j and (R ³) _n is 2,3-di-CF ₃ .
373	A is A-1j and (R ³) _n is 3- <i>c</i> -Pr.	758	A is A-1j and (R ³) _n is 2,6-di-CF ₃ .
374	A is A-1j and (R ³) _n is 2,5-di- <i>c</i> -Pr.	759	A is A-1j and (R ³) _n is 2-OMe.
375	A is A-1j and (R ³) _n is 3,5-di- <i>c</i> -Pr.	760	A is A-1j and (R ³) _n is 2,3-di-OMe.
376	A is A-1j and (R ³) _n is 3-CF ₃ .	761	A is A-1j and (R ³) _n is 2,6-di-OMe.
377	A is A-1j and (R ³) _n is 2,5-di-CF ₃ .	762	A is A-1j and (R ³) _n is 2-OCF ₃ .
378	A is A-1j and (R ³) _n is 3,5-di-CF ₃ .	763	A is A-1j and (R ³) _n is 2,3-di-OCF ₃ .
379	A is A-1j and (R ³) _n is 3-OMe.	764	A is A-1j and (R ³) _n is 2,6-di-OCF ₃ .
380	A is A-1j and (R ³) _n is 2,5-di-OMe.	765	A is A-1j and (R ³) _n is 2-TMS.
381	A is A-1j and (R ³) _n is 3,5-di-OMe.	766	A is A-1j and (R ³) _n is 2,3-di-TMS.
382	A is A-1j and (R ³) _n is 3-OCF ₃ .	767	A is A-1j and (R ³) _n is 2,6-di-TMS.
383	A is A-1j and (R ³) _n is 2,5-di-OCF ₃ .	768	A is A-1j and (R ³) _n is 2-Cl-6-F.
384	A is A-1j and (R ³) _n is 3,5-di-OCF ₃ .	769	A is A-1j and (R ³) _n is 2-Cl-5-F.
385	A is A-1j and (R ³) _n is 3-TMS.		

TABLE 770

A is A-1a, (R³)_n is H.

Q	Q	Q
3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	3-Me-1 <i>H</i> -pyrazol-1-yl	3-F-1 <i>H</i> -pyrazol-1-yl
3-Br-1 <i>H</i> -pyrazol-1-yl	4-CF ₃ -1 <i>H</i> -pyrazol-1-yl	4-Me-1 <i>H</i> -pyrazol-1-yl
4-F-1 <i>H</i> -pyrazol-1-yl	4-Br-1 <i>H</i> -pyrazol-1-yl	5-CF ₃ -1 <i>H</i> -pyrazol-1-yl
5-Me-1 <i>H</i> -pyrazol-1-yl	5-F-1 <i>H</i> -pyrazol-1-yl	5-Br-1 <i>H</i> -pyrazol-1-yl
3-CHF ₂ -1 <i>H</i> -pyrazol-1-yl	3-Et-1 <i>H</i> -pyrazol-1-yl	3-Cl-1 <i>H</i> -pyrazol-1-yl
3-I-1 <i>H</i> -pyrazol-1-yl	4-CHF ₂ -1 <i>H</i> -pyrazol-1-yl	4-Et-1 <i>H</i> -pyrazol-1-yl
4-Cl-1 <i>H</i> -pyrazol-1-yl	4-I-1 <i>H</i> -pyrazol-1-yl	5-CHF ₂ -1 <i>H</i> -pyrazol-1-yl
5-Et-1 <i>H</i> -pyrazol-1-yl	5-Cl-1 <i>H</i> -pyrazol-1-yl	3-I-1 <i>H</i> -pyrazol-1-yl
3-OMe-1 <i>H</i> -pyrazol-1-yl	3-CN-1 <i>H</i> -pyrazol-1-yl	3-OCF ₃ -1 <i>H</i> -pyrazol-1-yl

3-OCHF ₂ -1 <i>H</i> -pyrazol-1-yl	4-OMe-1 <i>H</i> -pyrazol-1-yl	4-CN-1 <i>H</i> -pyrazol-1-yl
4-OCF ₃ -1 <i>H</i> -pyrazol-1-yl	4-OCHF ₂ -1 <i>H</i> -pyrazol-1-yl	5-OCF ₃ -1 <i>H</i> -pyrazol-1-yl
5-CN-1 <i>H</i> -pyrazol-1-yl	5-OCF ₃ -1 <i>H</i> -pyrazol-1-yl	5-OCHF ₂ -1 <i>H</i> -pyrazol-1-yl
3-MeOC(=O)-1 <i>H</i> -pyrazol-1-yl	3-Ph-1 <i>H</i> -pyrazol-1-yl	3,5-di-Me-1 <i>H</i> -pyrazol-1-yl
3,5-di-F-1 <i>H</i> -pyrazol-1-yl	4-MeOC(=O)-1 <i>H</i> -pyrazol-1-yl	4-Ph-1 <i>H</i> -pyrazol-1-yl
3,5-di-CF ₃ -1 <i>H</i> -pyrazol-1-yl	3,5-di-Cl-1 <i>H</i> -pyrazol-1-yl	5-MeOC(=O)-1 <i>H</i> -pyrazol-1-yl
5-Ph-1 <i>H</i> -pyrazol-1-yl	3,5-di-CHF ₂ -1 <i>H</i> -pyrazol-1-yl	3,5-di-Br-1 <i>H</i> -pyrazol-1-yl
3-CF ₃ -5-Me-1 <i>H</i> -pyrazol-1-yl	3,4-di-Me-1 <i>H</i> -pyrazol-1-yl	3,4-di-CF ₃ -1 <i>H</i> -pyrazol-1-yl
3,4-di-Br-1 <i>H</i> -pyrazol-1-yl	3,4-di-Cl-1 <i>H</i> -pyrazol-1-yl	1 <i>H</i> -pyrazol-1-yl
3-Me-1 <i>H</i> -[1,2,4]triazol-1-yl	3-CF ₃ -1 <i>H</i> -[1,2,4]triazol-1-yl	3-CHF ₂ -1 <i>H</i> -[1,2,4]triazol-1-yl
3-F-1 <i>H</i> -[1,2,4]triazol-1-yl	3-Cl-1 <i>H</i> -[1,2,4]triazol-1-yl	3-Br-1 <i>H</i> -[1,2,4]triazol-1-yl
3,5-di-Cl-1 <i>H</i> -[1,2,4]triazol-1-yl	3,5-di-Br-1 <i>H</i> -[1,2,4]triazol-1-yl	3-Ph-1 <i>H</i> -[1,2,4]triazol-1-yl
1 <i>H</i> -[1,2,4]triazol-1-yl	4-Me-2 <i>H</i> -[1,2,3]triazol-2-yl	4-CF ₃ -2 <i>H</i> -[1,2,3]triazol-2-yl
4-CHF ₂ -2 <i>H</i> -[1,2,3]triazol-2-yl	4-F-2 <i>H</i> -[1,2,3]triazol-2-yl	4-Cl-2 <i>H</i> -[1,2,3]triazol-2-yl
4-Br-2 <i>H</i> -[1,2,3]triazol-2-yl	4-Ph-2 <i>H</i> -[1,2,3]triazol-2-yl	4,5-di-Me-2 <i>H</i> -[1,2,3]triazol-2-yl
4,5-di-CF ₃ -2 <i>H</i> -[1,2,3]triazol-2-yl	4,5-di-Cl-2 <i>H</i> -[1,2,3]triazol-2-yl	4,5-di-Br-2 <i>H</i> -[1,2,3]triazol-2-yl
2 <i>H</i> -[1,2,3]triazol-2-yl	4-Me-1 <i>H</i> -[1,2,3]triazol-1-yl	4-CF ₃ -1 <i>H</i> -[1,2,3]triazol-1-yl
4-CHF ₂ -1 <i>H</i> -[1,2,3]triazol-1-yl	4-F-1 <i>H</i> -[1,2,3]triazol-1-yl	4-Cl-1 <i>H</i> -[1,2,3]triazol-1-yl
4-Br-1 <i>H</i> -[1,2,3]triazol-1-yl	4-Ph-1 <i>H</i> -[1,2,3]triazol-1-yl	1 <i>H</i> -[1,2,3]triazol-1-yl
3-Me-1 <i>H</i> -pyrrol-1-yl	3-CF ₃ -1 <i>H</i> -pyrrol-1-yl	3-CHF ₂ -1 <i>H</i> -pyrrol-1-yl
3,4-di-Me-1 <i>H</i> -pyrrol-1-yl	2,4-di-Me-1 <i>H</i> -pyrrol-1-yl	3,4-di-CF ₃ -1 <i>H</i> -pyrrol-1-yl
2,4-di-CF ₃ -1 <i>H</i> -pyrrol-1-yl	3,4-di-Br-1 <i>H</i> -pyrrol-1-yl	3,4-di-Cl-1 <i>H</i> -pyrrol-1-yl
1 <i>H</i> -pyrrol-1-yl	1-Me-1 <i>H</i> -pyrazol-3-yl	1-CF ₃ -1 <i>H</i> -pyrazol-3-yl
1-Et-1 <i>H</i> -pyrazol-3-yl	1- <i>i</i> -Pr-1 <i>H</i> -pyrazol-3-yl	1-(F ₃ CCH ₂)-1 <i>H</i> -pyrazol-3-yl
1-Ph-1 <i>H</i> -pyrazol-3-yl	1,4-di-Me-1 <i>H</i> -pyrazol-3-yl	1-Me-4-CF ₃ -1 <i>H</i> -pyrazol-3-yl
1-Me-1 <i>H</i> -pyrazol-4-yl	1-CF ₃ -1 <i>H</i> -pyrazol-4-yl	1-Et-1 <i>H</i> -pyrazol-4-yl
1- <i>i</i> -Pr-1 <i>H</i> -pyrazol-4-yl	1-(F ₃ CCH ₂)-1 <i>H</i> -pyrazol-4-yl	1-Ph-1 <i>H</i> -pyrazol-4-yl
1,3-di-Me-1 <i>H</i> -pyrazol-4-yl	1-Me-3-CF ₃ -1 <i>H</i> -pyrazol-4-yl	3-Me-1-CF ₃ -1 <i>H</i> -pyrazol-4-yl
1-Me-1 <i>H</i> -[1,2,4]triazol-3-yl	1-CF ₃ -1 <i>H</i> -[1,2,4]triazol-3-yl	1-Et-1 <i>H</i> -[1,2,4]triazol-3-yl
1- <i>i</i> -Pr-1 <i>H</i> -[1,2,4]triazol-3-yl	1-Ph-1 <i>H</i> -[1,2,4]triazol-3-yl	5-Ph-4,5-dihydro-isoxazol-3-yl
3,5-di-Me-1 <i>H</i> -[1,2,4]triazol-1-yl	3,5-di-CF ₃ -1 <i>H</i> -[1,2,4]triazol-1-yl	3,5-di-CHF ₂ -1 <i>H</i> -[1,2,4]triazol-
5-CF ₃ -2,4-dihydro-3-oxopyrazol-	5-Me-2,4-dihydro-3-oxopyrazol-	1-yl
1-yl	1-yl	

The present disclosure also includes Tables 771 through 1539, each of which is constructed the same as Table 770 above, except that the row heading in Table 771 (i.e. “A is A-1a and R³ is H.”) is replaced with the respective row heading shown below. For Example, in Table 771 the row heading is “A is A-1a and R³ is 2-F” and Q is as defined in

Table 1 above. Thus, the first entry in Table 771 specifically discloses *N*-[[2-fluoro-3-(3-trifluoromethyl-1*H*-pyrazol-1-yl)phenyl]methyl]-*N*-cyclopropyl-3-(trifluoromethyl)-1-methyl-1*H*-pyrazole-4-carboxamide. Tables 772 through 1539 are constructed similarly.

TABLES 771-1539

Table	Row Heading	Table	Row Heading
771	A is A-1a and (R ³) _n is 2-F.	1156	A is A-1j and (R ³) _n is 2,4-di-TMS.
772	A is A-1a and (R ³) _n is 2,4-di-F.	1157	A is A-1j and (R ³) _n is 2,6-di-TMS.
773	A is A-1a and (R ³) _n is 2,6-di-F.	1158	A is A-1j and (R ³) _n is 2-Cl-6-F.
774	A is A-1a and (R ³) _n is 2-Cl.	1159	A is A-1j and (R ³) _n is 2-Cl-4-F.
775	A is A-1a and (R ³) _n is 2,4-di-Cl.	1160	A is A-1a and (R ³) _n is 4-F.
776	A is A-1a and (R ³) _n is 2,6-di-Cl.	1161	A is A-1a and (R ³) _n is 2,5-di-F.
777	A is A-1a and (R ³) _n is 2-Br.	1162	A is A-1a and (R ³) _n is 4,5-di-F.
778	A is A-1a and (R ³) _n is 2,4-di-Br.	1163	A is A-1a and (R ³) _n is 4-Cl.
779	A is A-1a and (R ³) _n is 2,6-di-Br.	1164	A is A-1a and (R ³) _n is 2,5-di-Cl.
780	A is A-1a and (R ³) _n is 2-I.	1165	A is A-1a and (R ³) _n is 4,5-di-Cl.
781	A is A-1a and (R ³) _n is 2,4-di-I.	1166	A is A-1a and (R ³) _n is 4-Br.
782	A is A-1a and (R ³) _n is 2,6-di-I.	1167	A is A-1a and (R ³) _n is 2,5-di-Br.
783	A is A-1a and (R ³) _n is 2-Me.	1168	A is A-1a and (R ³) _n is 4,5-di-Br.
784	A is A-1a and (R ³) _n is 2,4-di-Me.	1169	A is A-1a and (R ³) _n is 4-I.
785	A is A-1a and (R ³) _n is 2,6-di-Me.	1170	A is A-1a and (R ³) _n is 2,5-di-I.
786	A is A-1a and (R ³) _n is 2-Et.	1171	A is A-1a and (R ³) _n is 4,5-di-I.
787	A is A-1a and (R ³) _n is 2,4-di-Et.	1172	A is A-1a and (R ³) _n is 4-Me.
788	A is A-1a and (R ³) _n is 2,6-di-Et.	1173	A is A-1a and (R ³) _n is 2,5-di-Me.
789	A is A-1a and (R ³) _n is 2- <i>i</i> -Pr.	1174	A is A-1a and (R ³) _n is 4,5-di-Me.
790	A is A-1a and (R ³) _n is 2,4-di- <i>i</i> -Pr.	1175	A is A-1a and (R ³) _n is 4-Et.
791	A is A-1a and (R ³) _n is 2,6-di- <i>i</i> -Pr.	1176	A is A-1a and (R ³) _n is 2,5-di-Et.
792	A is A-1a and (R ³) _n is 2- <i>c</i> -Pr.	1177	A is A-1a and (R ³) _n is 4,5-di-Et.
793	A is A-1a and (R ³) _n is 2,4-di- <i>c</i> -Pr.	1178	A is A-1a and (R ³) _n is 4- <i>i</i> -Pr.
794	A is A-1a and (R ³) _n is 2,6-di- <i>c</i> -Pr.	1179	A is A-1a and (R ³) _n is 2,5-di- <i>i</i> -Pr.
795	A is A-1a and (R ³) _n is 2-CF ₃ .	1180	A is A-1a and (R ³) _n is 4,5-di- <i>i</i> -Pr.
796	A is A-1a and (R ³) _n is 2,4-di-CF ₃ .	1181	A is A-1a and (R ³) _n is 4- <i>c</i> -Pr.
797	A is A-1a and (R ³) _n is 2,6-di-CF ₃ .	1182	A is A-1a and (R ³) _n is 2,5-di- <i>c</i> -Pr.
798	A is A-1a and (R ³) _n is 2-OMe.	1183	A is A-1a and (R ³) _n is 4,5-di- <i>c</i> -Pr.
799	A is A-1a and (R ³) _n is 2,4-di-OMe.	1184	A is A-1a and (R ³) _n is 4-CF ₃ .
800	A is A-1a and (R ³) _n is 2,6-di-OMe.	1185	A is A-1a and (R ³) _n is 2,5-di-CF ₃ .
801	A is A-1a and (R ³) _n is 2-OCF ₃ .	1186	A is A-1a and (R ³) _n is 4,5-di-CF ₃ .
802	A is A-1a and (R ³) _n is 2,4-di-OCF ₃ .	1187	A is A-1a and (R ³) _n is 4-OMe.
803	A is A-1a and (R ³) _n is 2,6-di-OCF ₃ .	1188	A is A-1a and (R ³) _n is 2,5-di-OMe.

804	A is A-1a and (R ³) _n is 2-TMS.	1189	A is A-1a and (R ³) _n is 4,5-di-OMe.
805	A is A-1a and (R ³) _n is 2,4-di-TMS.	1190	A is A-1a and (R ³) _n is 4-CF ₃ O.
806	A is A-1a and (R ³) _n is 2,6-di-TMS.	1191	A is A-1a and (R ³) _n is 2,5-di-OCF ₃ .
807	A is A-1a and (R ³) _n is 2-Cl-6-F.	1192	A is A-1a and (R ³) _n is 4,5-di-OCF ₃ .
808	A is A-1a and (R ³) _n is 2-Cl-4-F.	1193	A is A-1a and (R ³) _n is 4-TMS.
809	A is A-1b and (R ³) _n is H.	1194	A is A-1a and (R ³) _n is 2,5-di-TMS.
810	A is A-1b and (R ³) _n is 2-F.	1195	A is A-1a and (R ³) _n is 4,5-di-TMS.
811	A is A-1b and (R ³) _n is 2,4-di-F.	1196	A is A-1a and (R ³) _n is 2-Cl-6-Me.
812	A is A-1b and (R ³) _n is 2,6-di-F.	1197	A is A-1a and (R ³) _n is 2-Cl-4-Me.
813	A is A-1b and (R ³) _n is 2-Cl.	1198	A is A-1b and (R ³) _n is 4-F.
814	A is A-1b and (R ³) _n is 2,4-di-Cl.	1199	A is A-1b and (R ³) _n is 2,5-di-F.
815	A is A-1b and (R ³) _n is 2,6-di-Cl.	1200	A is A-1b and (R ³) _n is 4,5-di-F.
816	A is A-1b and (R ³) _n is 2-Br.	1201	A is A-1b and (R ³) _n is 4-Cl.
817	A is A-1b and (R ³) _n is 2,4-di-Br.	1202	A is A-1b and (R ³) _n is 2,5-di-Cl.
818	A is A-1b and (R ³) _n is 2,6-di-Br.	1203	A is A-1b and (R ³) _n is 4,5-di-Cl.
819	A is A-1b and (R ³) _n is 2-I.	1204	A is A-1b and (R ³) _n is 4-Br.
820	A is A-1b and (R ³) _n is 2,4-di-I.	1205	A is A-1b and (R ³) _n is 2,5-di-Br.
821	A is A-1b and (R ³) _n is 2,6-di-I.	1206	A is A-1b and (R ³) _n is 4,5-di-Br.
822	A is A-1b and (R ³) _n is 2-Me.	1207	A is A-1b and (R ³) _n is 4-I.
823	A is A-1b and (R ³) _n is 2,4-di-Me.	1208	A is A-1b and (R ³) _n is 2,5-di-I.
824	A is A-1b and (R ³) _n is 2,6-di-Me.	1209	A is A-1b and (R ³) _n is 4,5-di-I.
825	A is A-1b and (R ³) _n is 2-Et.	1210	A is A-1b and (R ³) _n is 4-Me.
826	A is A-1b and (R ³) _n is 2,4-di-Et.	1211	A is A-1b and (R ³) _n is 2,5-di-Me.
827	A is A-1b and (R ³) _n is 2,6-di-Et.	1212	A is A-1b and (R ³) _n is 4,5-di-Me.
828	A is A-1b and (R ³) _n is 2- <i>i</i> -Pr.	1213	A is A-1b and (R ³) _n is 4-Et.
829	A is A-1b and (R ³) _n is 2,4-di- <i>i</i> -Pr.	1214	A is A-1b and (R ³) _n is 2,5-di-Et.
830	A is A-1b and (R ³) _n is 2,6-di- <i>i</i> -Pr.	1215	A is A-1b and (R ³) _n is 4,5-di-Et.
831	A is A-1b and (R ³) _n is 2- <i>c</i> -Pr.	1216	A is A-1b and (R ³) _n is 4- <i>i</i> -Pr.
832	A is A-1b and (R ³) _n is 2,4-di- <i>c</i> -Pr.	1217	A is A-1b and (R ³) _n is 2,5-di- <i>i</i> -Pr.
833	A is A-1b and (R ³) _n is 2,6-di- <i>c</i> -Pr.	1218	A is A-1b and (R ³) _n is 4,5-di- <i>i</i> -Pr.
834	A is A-1b and (R ³) _n is 2-CF ₃ .	1219	A is A-1b and (R ³) _n is 4- <i>c</i> -Pr.
835	A is A-1b and (R ³) _n is 2,4-di-CF ₃ .	1220	A is A-1b and (R ³) _n is 2,5-di- <i>c</i> -Pr.
836	A is A-1b and (R ³) _n is 2,6-di-CF ₃ .	1221	A is A-1b and (R ³) _n is 4,5-di- <i>c</i> -Pr.
837	A is A-1b and (R ³) _n is 2-OMe.	1222	A is A-1b and (R ³) _n is 4-CF ₃ .
838	A is A-1b and (R ³) _n is 2,4-di-OMe.	1223	A is A-1b and (R ³) _n is 2,5-di-CF ₃ .
839	A is A-1b and (R ³) _n is 2,6-di-OMe.	1224	A is A-1b and (R ³) _n is 4,5-di-CF ₃ .
840	A is A-1b and (R ³) _n is 2-OCF ₃ .	1225	A is A-1b and (R ³) _n is 4-OMe.
841	A is A-1b and (R ³) _n is 2,4-di-OCF ₃ .	1226	A is A-1b and (R ³) _n is 2,5-di-OMe.

842	A is A-1b and (R ³) _n is 2,6-di-OCF ₃ .	1227	A is A-1b and (R ³) _n is 4,5-di-OMe.
843	A is A-1b and (R ³) _n is 2-TMS.	1228	A is A-1b and (R ³) _n is 4-OCF ₃ .
844	A is A-1b and (R ³) _n is 2,4-di-TMS.	1229	A is A-1b and (R ³) _n is 2,5-di-OCF ₃ .
845	A is A-1b and (R ³) _n is 2,6-di-TMS.	1230	A is A-1b and (R ³) _n is 4,5-di-OCF ₃ .
846	A is A-1b and (R ³) _n is 2-Cl-6-F.	1231	A is A-1b and (R ³) _n is 4-TMS.
847	A is A-1b and (R ³) _n is 2-Cl-4-F.	1232	A is A-1b and (R ³) _n is 2,5-di-TMS.
848	A is A-1c and (R ³) _n is H.	1233	A is A-1b and (R ³) _n is 4,5-di-TMS.
849	A is A-1c and (R ³) _n is 2-F.	1234	A is A-1b and (R ³) _n is 2-Cl-6-Me.
850	A is A-1c and (R ³) _n is 2,4-di-F.	1235	A is A-1b and (R ³) _n is 2-Cl-4-Me.
851	A is A-1c and (R ³) _n is 2,6-di-F.	1236	A is A-1c and (R ³) _n is 4-F.
852	A is A-1c and (R ³) _n is 2-Cl.	1237	A is A-1c and (R ³) _n is 2,5-di-F.
853	A is A-1c and (R ³) _n is 2,4-di-Cl.	1238	A is A-1c and (R ³) _n is 4,5-di-F.
854	A is A-1c and (R ³) _n is 2,6-di-Cl.	1239	A is A-1c and (R ³) _n is 4-Cl.
855	A is A-1c and (R ³) _n is 2-Br.	1240	A is A-1c and (R ³) _n is 2,5-di-Cl.
856	A is A-1c and (R ³) _n is 2,4-di-Br.	1241	A is A-1c and (R ³) _n is 4,5-di-Cl.
857	A is A-1c and (R ³) _n is 2,6-di-Br.	1242	A is A-1c and (R ³) _n is 4-Br.
858	A is A-1c and (R ³) _n is 2-I.	1243	A is A-1c and (R ³) _n is 2,5-di-Br.
859	A is A-1c and (R ³) _n is 2,4-di-I.	1244	A is A-1c and (R ³) _n is 4,5-di-Br.
860	A is A-1c and (R ³) _n is 2,6-di-I.	1245	A is A-1c and (R ³) _n is 4-I.
861	A is A-1c and (R ³) _n is 2-Me.	1246	A is A-1c and (R ³) _n is 2,5-di-I.
862	A is A-1c and (R ³) _n is 2,4-di-Me.	1247	A is A-1c and (R ³) _n is 4,5-di-I.
863	A is A-1c and (R ³) _n is 2,6-di-Me.	1248	A is A-1c and (R ³) _n is 4-Me.
864	A is A-1c and (R ³) _n is 2-Et.	1249	A is A-1c and (R ³) _n is 2,5-di-Me.
865	A is A-1c and (R ³) _n is 2,4-di-Et.	1250	A is A-1c and (R ³) _n is 4,5-di-Me.
866	A is A-1c and (R ³) _n is 2,6-di-Et.	1251	A is A-1c and (R ³) _n is 4-Et.
867	A is A-1c and (R ³) _n is 2- <i>i</i> -Pr.	1252	A is A-1c and (R ³) _n is 2,5-di-Et.
868	A is A-1c and (R ³) _n is 2,4-di- <i>i</i> -Pr.	1253	A is A-1c and (R ³) _n is 4,5-di-Et.
869	A is A-1c and (R ³) _n is 2,6-di- <i>i</i> -Pr.	1254	A is A-1c and (R ³) _n is 4- <i>i</i> -Pr.
870	A is A-1c and (R ³) _n is 2- <i>c</i> -Pr.	1255	A is A-1c and (R ³) _n is 2,5-di- <i>i</i> -Pr.
871	A is A-1c and (R ³) _n is 2,4-di- <i>c</i> -Pr.	1256	A is A-1c and (R ³) _n is 4,5-di- <i>i</i> -Pr.
872	A is A-1c and (R ³) _n is 2,6-di- <i>c</i> -Pr.	1257	A is A-1c and (R ³) _n is 4- <i>c</i> -Pr.
873	A is A-1c and (R ³) _n is 2-CF ₃ .	1258	A is A-1c and (R ³) _n is 2,5-di- <i>c</i> -Pr.
874	A is A-1c and (R ³) _n is 2,4-di-CF ₃ .	1259	A is A-1c and (R ³) _n is 4,5-di- <i>c</i> -Pr.
875	A is A-1c and (R ³) _n is 2,6-di-CF ₃ .	1260	A is A-1c and (R ³) _n is 4-CF ₃ .
876	A is A-1c and (R ³) _n is 2-OMe.	1261	A is A-1c and (R ³) _n is 2,5-di-CF ₃ .
877	A is A-1c and (R ³) _n is 2,4-di-OMe.	1262	A is A-1c and (R ³) _n is 4,5-di-CF ₃ .
878	A is A-1c and (R ³) _n is 2,6-di-OMe.	1263	A is A-1c and (R ³) _n is 4-OMe.
879	A is A-1c and (R ³) _n is 2-OCF ₃ .	1264	A is A-1c and (R ³) _n is 2,5-di-OMe.

880	A is A-1c and (R ³) _n is 2,4-di-OCF ₃ .	1265	A is A-1c and (R ³) _n is 4,5-di-OMe.
881	A is A-1c and (R ³) _n is 2,6-di-OCF ₃ .	1266	A is A-1c and (R ³) _n is 4-OCF ₃ .
882	A is A-1c and (R ³) _n is 2-TMS.	1267	A is A-1c and (R ³) _n is 2,5-di-OCF ₃ .
883	A is A-1c and (R ³) _n is 2,4-di-TMS.	1268	A is A-1c and (R ³) _n is 4,5-di-OCF ₃ .
884	A is A-1c and (R ³) _n is 2,6-di-TMS.	1269	A is A-1c and (R ³) _n is 4-TMS.
885	A is A-1c and (R ³) _n is 2-Cl-6-F.	1270	A is A-1c and (R ³) _n is 2,5-di-TMS.
886	A is A-1c and (R ³) _n is 2-Cl-4-F.	1271	A is A-1c and (R ³) _n is 4,5-di-TMS.
887	A is A-1d and (R ³) _n is H.	1272	A is A-1c and (R ³) _n is 2-Cl-6-Me.
888	A is A-1d and (R ³) _n is 2-F.	1273	A is A-1c and (R ³) _n is 2-Cl-4-Me.
889	A is A-1d and (R ³) _n is 2,4-di-F.	1274	A is A-1d and (R ³) _n is 4-F.
890	A is A-1d and (R ³) _n is 2,6-di-F.	1275	A is A-1d and (R ³) _n is 2,5-di-F.
891	A is A-1d and (R ³) _n is 2-Cl.	1276	A is A-1d and (R ³) _n is 4,5-di-F.
892	A is A-1d and (R ³) _n is 2,4-di-Cl.	1277	A is A-1d and (R ³) _n is 4-Cl.
893	A is A-1d and (R ³) _n is 2,6-di-Cl.	1278	A is A-1d and (R ³) _n is 2,5-di-Cl.
894	A is A-1d and (R ³) _n is 2-Br.	1279	A is A-1d and (R ³) _n is 4,5-di-Cl.
895	A is A-1d and (R ³) _n is 2,4-di-Br.	1280	A is A-1d and (R ³) _n is 4-Br.
896	A is A-1d and (R ³) _n is 2,6-di-Br.	1281	A is A-1d and (R ³) _n is 2,5-di-Br.
897	A is A-1d and (R ³) _n is 2-I.	1282	A is A-1d and (R ³) _n is 4,5-di-Br.
898	A is A-1d and (R ³) _n is 2,4-di-I.	1283	A is A-1d and (R ³) _n is 4-I.
899	A is A-1d and (R ³) _n is 2,6-di-I.	1284	A is A-1d and (R ³) _n is 2,5-di-I.
900	A is A-1d and (R ³) _n is 2-Me.	1285	A is A-1d and (R ³) _n is 4,5-di-I.
901	A is A-1d and (R ³) _n is 2,4-di-Me.	1286	A is A-1d and (R ³) _n is 4-Me.
902	A is A-1d and (R ³) _n is 2,6-di-Me.	1287	A is A-1d and (R ³) _n is 2,5-di-Me.
903	A is A-1d and (R ³) _n is 2-Et.	1288	A is A-1d and (R ³) _n is 4,5-di-Me.
904	A is A-1d and (R ³) _n is 2,4-di-Et.	1289	A is A-1d and (R ³) _n is 4-Et.
905	A is A-1d and (R ³) _n is 2,6-di-Et.	1290	A is A-1d and (R ³) _n is 2,5-di-Et.
906	A is A-1d and (R ³) _n is 2- <i>i</i> -Pr.	1291	A is A-1d and (R ³) _n is 4,5-di-Et.
907	A is A-1d and (R ³) _n is 2,4-di- <i>i</i> -Pr.	1292	A is A-1d and (R ³) _n is 4- <i>i</i> -Pr.
908	A is A-1d and (R ³) _n is 2,6-di- <i>i</i> -Pr.	1293	A is A-1d and (R ³) _n is 2,5-di- <i>i</i> -Pr.
909	A is A-1d and (R ³) _n is 2- <i>c</i> -Pr.	1294	A is A-1d and (R ³) _n is 4,5-di- <i>i</i> -Pr.
910	A is A-1d and (R ³) _n is 2,4-di- <i>c</i> -Pr.	1295	A is A-1d and (R ³) _n is 4- <i>c</i> -Pr.
911	A is A-1d and (R ³) _n is 2,6-di- <i>c</i> -Pr.	1296	A is A-1d and (R ³) _n is 2,5-di- <i>c</i> -Pr.
912	A is A-1d and (R ³) _n is 2-CF ₃ .	1297	A is A-1d and (R ³) _n is 4,5-di- <i>c</i> -Pr.
913	A is A-1d and (R ³) _n is 2,4-di-CF ₃ .	1298	A is A-1d and (R ³) _n is 4-CF ₃ .
914	A is A-1d and (R ³) _n is 2,6-di-CF ₃ .	1299	A is A-1d and (R ³) _n is 2,5-di-CF ₃ .
915	A is A-1d and (R ³) _n is 2-OMe.	1300	A is A-1d and (R ³) _n is 4,5-di-CF ₃ .
916	A is A-1d and (R ³) _n is 2,4-di-OMe.	1301	A is A-1d and (R ³) _n is 4-OMe.
917	A is A-1d and (R ³) _n is 2,6-di-OMe.	1302	A is A-1d and (R ³) _n is 2,5-di-OMe.

- 918 A is A-1d and (R³)_n is 2-OCF₃.
919 A is A-1d and (R³)_n is 2,4-di-OCF₃.
920 A is A-1d and (R³)_n is 2,6-di-OCF₃.
921 A is A-1d and (R³)_n is 2-TMS.
922 A is A-1d and (R³)_n is 2,4-di-TMS.
923 A is A-1d and (R³)_n is 2,6-di-TMS.
924 A is A-1d and (R³)_n is 2-Cl-6-F.
925 A is A-1d and (R³)_n is 2-Cl-4-F.
926 A is A-1e and (R³)_n is H.
927 A is A-1e and (R³)_n is 2-F.
928 A is A-1e and (R³)_n is 2,4-di-F.
929 A is A-1e and (R³)_n is 2,6-di-F.
930 A is A-1e and (R³)_n is 2-Cl.
931 A is A-1e and (R³)_n is 2,4-di-Cl.
932 A is A-1e and (R³)_n is 2,6-di-Cl.
933 A is A-1e and (R³)_n is 2-Br.
934 A is A-1e and (R³)_n is 2,4-di-Br.
935 A is A-1e and (R³)_n is 2,6-di-Br.
936 A is A-1e and (R³)_n is 2-I.
937 A is A-1e and (R³)_n is 2,4-di-I.
938 A is A-1e and (R³)_n is 2,6-di-I.
939 A is A-1e and (R³)_n is 2-Me.
940 A is A-1e and (R³)_n is 2,4-di-Me.
941 A is A-1e and (R³)_n is 2,6-di-Me.
942 A is A-1e and (R³)_n is 2-Et.
943 A is A-1e and (R³)_n is 2,4-di-Et.
944 A is A-1e and (R³)_n is 2,6-di-Et.
945 A is A-1e and (R³)_n is 2-*i*-Pr.
946 A is A-1e and (R³)_n is 2,4-di-*i*-Pr.
947 A is A-1e and (R³)_n is 2,6-di-*i*-Pr.
948 A is A-1e and (R³)_n is 2-*c*-Pr.
949 A is A-1e and (R³)_n is 2,4-di-*c*-Pr.
950 A is A-1e and (R³)_n is 2,6-di-*c*-Pr.
951 A is A-1e and (R³)_n is 2-CF₃.
952 A is A-1e and (R³)_n is 2,4-di-CF₃.
953 A is A-1e and (R³)_n is 2,6-di-CF₃.
954 A is A-1e and (R³)_n is 2-OMe.
955 A is A-1e and (R³)_n is 2,4-di-OMe.
- 1303 A is A-1d and (R³)_n is 4,5-di-OMe.
1304 A is A-1d and (R³)_n is 4-OCF₃.
1305 A is A-1d and (R³)_n is 2,5-di-OCF₃.
1306 A is A-1d and (R³)_n is 4,5-di-OCF₃.
1307 A is A-1d and (R³)_n is 4-TMS.
1308 A is A-1d and (R³)_n is 2,5-di-TMS.
1309 A is A-1d and (R³)_n is 4,5-di-TMS.
1310 A is A-1d and (R³)_n is 2-Cl-6-Me.
1311 A is A-1d and (R³)_n is 2-Cl-4-Me.
1312 A is A-1e and (R³)_n is 4-F.
1313 A is A-1e and (R³)_n is 2,5-di-F.
1314 A is A-1e and (R³)_n is 4,5-di-F.
1315 A is A-1e and (R³)_n is 4-Cl.
1316 A is A-1e and (R³)_n is 2,5-di-Cl.
1317 A is A-1e and (R³)_n is 4,5-di-Cl.
1318 A is A-1e and (R³)_n is 4-Br.
1319 A is A-1e and (R³)_n is 2,5-di-Br.
1320 A is A-1e and (R³)_n is 4,5-di-Br.
1321 A is A-1e and (R³)_n is 4-I.
1322 A is A-1e and (R³)_n is 2,5-di-I.
1323 A is A-1e and (R³)_n is 4,5-di-I.
1324 A is A-1e and (R³)_n is 4-Me.
1325 A is A-1e and (R³)_n is 2,5-di-Me.
1326 A is A-1e and (R³)_n is 4,5-di-Me.
1327 A is A-1e and (R³)_n is 4-Et.
1328 A is A-1e and (R³)_n is 2,5-di-Et.
1329 A is A-1e and (R³)_n is 4,5-di-Et.
1330 A is A-1e and (R³)_n is 4-*i*-Pr.
1331 A is A-1e and (R³)_n is 2,5-di-*i*-Pr.
1332 A is A-1e and (R³)_n is 4,5-di-*i*-Pr.
1333 A is A-1e and (R³)_n is 4-*c*-Pr.
1334 A is A-1e and (R³)_n is 2,5-di-*c*-Pr.
1335 A is A-1e and (R³)_n is 4,5-di-*c*-Pr.
1336 A is A-1e and (R³)_n is 4-CF₃.
1337 A is A-1e and (R³)_n is 2,5-di-CF₃.
1338 A is A-1e and (R³)_n is 4,5-di-CF₃.
1339 A is A-1e and (R³)_n is 4-OMe.
1340 A is A-1e and (R³)_n is 2,5-di-OMe.

956	A is A-1e and (R ³) _n is 2,6-di-OMe.	1341	A is A-1e and (R ³) _n is 4,5-di-OMe.
957	A is A-1e and (R ³) _n is 2-OCF ₃ .	1342	A is A-1e and (R ³) _n is 4-OCF ₃ .
958	A is A-1e and (R ³) _n is 2,4-di-OCF ₃ .	1343	A is A-1e and (R ³) _n is 2,5-di-OCF ₃ .
959	A is A-1e and (R ³) _n is 2,6-di-OCF ₃ .	1344	A is A-1e and (R ³) _n is 4,5-di-OCF ₃ .
960	A is A-1e and (R ³) _n is 2-TMS.	1345	A is A-1e and (R ³) _n is 4-TMS.
961	A is A-1e and (R ³) _n is 2,4-di-TMS.	1346	A is A-1e and (R ³) _n is 2,5-di-TMS.
962	A is A-1e and (R ³) _n is 2,6-di-TMS.	1347	A is A-1e and (R ³) _n is 4,5-di-TMS.
963	A is A-1e and (R ³) _n is 2-Cl-6-F.	1348	A is A-1e and (R ³) _n is 2-Cl-6-Me.
964	A is A-1e and (R ³) _n is 2-Cl-4-F.	1349	A is A-1e and (R ³) _n is 2-Cl-4-Me.
965	A is A-1f and (R ³) _n is H.	1350	A is A-1f and (R ³) _n is 4-F.
966	A is A-1f and (R ³) _n is 2-F.	1351	A is A-1f and (R ³) _n is 2,5-di-F.
967	A is A-1f and (R ³) _n is 2,4-di-F.	1352	A is A-1f and (R ³) _n is 4,5-di-F.
968	A is A-1f and (R ³) _n is 2,6-di-F.	1353	A is A-1f and (R ³) _n is 4-Cl.
969	A is A-1f and (R ³) _n is 2-Cl.	1354	A is A-1f and (R ³) _n is 2,5-di-Cl.
970	A is A-1f and (R ³) _n is 2,4-di-Cl.	1355	A is A-1f and (R ³) _n is 4,5-di-Cl.
971	A is A-1f and (R ³) _n is 2,6-di-Cl.	1356	A is A-1f and (R ³) _n is 4-Br.
972	A is A-1f and (R ³) _n is 2-Br.	1357	A is A-1f and (R ³) _n is 2,5-di-Br.
973	A is A-1f and (R ³) _n is 2,4-di-Br.	1358	A is A-1f and (R ³) _n is 4,5-di-Br.
974	A is A-1f and (R ³) _n is 2,6-di-Br.	1359	A is A-1f and (R ³) _n is 4-I.
975	A is A-1f and (R ³) _n is 2-I.	1360	A is A-1f and (R ³) _n is 2,5-di-I.
976	A is A-1f and (R ³) _n is 2,4-di-I.	1361	A is A-1f and (R ³) _n is 4,5-di-I.
977	A is A-1f and (R ³) _n is 2,6-di-I.	1362	A is A-1f and (R ³) _n is 4-Me.
978	A is A-1f and (R ³) _n is 2-Me.	1363	A is A-1f and (R ³) _n is 2,5-di-Me.
979	A is A-1f and (R ³) _n is 2,4-di-Me.	1364	A is A-1f and (R ³) _n is 4,5-di-Me.
980	A is A-1f and (R ³) _n is 2,6-di-Me.	1365	A is A-1f and (R ³) _n is 4-Et.
981	A is A-1f and (R ³) _n is 2-Et.	1366	A is A-1f and (R ³) _n is 2,5-di-Et.
982	A is A-1f and (R ³) _n is 2,4-di-Et.	1367	A is A-1f and (R ³) _n is 4,5-di-Et.
983	A is A-1f and (R ³) _n is 2,6-di-Et.	1368	A is A-1f and (R ³) _n is 4- <i>i</i> -Pr.
984	A is A-1f and (R ³) _n is 2- <i>i</i> -Pr.	1369	A is A-1f and (R ³) _n is 2,5-di- <i>i</i> -Pr.
985	A is A-1f and (R ³) _n is 2,4-di- <i>i</i> -Pr.	1370	A is A-1f and (R ³) _n is 4,5-di- <i>i</i> -Pr.
986	A is A-1f and (R ³) _n is 2,6-di- <i>i</i> -Pr.	1371	A is A-1f and (R ³) _n is 4- <i>c</i> -Pr.
987	A is A-1f and (R ³) _n is 2- <i>c</i> -Pr.	1372	A is A-1f and (R ³) _n is 2,5-di- <i>c</i> -Pr.
988	A is A-1f and (R ³) _n is 2,4-di- <i>c</i> -Pr.	1373	A is A-1f and (R ³) _n is 4,5-di- <i>c</i> -Pr.
989	A is A-1f and (R ³) _n is 2,6-di- <i>c</i> -Pr.	1374	A is A-1f and (R ³) _n is 4-CF ₃ .
990	A is A-1f and (R ³) _n is 2-CF ₃ .	1375	A is A-1f and (R ³) _n is 2,5-di-CF ₃ .
991	A is A-1f and (R ³) _n is 2,4-di-CF ₃ .	1376	A is A-1f and (R ³) _n is 4,5-di-CF ₃ .
992	A is A-1f and (R ³) _n is 2,6-di-CF ₃ .	1377	A is A-1f and (R ³) _n is 4-OMe.
993	A is A-1f and (R ³) _n is 2-OMe.	1378	A is A-1f and (R ³) _n is 2,5-di-OMe.

- 994 A is A-1f and $(R^3)_n$ is 2,4-di-OMe.
995 A is A-1f and $(R^3)_n$ is 2,6-di-OMe.
996 A is A-1f and $(R^3)_n$ is 2-OCF₃.
997 A is A-1f and $(R^3)_n$ is 2,4-di-OCF₃.
998 A is A-1f and $(R^3)_n$ is 2,6-di-OCF₃.
999 A is A-1f and $(R^3)_n$ is 2-TMS.
1000 A is A-1f and $(R^3)_n$ is 2,4-di-TMS.
1001 A is A-1f and $(R^3)_n$ is 2,6-di-TMS.
1002 A is A-1f and $(R^3)_n$ is 2-Cl-6-F.
1003 A is A-1f and $(R^3)_n$ is 2-Cl-4-F.
1004 A is A-1g and $(R^3)_n$ is H.
1005 A is A-1g and $(R^3)_n$ is 2-F.
1006 A is A-1g and $(R^3)_n$ is 2,4-di-F.
1007 A is A-1g and $(R^3)_n$ is 2,6-di-F.
1008 A is A-1g and $(R^3)_n$ is 2-Cl.
1009 A is A-1g and $(R^3)_n$ is 2,4-di-Cl.
1010 A is A-1g and $(R^3)_n$ is 2,6-di-Cl.
1011 A is A-1g and $(R^3)_n$ is 2-Br.
1012 A is A-1g and $(R^3)_n$ is 2,4-di-Br.
1013 A is A-1g and $(R^3)_n$ is 2,6-di-Br.
1014 A is A-1g and $(R^3)_n$ is 2-I.
1015 A is A-1g and $(R^3)_n$ is 2,4-di-I.
1016 A is A-1g and $(R^3)_n$ is 2,6-di-I.
1017 A is A-1g and $(R^3)_n$ is 2-Me.
1018 A is A-1g and $(R^3)_n$ is 2,4-di-Me.
1019 A is A-1g and $(R^3)_n$ is 2,6-di-Me.
1020 A is A-1g and $(R^3)_n$ is 2-Et.
1021 A is A-1g and $(R^3)_n$ is 2,4-di-Et.
1022 A is A-1g and $(R^3)_n$ is 2,6-di-Et.
1023 A is A-1g and $(R^3)_n$ is 2-*i*-Pr.
1024 A is A-1g and $(R^3)_n$ is 2,4-di-*i*-Pr.
1025 A is A-1g and $(R^3)_n$ is 2,6-di-*i*-Pr.
1026 A is A-1g and $(R^3)_n$ is 2-*c*-Pr.
1027 A is A-1g and $(R^3)_n$ is 2,4-di-*c*-Pr.
1028 A is A-1g and $(R^3)_n$ is 2,6-di-*c*-Pr.
1029 A is A-1g and $(R^3)_n$ is 2-CF₃.
1030 A is A-1g and $(R^3)_n$ is 2,4-di-CF₃.
1031 A is A-1g and $(R^3)_n$ is 2,6-di-CF₃.
1379 A is A-1f and $(R^3)_n$ is 4,5-di-OMe.
1380 A is A-1f and $(R^3)_n$ is 4-OCF₃.
1381 A is A-1f and $(R^3)_n$ is 2,5-di-OCF₃.
1382 A is A-1f and $(R^3)_n$ is 4,5-di-OCF₃.
1383 A is A-1f and $(R^3)_n$ is 4-TMS.
1384 A is A-1f and $(R^3)_n$ is 2,5-di-TMS.
1385 A is A-1f and $(R^3)_n$ is 4,5-di-TMS.
1386 A is A-1f and $(R^3)_n$ is 2-Cl-6-Me.
1387 A is A-1f and $(R^3)_n$ is 2-Cl-4-Me.
1388 A is A-1g and $(R^3)_n$ is 4-F.
1389 A is A-1g and $(R^3)_n$ is 2,5-di-F.
1390 A is A-1g and $(R^3)_n$ is 4,5-di-F.
1391 A is A-1g and $(R^3)_n$ is 4-Cl.
1392 A is A-1g and $(R^3)_n$ is 2,5-di-Cl.
1393 A is A-1g and $(R^3)_n$ is 4,5-di-Cl.
1394 A is A-1g and $(R^3)_n$ is 4-Br.
1395 A is A-1g and $(R^3)_n$ is 2,5-di-Br.
1396 A is A-1g and $(R^3)_n$ is 4,5-di-Br.
1397 A is A-1g and $(R^3)_n$ is 4-I.
1398 A is A-1g and $(R^3)_n$ is 2,5-di-I.
1399 A is A-1g and $(R^3)_n$ is 4,5-di-I.
1400 A is A-1g and $(R^3)_n$ is 4-Me.
1401 A is A-1g and $(R^3)_n$ is 2,5-di-Me.
1402 A is A-1g and $(R^3)_n$ is 4,5-di-Me.
1403 A is A-1g and $(R^3)_n$ is 4-Et.
1404 A is A-1g and $(R^3)_n$ is 2,5-di-Et.
1405 A is A-1g and $(R^3)_n$ is 4,5-di-Et.
1406 A is A-1g and $(R^3)_n$ is 4-*i*-Pr.
1407 A is A-1g and $(R^3)_n$ is 2,5-di-*i*-Pr.
1408 A is A-1g and $(R^3)_n$ is 4,5-di-*i*-Pr.
1409 A is A-1g and $(R^3)_n$ is 4-*c*-Pr.
1410 A is A-1g and $(R^3)_n$ is 2,5-di-*c*-Pr.
1411 A is A-1g and $(R^3)_n$ is 4,5-di-*c*-Pr.
1412 A is A-1g and $(R^3)_n$ is 4-CF₃.
1413 A is A-1g and $(R^3)_n$ is 2,5-di-CF₃.
1414 A is A-1g and $(R^3)_n$ is 4,5-di-CF₃.
1415 A is A-1g and $(R^3)_n$ is 4-OMe.
1416 A is A-1g and $(R^3)_n$ is 2,5-di-OMe.

- 1032 A is A-1g and (R³)_n is 2-OMe.
1033 A is A-1g and (R³)_n is 2,4-di-OMe.
1034 A is A-1g and (R³)_n is 2,6-di-OMe.
1035 A is A-1g and (R³)_n is 2-OCF₃.
1036 A is A-1g and (R³)_n is 2,4-di-OCF₃.
1037 A is A-1g and (R³)_n is 2,6-di-OCF₃.
1038 A is A-1g and (R³)_n is 2-TMS.
1039 A is A-1g and (R³)_n is 2,4-di-TMS.
1040 A is A-1g and (R³)_n is 2,6-di-TMS.
1041 A is A-1g and (R³)_n is 2-Cl-6-F.
1042 A is A-1g and (R³)_n is 2-Cl-4-F.
1043 A is A-1h and (R³)_n is H.
1044 A is A-1h and (R³)_n is 2-F.
1045 A is A-1h and (R³)_n is 2,4-di-F.
1046 A is A-1h and (R³)_n is 2,6-di-F.
1047 A is A-1h and (R³)_n is 2-Cl.
1048 A is A-1h and (R³)_n is 2,4-di-Cl.
1049 A is A-1h and (R³)_n is 2,6-di-Cl.
1050 A is A-1h and (R³)_n is 2-Br.
1051 A is A-1h and (R³)_n is 2,4-di-Br.
1052 A is A-1h and (R³)_n is 2,6-di-Br.
1053 A is A-1h and (R³)_n is 2-I.
1054 A is A-1h and (R³)_n is 2,4-di-I.
1055 A is A-1h and (R³)_n is 2,6-di-I.
1056 A is A-1h and (R³)_n is 2-Me.
1057 A is A-1h and (R³)_n is 2,4-di-Me.
1058 A is A-1h and (R³)_n is 2,6-di-Me.
1059 A is A-1h and (R³)_n is 2-Et.
1060 A is A-1h and (R³)_n is 2,4-di-Et.
1061 A is A-1h and (R³)_n is 2,6-di-Et.
1062 A is A-1h and (R³)_n is 2-*i*-Pr.
1063 A is A-1h and (R³)_n is 2,4-di-*i*-Pr.
1064 A is A-1h and (R³)_n is 2,6-di-*i*-Pr.
1065 A is A-1h and (R³)_n is 2-*c*-Pr.
1066 A is A-1h and (R³)_n is 2,4-di-*c*-Pr.
1067 A is A-1h and (R³)_n is 2,6-di-*c*-Pr.
1068 A is A-1h and (R³)_n is 2-CF₃.
1069 A is A-1h and (R³)_n is 2,4-di-CF₃.
1417 A is A-1g and (R³)_n is 4,5-di-OMe.
1418 A is A-1g and (R³)_n is 4-OCF₃.
1419 A is A-1g and (R³)_n is 2,5-di-OCF₃.
1420 A is A-1g and (R³)_n is 4,5-di-OCF₃.
1421 A is A-1g and (R³)_n is 4-TMS.
1422 A is A-1g and (R³)_n is 2,5-di-TMS.
1423 A is A-1g and (R³)_n is 4,5-di-TMS.
1424 A is A-1g and (R³)_n is 2-Cl-6-Me.
1425 A is A-1g and (R³)_n is 2-Cl-4-Me.
1426 A is A-1h and (R³)_n is 4-F.
1427 A is A-1h and (R³)_n is 2,5-di-F.
1428 A is A-1h and (R³)_n is 4,5-di-F.
1429 A is A-1h and (R³)_n is 4-Cl.
1430 A is A-1h and (R³)_n is 2,5-di-Cl.
1431 A is A-1h and (R³)_n is 4,5-di-Cl.
1432 A is A-1h and (R³)_n is 4-Br.
1433 A is A-1h and (R³)_n is 2,5-di-Br.
1434 A is A-1h and (R³)_n is 4,5-di-Br.
1435 A is A-1h and (R³)_n is 4-I.
1436 A is A-1h and (R³)_n is 2,5-di-I.
1437 A is A-1h and (R³)_n is 4,5-di-I.
1438 A is A-1h and (R³)_n is 4-Me.
1439 A is A-1h and (R³)_n is 2,5-di-Me.
1440 A is A-1h and (R³)_n is 4,5-di-Me.
1441 A is A-1h and (R³)_n is 4-Et.
1442 A is A-1h and (R³)_n is 2,5-di-Et.
1443 A is A-1h and (R³)_n is 4,5-di-Et.
1444 A is A-1h and (R³)_n is 4-*i*-Pr.
1445 A is A-1h and (R³)_n is 2,5-di-*i*-Pr.
1446 A is A-1h and (R³)_n is 4,5-di-*i*-Pr.
1447 A is A-1h and (R³)_n is 4-*c*-Pr.
1448 A is A-1h and (R³)_n is 2,5-di-*c*-Pr.
1449 A is A-1h and (R³)_n is 4,5-di-*c*-Pr.
1450 A is A-1h and (R³)_n is 4-CF₃.
1451 A is A-1h and (R³)_n is 2,5-di-CF₃.
1452 A is A-1h and (R³)_n is 4,5-di-CF₃.
1453 A is A-1h and (R³)_n is 4-OMe.
1454 A is A-1h and (R³)_n is 2,5-di-OMe.

- 1070 A is A-1h and (R³)_n is 2,6-di-CF₃.
1071 A is A-1h and (R³)_n is 2-OMe.
1072 A is A-1h and (R³)_n is 2,4-di-OMe.
1073 A is A-1h and (R³)_n is 2,6-di-OMe.
1074 A is A-1h and (R³)_n is 2-OCF₃.
1075 A is A-1h and (R³)_n is 2,4-di-OCF₃.
1076 A is A-1h and (R³)_n is 2,6-di-OCF₃.
1077 A is A-1h and (R³)_n is 2-TMS.
1078 A is A-1h and (R³)_n is 2,4-di-TMS.
1079 A is A-1h and (R³)_n is 2,6-di-TMS.
1080 A is A-1h and (R³)_n is 2-Cl-6-F.
1081 A is A-1h and (R³)_n is 2-Cl-4-F.
1082 A is A-1i and (R³)_n is H.
1083 A is A-1i and (R³)_n is 2-F.
1084 A is A-1i and (R³)_n is 2,4-di-F.
1085 A is A-1i and (R³)_n is 2,6-di-F.
1086 A is A-1i and (R³)_n is 2-Cl.
1087 A is A-1i and (R³)_n is 2,4-di-Cl.
1088 A is A-1i and (R³)_n is 2,6-di-Cl.
1089 A is A-1i and (R³)_n is 2-Br.
1090 A is A-1i and (R³)_n is 2,4-di-Br.
1091 A is A-1i and (R³)_n is 2,6-di-Br.
1092 A is A-1i and (R³)_n is 2-I.
1093 A is A-1i and (R³)_n is 2,4-di-I.
1094 A is A-1i and (R³)_n is 2,6-di-I.
1095 A is A-1i and (R³)_n is 2-Me.
1096 A is A-1i and (R³)_n is 2,4-di-Me.
1097 A is A-1i and (R³)_n is 2,6-di-Me.
1098 A is A-1i and (R³)_n is 2-Et.
1099 A is A-1i and (R³)_n is 2,4-di-Et.
1100 A is A-1i and (R³)_n is 2,6-di-Et.
1101 A is A-1i and (R³)_n is 2-*i*-Pr.
1102 A is A-1i and (R³)_n is 2,4-di-*i*-Pr.
1103 A is A-1i and (R³)_n is 2,6-di-*i*-Pr.
1104 A is A-1i and (R³)_n is 2-*c*-Pr.
1105 A is A-1i and (R³)_n is 2,4-di-*c*-Pr.
1106 A is A-1i and (R³)_n is 2,6-di-*c*-Pr.
1107 A is A-1i and (R³)_n is 2-CF₃.
1455 A is A-1h and (R³)_n is 4,5-di-OMe.
1456 A is A-1h and (R³)_n is 4-OCF₃.
1457 A is A-1h and (R³)_n is 2,5-di-OCF₃.
1458 A is A-1h and (R³)_n is 4,5-di-OCF₃.
1459 A is A-1h and (R³)_n is 4-TMS.
1460 A is A-1h and (R³)_n is 2,5-di-TMS.
1461 A is A-1h and (R³)_n is 4,5-di-TMS.
1462 A is A-1h and (R³)_n is 2-Cl-6-Me.
1463 A is A-1h and (R³)_n is 2-Cl-4-Me.
1464 A is A-1i and (R³)_n is 4-F.
1465 A is A-1i and (R³)_n is 2,5-di-F.
1466 A is A-1i and (R³)_n is 4,5-di-F.
1467 A is A-1i and (R³)_n is 4-Cl.
1468 A is A-1i and (R³)_n is 2,5-di-Cl.
1469 A is A-1i and (R³)_n is 4,5-di-Cl.
1470 A is A-1i and (R³)_n is 4-Br.
1471 A is A-1i and (R³)_n is 2,5-di-Br.
1472 A is A-1i and (R³)_n is 4,5-di-Br.
1473 A is A-1i and (R³)_n is 4-I.
1474 A is A-1i and (R³)_n is 2,5-di-I.
1475 A is A-1i and (R³)_n is 4,5-di-I.
1476 A is A-1i and (R³)_n is 4-Me.
1477 A is A-1i and (R³)_n is 2,5-di-Me.
1478 A is A-1i and (R³)_n is 4,5-di-Me.
1479 A is A-1i and (R³)_n is 4-Et.
1480 A is A-1i and (R³)_n is 2,5-di-Et.
1481 A is A-1i and (R³)_n is 4,5-di-Et.
1482 A is A-1i and (R³)_n is 4-*i*-Pr.
1483 A is A-1i and (R³)_n is 2,5-di-*i*-Pr.
1484 A is A-1i and (R³)_n is 4,5-di-*i*-Pr.
1485 A is A-1i and (R³)_n is 4-*c*-Pr.
1486 A is A-1i and (R³)_n is 2,5-di-*c*-Pr.
1487 A is A-1i and (R³)_n is 4,5-di-*c*-Pr.
1488 A is A-1i and (R³)_n is 4-CF₃.
1489 A is A-1i and (R³)_n is 2,5-di-CF₃.
1490 A is A-1i and (R³)_n is 4,5-di-CF₃.
1491 A is A-1i and (R³)_n is 4-OMe.
1492 A is A-1i and (R³)_n is 2,5-di-OMe.

- 1108 A is A-1i and (R³)_n is 2,4-di-CF₃.
 1109 A is A-1i and (R³)_n is 2,6-di-CF₃.
 1110 A is A-1i and (R³)_n is 2-OMe.
 1111 A is A-1i and (R³)_n is 2,4-di-OMe.
 1112 A is A-1i and (R³)_n is 2,6-di-OMe.
 1113 A is A-1i and (R³)_n is 2-OCF₃.
 1114 A is A-1i and (R³)_n is 2,4-di-OCF₃.
 1115 A is A-1i and (R³)_n is 2,6-di-OCF₃.
 1116 A is A-1i and (R³)_n is 2-TMS.
 1117 A is A-1i and (R³)_n is 2,4-di-TMS.
 1118 A is A-1i and (R³)_n is 2,6-di-TMS.
 1119 A is A-1i and (R³)_n is 2-Cl-6-F.
 1120 A is A-1i and (R³)_n is 2-Cl-4-F.
 1121 A is A-1j and (R³)_n is H.
 1122 A is A-1j and (R³)_n is 2-F.
 1123 A is A-1j and (R³)_n is 2,4-di-F.
 1124 A is A-1j and (R³)_n is 2,6-di-F.
 1125 A is A-1j and (R³)_n is 2-Cl.
 1126 A is A-1j and (R³)_n is 2,4-di-Cl.
 1127 A is A-1j and (R³)_n is 2,6-di-Cl.
 1128 A is A-1j and (R³)_n is 2-Br.
 1129 A is A-1j and (R³)_n is 2,4-di-Br.
 1130 A is A-1j and (R³)_n is 2,6-di-Br.
 1131 A is A-1j and (R³)_n is 2-I.
 1132 A is A-1j and (R³)_n is 2,4-di-I.
 1133 A is A-1j and (R³)_n is 2,6-di-I.
 1134 A is A-1j and (R³)_n is 2-Me.
 1135 A is A-1j and (R³)_n is 2,4-di-Me.
 1136 A is A-1j and (R³)_n is 2,6-di-Me.
 1137 A is A-1j and (R³)_n is 2-Et.
 1138 A is A-1j and (R³)_n is 2,4-di-Et.
 1139 A is A-1j and (R³)_n is 2,6-di-Et.
 1140 A is A-1j and (R³)_n is 2-*i*-Pr.
 1141 A is A-1j and (R³)_n is 2,4-di-*i*-Pr.
 1142 A is A-1j and (R³)_n is 2,6-di-*i*-Pr.
 1143 A is A-1j and (R³)_n is 2-*c*-Pr.
 1144 A is A-1j and (R³)_n is 2,4-di-*c*-Pr.
 1145 A is A-1j and (R³)_n is 2,6-di-*c*-Pr.
 1493 A is A-1i and (R³)_n is 4,5-di-OMe.
 1494 A is A-1i and (R³)_n is 4-OCF₃.
 1495 A is A-1i and (R³)_n is 2,5-di-OCF₃.
 1496 A is A-1i and (R³)_n is 4,5-di-OCF₃.
 1497 A is A-1i and (R³)_n is 4-TMS.
 1498 A is A-1i and (R³)_n is 2,5-di-TMS.
 1499 A is A-1i and (R³)_n is 4,5-di-TMS.
 1500 A is A-1i and (R³)_n is 2-Cl-6-Me.
 1501 A is A-1i and (R³)_n is 2-Cl-4-Me.
 1502 A is A-1j and (R³)_n is 4-F.
 1503 A is A-1j and (R³)_n is 2,5-di-F.
 1504 A is A-1j and (R³)_n is 4,5-di-F.
 1505 A is A-1j and (R³)_n is 4-Cl.
 1506 A is A-1j and (R³)_n is 2,5-di-Cl.
 1507 A is A-1j and (R³)_n is 4,5-di-Cl.
 1508 A is A-1j and (R³)_n is 4-Br.
 1509 A is A-1j and (R³)_n is 2,5-di-Br.
 1510 A is A-1j and (R³)_n is 4,5-di-Br.
 1511 A is A-1j and (R³)_n is 4-I.
 1512 A is A-1j and (R³)_n is 2,5-di-I.
 1513 A is A-1j and (R³)_n is 4,5-di-I.
 1514 A is A-1j and (R³)_n is 4-Me.
 1515 A is A-1j and (R³)_n is 2,5-di-Me.
 1516 A is A-1j and (R³)_n is 4,5-di-Me.
 1517 A is A-1j and (R³)_n is 4-Et.
 1518 A is A-1j and (R³)_n is 2,5-di-Et.
 1519 A is A-1j and (R³)_n is 4,5-di-Et.
 1520 A is A-1j and (R³)_n is 4-*i*-Pr.
 1521 A is A-1j and (R³)_n is 2,5-di-*i*-Pr.
 1522 A is A-1j and (R³)_n is 4,5-di-*i*-Pr.
 1523 A is A-1j and (R³)_n is 4-*c*-Pr.
 1524 A is A-1j and (R³)_n is 2,5-di-*c*-Pr.
 1525 A is A-1j and (R³)_n is 4,5-di-*c*-Pr.
 1526 A is A-1j and (R³)_n is 4-CF₃.
 1527 A is A-1j and (R³)_n is 2,5-di-CF₃.
 1528 A is A-1j and (R³)_n is 4,5-di-CF₃.
 1529 A is A-1j and (R³)_n is 4-OMe.
 1530 A is A-1j and (R³)_n is 2,5-di-OMe.

- | | | | |
|------|---------------------------------------------------------------------------|------|---------------------------------------------------------------------------|
| 1146 | A is A-1j and (R ³) _n is 2-CF ₃ . | 1531 | A is A-1j and (R ³) _n is 4,5-di-OMe. |
| 1147 | A is A-1j and (R ³) _n is 2,4-di-CF ₃ . | 1532 | A is A-1j and (R ³) _n is 4-OCF ₃ . |
| 1148 | A is A-1j and (R ³) _n is 2,6-di-CF ₃ . | 1533 | A is A-1j and (R ³) _n is 2,5-di-OCF ₃ . |
| 1149 | A is A-1j and (R ³) _n is 2-OMe. | 1534 | A is A-1j and (R ³) _n is 4,5-di-OCF ₃ . |
| 1150 | A is A-1j and (R ³) _n is 2,4-di-OMe. | 1535 | A is A-1j and (R ³) _n is 4-TMS. |
| 1151 | A is A-1j and (R ³) _n is 2,6-di-OMe. | 1536 | A is A-1j and (R ³) _n is 2,5-di-TMS. |
| 1152 | A is A-1j and (R ³) _n is 2-OCF ₃ . | 1537 | A is A-1j and (R ³) _n is 4,5-di-TMS. |
| 1153 | A is A-1j and (R ³) _n is 2,4-di-OCF ₃ . | 1538 | A is A-1j and (R ³) _n is 2-Cl-6-Me. |
| 1154 | A is A-1j and (R ³) _n is 2,6-di-OCF ₃ . | 1539 | A is A-1j and (R ³) _n is 2-Cl-4-Me. |
| 1155 | A is A-1j and (R ³) _n is 2-TMS. | | |

Formulation/Utility

A compound of Formula 1 of this invention (including *N*-oxides and salts thereof) will generally be used as a fungicidal active ingredient in a composition, i.e. formulation, with at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, which serve as a carrier. The formulation or composition ingredients are selected to be consistent with the physical properties of the active ingredient, mode of application and environmental factors such as soil type, moisture and temperature.

Useful formulations include both liquid and solid compositions. Liquid compositions include solutions (including emulsifiable concentrates), suspensions, emulsions (including microemulsions, oil-in-water emulsions, flowable concentrates and/or suspoemulsions) and the like, which optionally can be thickened into gels. The general types of aqueous liquid compositions are soluble concentrate, suspension concentrate, capsule suspension, concentrated emulsion, microemulsion, oil-in-water emulsion, flowable concentrate and suspo-emulsion. The general types of nonaqueous liquid compositions are emulsifiable concentrate, microemulsifiable concentrate, dispersible concentrate and oil dispersion.

The general types of solid compositions are dusts, powders, granules, pellets, prills, pastilles, tablets, filled films (including seed coatings) and the like, which can be water-dispersible ("wettable") or water-soluble. Films and coatings formed from film-forming solutions or flowable suspensions are particularly useful for seed treatment. Active ingredient can be (micro)encapsulated and further formed into a suspension or solid formulation; alternatively the entire formulation of active ingredient can be encapsulated (or "overcoated"). Encapsulation can control or delay release of the active ingredient. An emulsifiable granule combines the advantages of both an emulsifiable concentrate formulation and a dry granular formulation. High-strength compositions are primarily used as intermediates for further formulation.

Sprayable formulations are typically extended in a suitable medium before spraying. Such liquid and solid formulations are formulated to be readily diluted in the spray medium, usually water, but occasionally another suitable medium like an aromatic or paraffinic

hydrocarbon or vegetable oil. Spray volumes can range from about one to several thousand liters per hectare, but more typically are in the range from about ten to several hundred liters per hectare. Sprayable formulations can be tank mixed with water or another suitable medium for foliar treatment by aerial or ground application, or for application to the growing medium of the plant. Liquid and dry formulations can be metered directly into drip irrigation systems or metered into the furrow during planting. Liquid and solid formulations can be applied onto seeds of crops and other desirable vegetation as seed treatments before planting to protect developing roots and other subterranean plant parts and/or foliage through systemic uptake.

- 10 The formulations will typically contain effective amounts of active ingredient, diluent and surfactant within the following approximate ranges which add up to 100 percent by weight.

	Weight Percent		
	<u>Active Ingredient</u>	<u>Diluent</u>	<u>Surfactant</u>
Water-Dispersible and Water-soluble Granules, Tablets and Powders	0.001–90	0–99.999	0–15
Oil Dispersions, Suspensions, Emulsions, Solutions (including Emulsifiable Concentrates)	1–50	40–99	0–50
Dusts	1–25	70–99	0–5
Granules and Pellets	0.001–95	5–99.999	0–15
High Strength Compositions	90–99	0–10	0–2

- 15 Solid diluents include, for example, clays such as bentonite, montmorillonite, attapulgite and kaolin, gypsum, cellulose, titanium dioxide, zinc oxide, starch, dextrin, sugars (e.g., lactose, sucrose), silica, talc, mica, diatomaceous earth, urea, calcium carbonate, sodium carbonate and bicarbonate, and sodium sulfate. Typical solid diluents are described in Watkins et al., *Handbook of Insecticide Dust Diluents and Carriers*, 2nd Ed., Dorland Books, Caldwell, New Jersey.

- 20 Liquid diluents include, for example, water, *N,N*-dimethylalkanamides (e.g., *N,N*-dimethylformamide), limonene, dimethyl sulfoxide, *N*-alkylpyrrolidones (e.g., *N*-methylpyrrolidinone), alkyl phosphates (e.g., triethyl phosphate), ethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, propylene carbonate, butylene carbonate, paraffins (e.g., white mineral oils, normal paraffins, isoparaffins), alkylbenzenes, alkylnaphthalenes, glycerine, glycerol triacetate, sorbitol,
25 aromatic hydrocarbons, dearomatized aliphatics, alkylbenzenes, alkylnaphthalenes, ketones such as cyclohexanone, 2-heptanone, isophorone and 4-hydroxy-4-methyl-2-pentanone,

acetates such as isoamyl acetate, hexyl acetate, heptyl acetate, octyl acetate, nonyl acetate, tridecyl acetate and isobornyl acetate, other esters such as alkylated lactate esters, dibasic esters, alkyl and aryl benzoates and γ -butyrolactone, and alcohols, which can be linear, branched, saturated or unsaturated, such as methanol, ethanol, *n*-propanol, isopropyl alcohol, 5 *n*-butanol, isobutyl alcohol, *n*-hexanol, 2-ethylhexanol, *n*-octanol, decanol, isodecyl alcohol, isooctadecanol, cetyl alcohol, lauryl alcohol, tridecyl alcohol, oleyl alcohol, cyclohexanol, tetrahydrofurfuryl alcohol, diacetone alcohol, cresol and benzyl alcohol. Liquid diluents also include glycerol esters of saturated and unsaturated fatty acids (typically C₆–C₂₂), such as plant seed and fruit oils (e.g., oils of olive, castor, linseed, sesame, corn 10 (maize), peanut, sunflower, grapeseed, safflower, cottonseed, soybean, rapeseed, coconut and palm kernel), animal-sourced fats (e.g., beef tallow, pork tallow, lard, cod liver oil, fish oil), and mixtures thereof. Liquid diluents also include alkylated fatty acids (e.g., methylated, ethylated, butylated) wherein the fatty acids may be obtained by hydrolysis of glycerol esters from plant and animal sources, and can be purified by distillation. Typical 15 liquid diluents are described in Marsden, *Solvents Guide*, 2nd Ed., Interscience, New York, 1950.

The solid and liquid compositions of the present invention often include one or more surfactants. When added to a liquid, surfactants (also known as “surface-active agents”) generally modify, most often reduce, the surface tension of the liquid. Depending on the 20 nature of the hydrophilic and lipophilic groups in a surfactant molecule, surfactants can be useful as wetting agents, dispersants, emulsifiers or defoaming agents.

Surfactants can be classified as nonionic, anionic or cationic. Nonionic surfactants useful for the present compositions include, but are not limited to: alcohol alkoxylates such as alcohol alkoxylates based on natural and synthetic alcohols (which may be branched or 25 linear) and prepared from the alcohols and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof; amine ethoxylates, alkanolamides and ethoxylated alkanolamides; alkoxylated triglycerides such as ethoxylated soybean, castor and rapeseed oils; alkylphenol alkoxylates such as octylphenol ethoxylates, nonylphenol ethoxylates, dinonyl phenol ethoxylates and dodecyl phenol ethoxylates (prepared from the phenols and ethylene oxide, 30 propylene oxide, butylene oxide or mixtures thereof); block polymers prepared from ethylene oxide or propylene oxide and reverse block polymers where the terminal blocks are prepared from propylene oxide; ethoxylated fatty acids; ethoxylated fatty esters and oils; ethoxylated methyl esters; ethoxylated tristyrylphenol (including those prepared from ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); fatty acid esters, 35 glycerol esters, lanolin-based derivatives, polyethoxylate esters such as polyethoxylated sorbitan fatty acid esters, polyethoxylated sorbitol fatty acid esters and polyethoxylated glycerol fatty acid esters; other sorbitan derivatives such as sorbitan esters; polymeric surfactants such as random copolymers, block copolymers, alkyd peg (polyethylene glycol)

resins, graft or comb polymers and star polymers; polyethylene glycols (pegs); polyethylene glycol fatty acid esters; silicone-based surfactants; and sugar-derivatives such as sucrose esters, alkyl polyglycosides and alkyl polysaccharides.

Useful anionic surfactants include, but are not limited to: alkylaryl sulfonic acids and their salts; carboxylated alcohol or alkylphenol ethoxylates; diphenyl sulfonate derivatives; lignin and lignin derivatives such as lignosulfonates; maleic or succinic acids or their anhydrides; olefin sulfonates; phosphate esters such as phosphate esters of alcohol alkoxylates, phosphate esters of alkylphenol alkoxylates and phosphate esters of styryl phenol ethoxylates; protein-based surfactants; sarcosine derivatives; styryl phenol ether sulfate; sulfates and sulfonates of oils and fatty acids; sulfates and sulfonates of ethoxylated alkylphenols; sulfates of alcohols; sulfates of ethoxylated alcohols; sulfonates of amines and amides such as *N,N*-alkyltaurates; sulfonates of benzene, cumene, toluene, xylene, and dodecyl and tridecylbenzenes; sulfonates of condensed naphthalenes; sulfonates of naphthalene and alkyl naphthalene; sulfonates of fractionated petroleum; sulfosuccinamates; and sulfosuccinates and their derivatives such as dialkyl sulfosuccinate salts.

Useful cationic surfactants include, but are not limited to: amides and ethoxylated amides; amines such as *N*-alkyl propanediamines, tripropylenetriamines and dipropylenetetramines, and ethoxylated amines, ethoxylated diamines and propoxylated amines (prepared from the amines and ethylene oxide, propylene oxide, butylene oxide or mixtures thereof); amine salts such as amine acetates and diamine salts; quaternary ammonium salts such as quaternary salts, ethoxylated quaternary salts and diquaternary salts; and amine oxides such as alkyldimethylamine oxides and bis-(2-hydroxyethyl)-alkylamine oxides.

Also useful for the present compositions are mixtures of nonionic and anionic surfactants or mixtures of nonionic and cationic surfactants. Nonionic, anionic and cationic surfactants and their recommended uses are disclosed in a variety of published references including *McCutcheon's Emulsifiers and Detergents*, annual American and International Editions published by McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; Sisely and Wood, *Encyclopedia of Surface Active Agents*, Chemical Publ. Co., Inc., New York, 1964; and A. S. Davidson and B. Milwidsky, *Synthetic Detergents*, Seventh Edition, John Wiley and Sons, New York, 1987.

Compositions of this invention may also contain formulation auxiliaries and additives, known to those skilled in the art as formulation aids (some of which may be considered to also function as solid diluents, liquid diluents or surfactants). Such formulation auxiliaries and additives may control: pH (buffers), foaming during processing (antifoams such as polyorganosiloxanes), sedimentation of active ingredients (suspending agents), viscosity (thixotropic thickeners), in-container microbial growth (antimicrobials), product freezing (antifreezes), color (dyes/pigment dispersions), wash-off (film formers or stickers),

evaporation (evaporation retardants), and other formulation attributes. Film formers include, for example, polyvinyl acetates, polyvinyl acetate copolymers, polyvinylpyrrolidone-vinyl acetate copolymer, polyvinyl alcohols, polyvinyl alcohol copolymers and waxes. Examples of formulation auxiliaries and additives include those listed in *McCutcheon's Volume 2: Functional Materials*, annual International and North American editions published by
5 McCutcheon's Division, The Manufacturing Confectioner Publishing Co.; and PCT Publication WO 03/024222.

The compound of Formula 1 and any other active ingredients are typically incorporated into the present compositions by dissolving the active ingredient in a solvent or
10 by grinding in a liquid or dry diluent. Solutions, including emulsifiable concentrates, can be prepared by simply mixing the ingredients. If the solvent of a liquid composition intended for use as an emulsifiable concentrate is water-immiscible, an emulsifier is typically added to emulsify the active-containing solvent upon dilution with water. Active ingredient slurries, with particle diameters of up to 2,000 μm can be wet milled using media mills to obtain
15 particles with average diameters below 3 μm . Aqueous slurries can be made into finished suspension concentrates (see, for example, U.S. 3,060,084) or further processed by spray drying to form water-dispersible granules. Dry formulations usually require dry milling processes, which produce average particle diameters in the 2 to 10 μm range. Dusts and powders can be prepared by blending and usually grinding (such as with a hammer mill or
20 fluid-energy mill). Granules and pellets can be prepared by spraying the active material upon preformed granular carriers or by agglomeration techniques. See Browning, "Agglomeration", *Chemical Engineering*, December 4, 1967, pp 147-48, *Perry's Chemical Engineer's Handbook*, 4th Ed., McGraw-Hill, New York, 1963, pages 8-57 and following, and WO 91/13546. Pellets can be prepared as described in U.S. 4,172,714.
25 Water-dispersible and water-soluble granules can be prepared as taught in U.S. 4,144,050, U.S. 3,920,442 and DE 3,246,493. Tablets can be prepared as taught in U.S. 5,180,587, U.S. 5,232,701 and U.S. 5,208,030. Films can be prepared as taught in GB 2,095,558 and U.S. 3,299,566. One embodiment of the present invention relates to a method for controlling fungal pathogens, comprising diluting the fungicidal composition of the present invention (a
30 compound of Formula 1 formulated with surfactants, solid diluents and liquid diluents or a formulated mixture of a compound of Formula 1 and at least one other fungicide) with water, and optionally adding an adjuvant to form a diluted composition, and contacting the fungal pathogen or its environment with an effective amount of said diluted composition.

Although a spray composition formed by diluting with water a sufficient concentration
35 of the present fungicidal composition can provide sufficient efficacy for controlling fungal pathogens, separately formulated adjuvant products can also be added to spray tank mixtures. These additional adjuvants are commonly known as "spray adjuvants" or "tank-mix adjuvants", and include any substance mixed in a spray tank to improve the performance

of a pesticide or alter the physical properties of the spray mixture. Adjuvants can be anionic or nonionic surfactants, emulsifying agents, petroleum-based crop oils, crop-derived seed oils, acidifiers, buffers, thickeners or defoaming agents. Adjuvants are used to enhancing efficacy (e.g., biological availability, adhesion, penetration, uniformity of coverage and durability of protection), or minimizing or eliminating spray application problems associated with incompatibility, foaming, drift, evaporation, volatilization and degradation. To obtain optimal performance, adjuvants are selected with regard to the properties of the active ingredient, formulation and target (e.g., crops, insect pests).

The amount of adjuvants added to spray mixtures is generally in the range of about 2.5% to 0.1 % by volume. The application rates of adjuvants added to spray mixtures are typically between about 1 to 5 L per hectare. Representative examples of spray adjuvants include: Adigor[®] (Syngenta) 47% methylated rapeseed oil in liquid hydrocarbons, Silwet[®] (Helena Chemical Company) polyalkyleneoxide modified heptamethyltrisiloxane and Assist[®] (BASF) 17% surfactant blend in 83% paraffin based mineral oil.

One method of seed treatment is by spraying or dusting the seed with a compound of the invention (i.e. as a formulated composition) before sowing the seeds. Compositions formulated for seed treatment generally comprise a film former or adhesive agent. Therefore typically a seed coating composition of the present invention comprises a biologically effective amount of a compound of Formula 1 and a film former or adhesive agent. Seed can be coated by spraying a flowable suspension concentrate directly into a tumbling bed of seeds and then drying the seeds. Alternatively, other formulation types such as wetted powders, solutions, suspoemulsions, emulsifiable concentrates and emulsions in water can be sprayed on the seed. This process is particularly useful for applying film coatings on seeds. Various coating machines and processes are available to one skilled in the art. Suitable processes include those listed in P. Kusters et al., *Seed Treatment: Progress and Prospects*, 1994 BCPC Mongraph No. 57, and references listed therein.

For further information regarding the art of formulation, see T. S. Woods, "The Formulator's Toolbox – Product Forms for Modern Agriculture" in *Pesticide Chemistry and Bioscience, The Food–Environment Challenge*, T. Brooks and T. R. Roberts, Eds., Proceedings of the 9th International Congress on Pesticide Chemistry, The Royal Society of Chemistry, Cambridge, 1999, pp. 120–133. See also U.S. 3,235,361, Col. 6, line 16 through Col. 7, line 19 and Examples 10–41; U.S. 3,309,192, Col. 5, line 43 through Col. 7, line 62 and Examples 8, 12, 15, 39, 41, 52, 53, 58, 132, 138–140, 162–164, 166, 167 and 169–182; U.S. 2,891,855, Col. 3, line 66 through Col. 5, line 17 and Examples 1–4; Klingman, *Weed Control as a Science*, John Wiley and Sons, Inc., New York, 1961, pp 81–96; Hance et al., *Weed Control Handbook*, 8th Ed., Blackwell Scientific Publications, Oxford, 1989; and *Developments in formulation technology*, PJB Publications, Richmond, UK, 2000.

In the following Examples, all percentages are by weight and all formulations are prepared in conventional ways. Compound numbers refer to compounds in Index Tables A-F. Without further elaboration, it is believed that one skilled in the art using the preceding description can utilize the present invention to its fullest extent. The following

5 Examples are, therefore, to be constructed as merely illustrative, and not limiting of the disclosure in any way whatsoever. Percentages are by weight except where otherwise indicated.

Example A

High Strength Concentrate

Compound 3	98.5%
silica aerogel	0.5%
synthetic amorphous fine silica	1.0%

Example B

Wettable Powder

Compound 12	65.0%
dodecylphenol polyethylene glycol ether	2.0%
sodium ligninsulfonate	4.0%
sodium silicoaluminate	6.0%
montmorillonite (calcined)	23.0%

Example C

Granule

Compound 3	10.0%
attapulgit granules (low volatile matter, 0.71/0.30 mm; U.S.S. No. 25–50 sieves)	90.0%

Example D

Extruded Pellet

Compound 12	25.0%
anhydrous sodium sulfate	10.0%
crude calcium ligninsulfonate	5.0%
sodium alkyl naphthalenesulfonate	1.0%
calcium/magnesium bentonite	59.0%

Example E

Emulsifiable Concentrate

Compound 3	10.0%
polyoxyethylene sorbitol hexoleate	20.0%
C ₆ –C ₁₀ fatty acid methyl ester	70.0%

Example F

Microemulsion

Compound 12	5.0%
polyvinylpyrrolidone-vinyl acetate copolymer	30.0%
alkylpolyglycoside	30.0%
glyceryl monooleate	15.0%
water	20.0%

Example GSeed Treatment

Compound 3	20.00%
polyvinylpyrrolidone-vinyl acetate copolymer	5.00%
montan acid wax	5.00%
calcium ligninsulfonate	1.00%
polyoxyethylene/polyoxypropylene block copolymers	1.00%
stearyl alcohol (POE 20)	2.00%
polyorganosilane	0.20%
colorant red dye	0.05%
water	65.75%

Example HFertilizer Stick

compound 3	2.50%
pyrrolidone-styrene copolymer	4.80%
tristyrylphenyl 16-ethoxylate	2.30%
talc	0.80%
corn starch	5.00%
slow-release fertilizer	36.00%
kaolin	38.00%
water	10.60%

Example ISuspension Concentrate

compound 12	35%
butyl polyoxyethylene/polypropylene block copolymer	4.0%
stearic acid/polyethylene glycol copolymer	1.0%
styrene acrylic polymer	1.0%
xanthan gum	0.1%
propylene glycol	5.0%
silicone based defoamer	0.1%
1,2-benzisothiazolin-3-one	0.1%
water	53.7%

Example JEmulsion in Water

compound 3	10.0%
butyl polyoxyethylene/polypropylene block copolymer	4.0%
stearic acid/polyethylene glycol copolymer	1.0%
styrene acrylic polymer	1.0%
xanthan gum	0.1%
propylene glycol	5.0%
silicone based defoamer	0.1%
1,2-benzisothiazolin-3-one	0.1%
aromatic petroleum based hydrocarbon	20.0
water	58.7%

Example KOil Dispersion

compound 12	25%
polyoxyethylene sorbitol hexaoleate	15%
organically modified bentonite clay	2.5%
fatty acid methyl ester	57.5%

Example LSuspoemulsion

compound 3	10.0%
imidacloprid	5.0%
butyl polyoxyethylene/polypropylene block copolymer	4.0%
stearic acid/polyethylene glycol copolymer	1.0%
styrene acrylic polymer	1.0%
xanthan gum	0.1%
propylene glycol	5.0%
silicone based defoamer	0.1%
1,2-benzisothiazolin-3-one	0.1%
aromatic petroleum based hydrocarbon	20.0%
water	53.7%

Water-soluble and water-dispersible formulations are typically diluted with water to
5 form aqueous compositions before application. Aqueous compositions for direct
applications to the plant or portion thereof (e.g., spray tank compositions) typically contain
at least about 1 ppm or more (e.g., from 1 ppm to 100 ppm) of the compound(s) of this
invention.

Seed is normally treated at a rate of from about 0.001 g (more typically about 0.1 g) to about 10 g per kilogram of seed (i.e. from about 0.0001 to 1% by weight of the seed before treatment). A flowable suspension formulated for seed treatment typically comprises from about 0.5 to about 70% of the active ingredient, from about 0.5 to about 30% of a film-forming adhesive, from about 0.5 to about 20% of a dispersing agent, from 0 to about 5% of a thickener, from 0 to about 5% of a pigment and/or dye, from 0 to about 2% of an antifoaming agent, from 0 to about 1% of a preservative, and from 0 to about 75% of a volatile liquid diluent.

The compounds of this invention are useful as plant disease control agents. The present invention therefore further comprises a method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof to be protected, or to the plant seed to be protected, an effective amount of a compound of the invention or a fungicidal composition containing said compound. The compounds and/or compositions of this invention provide control of diseases caused by a broad spectrum of fungal plant pathogens in the Ascomycota, Basidiomycota, Zygomycota phyla, and the fungal-like Oomycata class. They are effective in controlling a broad spectrum of plant diseases, particularly foliar pathogens of ornamental, turf, vegetable, field, cereal, and fruit crops. These pathogens include but are not limited to those listed in Table 1. For Ascomycetes and Basidiomycetes, names for both the sexual/teleomorph/perfect stage as well as names for the asexual/anamorph/imperfect stage (in parentheses) are listed where known. Synonymous names for pathogens are indicated by an equal sign. For example, the sexual/teleomorph/perfect stage name *Phaeosphaeria nodorum* is followed by the corresponding asexual/anamorph/imperfect stage name *Stagonospora nodorum* and the synonymous older name *Septoria nodorum*.

Table 1

Ascomycetes in the order Pleosporales including <i>Alternaria solani</i> , <i>A. alternata</i> and <i>A. brassicae</i> , <i>Guignardia bidwellii</i> , <i>Venturia inaequalis</i> , <i>Pyrenophora tritici-repentis</i> (<i>Dreschlera tritici-repentis</i> = <i>Helminthosporium tritici-repentis</i>) and <i>Pyrenophora teres</i> (<i>Dreschlera teres</i> = <i>Helminthosporium teres</i>), <i>Corynespora cassiicola</i> , <i>Phaeosphaeria nodorum</i> (<i>Stagonospora nodorum</i> = <i>Septoria nodorum</i>), <i>Cochliobolus carbonum</i> and <i>C. heterostrophus</i> , <i>Leptosphaeria biglobosa</i> and <i>L. maculans</i> ;
Ascomycetes in the order Mycosphaerellales including <i>Mycosphaerella graminicola</i> (<i>Zymoseptoria tritici</i> = <i>Septoria tritici</i>), <i>M. berkeleyi</i> (<i>Cercosporidium personatum</i>), <i>M. arachidis</i> (<i>Cercospora arachidicola</i>), <i>Passalora sojae</i> (<i>Cercospora sojae</i>), <i>Cercospora zea-maydis</i> and <i>C. beticola</i> ;
Ascomycetes in the order Erysiphales (the powdery mildews) such as <i>Blumeria graminis</i> f.sp. <i>tritici</i> and <i>Blumeria graminis</i> f.sp. <i>hordei</i> , <i>Erysiphe polygoni</i> , <i>E. necator</i> (= <i>Uncinula necator</i>), <i>Podosphaera fuliginea</i> (= <i>Sphaerotheca fuliginea</i>), and <i>Podosphaera leucotricha</i>

(= <i>Sphaerotheca fuliginea</i>);
Ascomycetes in the order Helotiales such as <i>Botryotinia fuckeliana</i> (<i>Botrytis cinerea</i>), <i>Oculimacula yallundae</i> (= <i>Tapesia yallundae</i> ; anamorph <i>Helgardia herpotrichoides</i> = <i>Pseudocercospora herpotrichoides</i>), <i>Monilinia fructicola</i> , <i>Sclerotinia sclerotiorum</i> , <i>Sclerotinia minor</i> , and <i>Sclerotinia homoeocarpa</i> ;
Ascomycetes in the order Hypocreales such as <i>Giberella zeae</i> (<i>Fusarium graminearum</i>), <i>G. moniliformis</i> (<i>Fusarium moniliforme</i>), <i>Fusarium solani</i> and <i>Verticillium dahliae</i> ;
Ascomycetes in the order Eurotiales such as <i>Aspergillus flavus</i> and <i>A. parasiticus</i> ;
Ascomycetes in the order Diaporthales such as <i>Cryptosporophora viticola</i> (= <i>Phomopsis viticola</i>), <i>Phomopsis longicolla</i> , and <i>Diaporthe phaseolorum</i> ;
Other Ascomycete pathogens including <i>Magnaporthe grisea</i> , <i>Gaeumannomyces graminis</i> , <i>Rhynchosporium secalis</i> , and anthracnose pathogens such as <i>Glomerella acutata</i> (<i>Colletotrichum acutatum</i>), <i>G. graminicola</i> (<i>C. graminicola</i>) and <i>G. lagenaria</i> (<i>C. orbiculare</i>);
Basidiomycetes in the order Uredinales (the rusts) including <i>Puccinia recondita</i> , <i>P. striiformis</i> , <i>Puccinia hordei</i> , <i>P. graminis</i> and <i>P. arachidis</i> , <i>Hemileia vastatrix</i> and <i>Phakopsora pachyrhizi</i> ;
Basidiomycetes in the order Ceratobasidiales such as <i>Thanatophorum cucumeris</i> (<i>Rhizoctonia solani</i>) and <i>Ceratobasidium oryzae-sativae</i> (<i>Rhizoctonia oryzae</i>);
Basidiomycetes in the order Polyporales such as <i>Athelia rolfsii</i> (<i>Sclerotium rolfsii</i>);
Basidiomycetes in the order Ustilaginales such as <i>Ustilago maydis</i> ;
Zygomycetes in the order Mucorales such as <i>Rhizopus stolonifer</i> ;
Oomycetes in the order Pythiales, including <i>Phytophthora infestans</i> , <i>P. megasperma</i> , <i>P. parasitica</i> , <i>P. sojae</i> , <i>P. cinnamomi</i> and <i>P. capsici</i> , and <i>Pythium</i> pathogens such as <i>Pythium aphanidermatum</i> , <i>P. graminicola</i> , <i>P. irregulare</i> , <i>P. ultimum</i> and <i>P. dissotocum</i> ;
Oomycetes in the order Peronosporales such as <i>Plasmopara viticola</i> , <i>P. halstedii</i> , <i>Peronospora hyoscyami</i> (= <i>Peronospora tabacina</i>), <i>P. manshurica</i> , <i>Hyaloperonospora parasitica</i> (= <i>Peronospora parasitica</i>), <i>Pseudoperonospora cubensis</i> and <i>Bremia lactucae</i> ;
and other genera and species closely related to all of the above pathogens.

The compounds of the invention are believed to provide protection from fungal plant pathogens by inhibiting Complex II (succinate dehydrogenase) fungal respiration by disrupting a key enzyme in the Krebs Cycle (TCA cycle) named succinate dehydrogenase (SDH). SDH is composed of four nuclear-encoded polypeptides, identified as SDHA, SDHB, SDHC and SDHD. Inhibiting respiration prevents the fungus from making ATP, and thus inhibits growth and reproduction. At the molecular level, carboxamides inhibit ubiquinone reduction by binding to the ubiquinone binding site (Q_p site) formed by subunits SDHB, SDHC and SDHD in the SDH enzyme. The Fungicide Resistance Action

Committee (FRAC) has identified chemical compounds having this fungicidal mode of action as “SDHIs” as an abbreviation for succinate dehydrogenase inhibitors and categorized them with FRAC Code 7.

A variety of mutations in subunits SDHB, SDHC and SDHD forming the ubiquinone binding site are now known to cause resistance to SDHIs. FRAC has published on their website a “List of fungal species with resistance reports towards SDHI fungicides and mutations in the succinate dehydrogenates gene (updated March 2012)” (<http://frac.info/frac/work/List%20of%20SDHI%20resistant%20species.pdf> available as of 28 June 2012), which includes both mutants produced in the laboratory through artificial mutagenesis and naturally occurring mutants found in the field showing resistance to SDHIs. Scalliet et al., “Mutagenesis and Functional Studies with Succinate Dehydrogenase Inhibitors in the Wheat Pathogen *Mycosphaerella graminicola*”, *PLoS ONE*, **2012**, 7 (4), 1–20 (published in Adobe Acrobat file format as [journal.pone.0035429.pdf](http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0035429) and available through <http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0035429> on 28 June 2012) describes additional mutants of *Mycosphaerella graminicola*. These publications disclose fungal pathogens having known resistant mutants include *Alternaria alternata* (SDHB: H277Y, H277R; SDHC: H134R; SDHD: D123E, H133R), *Aspergillus oryzae* (SDHB: H249Y, H249L, H249N; SDHC: T90I; SDHD: D124E), *Botrytis cinerea* (SDHB: P225L, P225T, P225F, H272Y, H272R, H272L, N230I; SDHD: H132R), *Botrytis elliptica* (SDHB: H272Y, H272R), *Corynespora cassiicola* (SDHB: H287Y, H287R; SDHC: S73P, SDHD: S89P), *Didymella bryoniae* (SDHB: H277R, H277Y), *Mycosphaerella graminicola* (SDHB: S218F, P220T, P220L, S221P, N225H, N225I, R265P, H267L, H267N, H267R, H267Q, H267Y, I269V, N271K; SDHC: T79I, S83G, A84V, A84I, L85P, N86K, R87C, V88D, H145R, H152R; SDHD: D129E, D129G, D129S, D129T, H139E), *Podosphaera xanthii* (SDHB: H[???]Y), *Sclerotinia sclerotiorum* (SDHD: H132R), *Ustilago maydis* (SDHB: H257L), *Stemphylium botryose* (SDHB: P225L, H272Y, H272R) and *Ustilago maydis* (SDHB: H257L), wherein the left letter identifies the amino acid in the prevalent wild-type enzyme subunit, the number specifies the amino acid location in the subunit, and the right letter identifies the amino acid in the mutant subunit (the amino acids are identified by standard single letter codes; see for example <http://www.bio.davidson.edu/Biology/aatable.html>, accessed 28 June 2012). Because the metabolism of other fungal pathogens, such as *Septoria tritici*, also involve succinate dehydrogenase, SDHI-resistant mutants are possible for them as well.

Remarkably, compounds of the present invention, retain sufficient activity against mutant fungal pathogens highly resistant to other SDHIs, so that the present compounds remain agronomically useful for protecting plants against the mutant as well as wild-type pathogens. The improved efficacy of the present compounds compared to other SDHI fungicides for controlling plant disease caused by the SDHI-resistant fungal pathogens can

be determined by simple plant disease control testing, for example tests similar to Tests A–E disclosed herein, but using SDHI-resistant instead of wild-type fungal pathogens.

In addition to their fungicidal activity, the compositions or combinations also have activity against bacteria such as *Erwinia amylovora*, *Xanthomonas campestris*, *Pseudomonas syringae*, and other related species. By controlling harmful microorganisms, the compounds of the invention are useful for improving (i.e. increasing) the ratio of beneficial to harmful microorganisms in contact with crop plants or their propagules (e.g., seeds, corms, bulbs, tubers, cuttings) or in the agronomic environment of the crop plants or their propagules.

Compounds of the invention are useful in treating all plants, plant parts and seeds. Plant and seed varieties and cultivars can be obtained by conventional propagation and breeding methods or by genetic engineering methods. Genetically modified plants or seeds (transgenic plants or seeds) are those in which a heterologous gene (transgene) has been stably integrated into the plant's or seed's genome. A transgene that is defined by its particular location in the plant genome is called a transformation or transgenic event.

Genetically modified plant cultivars which can be treated according to the invention include those that are resistant against one or more biotic stresses (pests such as nematodes, insects, mites, fungi, etc.) or abiotic stresses (drought, cold temperature, soil salinity, etc.), or that contain other desirable characteristics. Plants can be genetically modified to exhibit traits of, for example, herbicide tolerance, insect-resistance, modified oil profiles or drought tolerance. Useful genetically modified plants containing single gene transformation events or combinations of transformation events are listed in Table 2. Additional information for the genetic modifications listed in Table 2 can be obtained from publicly available databases maintained, for example, by the U.S. Department of Agriculture.

The following abbreviations, T1 through T37, are used in Table 2 for traits. A “–” means the entry is not available.

Trait	Description	Trait	Description	Trait	Description
T1	Glyphosate tolerance	T15	Cold tolerance	T27	High tryptophan
T2	High lauric acid oil	T16	Imidazolinone herbicide tol.	T28	Erect leaves semidwarf
T3	Glufosinate tolerance	T17	Modified alpha-amylase	T29	Semidwarf
T4	Phytate breakdown	T18	Pollination control	T30	Low iron tolerance
T5	Oxynil tolerance	T19	2,4-D tolerance	T31	Modified oil/fatty acid
T6	Disease resistance	T20	Increased lysine	T32	HPPD tolerance
T7	Insect resistance	T21	Drought tolerance	T33	High oil
T9	Modified flower color	T22	Delayed ripening/senescence	T34	Aryloxyalkanoate tol.
T11	ALS herbicide tol.	T23	Modified product quality	T35	Mesotrione tolerance
T12	Dicamba tolerance	T24	High cellulose	T36	Reduced nicotine
T13	Anti-allergy	T25	Modified starch/carbohydrate	T37	Modified product
T14	Salt tolerance	T26	Insect & disease resist.		

Table 2

Crop	Event Name	Event Code	Trait(s)	Gene(s)
Alfalfa	J101	MON-00101-8	T1	cp4 epsps (aroA:CP4)
Alfalfa	J163	MON-00163-7	T1	cp4 epsps (aroA:CP4)
Canola*	23-18-17 (Event 18)	CGN-89465-2	T2	te
Canola*	23-198 (Event 23)	CGN-89465-2	T2	te
Canola*	61061	DP-061061-7	T1	gat4621
Canola*	73496	DP-073496-4	T1	gat4621
Canola*	GT200 (RT200)	MON-89249-2	T1	cp4 epsps (aroA:CP4); goxv247
Canola*	GT73 (RT73)	MON-00073-7	T1	cp4 epsps (aroA:CP4); goxv247
Canola*	HCN10 (Topas 19/2)	-	T3	bar
Canola*	HCN28 (T45)	ACS-BN008-2	T3	pat (syn)
Canola*	HCN92 (Topas 19/2)	ACS-BN007-1	T3	bar
Canola*	MON88302	MON-88302-9	T1	cp4 epsps (aroA:CP4)
Canola*	MPS961	-	T4	phyA
Canola*	MPS962	-	T4	phyA
Canola*	MPS963	-	T4	phyA
Canola*	MPS964	-	T4	phyA
Canola*	MPS965	-	T4	phyA
Canola*	MS1 (B91-4)	ACS-BN004-7	T3	bar
Canola*	MS8	ACS-BN005-8	T3	bar
Canola*	OXY-235	ACS-BN011-5	T5	bxn
Canola*	PHY14	-	T3	bar
Canola*	PHY23	-	T3	bar
Canola*	PHY35	-	T3	bar
Canola*	PHY36	-	T3	bar
Canola*	RF1 (B93-101)	ACS-BN001-4	T3	bar
Canola*	RF2 (B94-2)	ACS-BN002-5	T3	bar
Canola*	RF3	ACS-BN003-6	T3	bar
Bean	EMBRAPA 5.1	EMB-PV051-1	T6	ac1 (sense and antisense)
Brinjal#	EE-1	-	T7	cry1Ac
Carnation	11 (7442)	FLO-07442-4	T8; T9	surB; dfr; hfl (f3'5'h)
Carnation	11363 (1363A)	FLO-11363-1	T8; T9	surB; dfr; bp40 (f3'5'h)
Carnation	1226A (11226)	FLO-11226-8	T8; T9	surB; dfr; bp40 (f3'5'h)
Carnation	123.2.2 (40619)	FLO-40619-7	T8; T9	surB; dfr; hfl (f3'5'h)
Carnation	123.2.38 (40644)	FLO-40644-4	T8; T9	surB; dfr; hfl (f3'5'h)
Carnation	123.8.12	FLO-40689-6	T8; T9	surB; dfr; bp40 (f3'5'h)
Carnation	123.8.8 (40685)	FLO-40685-1	T8; T9	surB; dfr; bp40 (f3'5'h)
Carnation	1351A (11351)	FLO-11351-7	T8; T9	surB; dfr; bp40 (f3'5'h)
Carnation	1400A (11400)	FLO-11400-2	T8; T9	surB; dfr; bp40 (f3'5'h)
Carnation	15	FLO-00015-2	T8; T9	surB; dfr; hfl (f3'5'h)

Carnation	16	FLO-00016-3	T8; T9	surB; dfr; hfl (f3'5'h)
Carnation	4	FLO-00004-9	T8; T9	surB; dfr; hfl (f3'5'h)
Carnation	66	FLO-00066-8	T8; T10	surB; acc
Carnation	959A (11959)	FLO-11959-3	T8; T9	surB; dfr; bp40 (f3'5'h)
Carnation	988A (11988)	FLO-11988-7	T8; T9	surB; dfr; bp40 (f3'5'h)
Carnation	26407	IFD-26497-2	ST8; T9	surB; dfr; bp40 (f3'5'h)
Carnation	25958	IFD-25958-3	T8; T9	surB; dfr; bp40 (f3'5'h)
Chicory	RM3-3	-	T3	bar
Chicory	RM3-4	-	T3	bar
Chicory	RM3-6	-	T3	bar
Cotton	19-51a	DD-01951A-7	T11	S4-HrA
Cotton	281-24-236	DAS-24236-5	T3;T7	pat (syn); cry1F
Cotton	3006-210-23	DAS-21023-5	T3;T7	pat (syn); cry1Ac
Cotton	31707	-	T5;T7	bxn; cry1Ac
Cotton	31803	-	T5;T7	bxn; cry1Ac
Cotton	31807	-	T5;T7	bxn; cry1Ac
Cotton	31808	-	T5;T7	bxn; cry1Ac
Cotton	42317	-	T5;T7	bxn; cry1Ac
Cotton	BNLA-601	-	T7	cry1Ac
Cotton	BXN10211	BXN10211-9	T5	bxn; cry1Ac
Cotton	BXN10215	BXN10215-4	T5	bxn; cry1Ac
Cotton	BXN10222	BXN10222-2	T5	bxn; cry1Ac
Cotton	BXN10224	BXN10224-4	T5	bxn; cry1Ac
Cotton	COT102	SYN-IR102-7	T7	vip3A(a)
Cotton	COT67B	SYN-IR67B-1	T7	cry1Ab
Cotton	COT202	-	T7	vip3A
Cotton	Event 1	-	T7	cry1Ac
Cotton	GMF Cry1A	GTL-GMF311-7	T7	cry1Ab-Ac
Cotton	GHB119	BCS-GH005-8	T7	cry2Ae
Cotton	GHB614	BCS-GH002-5	T1	2mepsps
Cotton	GK12	-	T7	cry1Ab-Ac
Cotton	LLCotton25	ACS-GH001-3	T3	bar
Cotton	MLS 9124	-	T7	cry1C
Cotton	MON1076	MON-89924-2	T7	cry1Ac
Cotton	MON1445	MON-01445-2	T1	cp4 epsps (aroA:CP4)
Cotton	MON15985	MON-15985-7	T7	cry1Ac; cry2Ab2
Cotton	MON1698	MON-89383-1	T7	cp4 epsps (aroA:CP4)
Cotton	MON531	MON-00531-6	T7	cry1Ac
Cotton	MON757	MON-00757-7	T7	cry1Ac
Cotton	MON88913	MON-88913-8	T1	cp4 epsps (aroA:CP4)
Cotton	Nqwe Chi 6 Bt	-	T7	-

Cotton	SKG321	-	T7	cry1A; CpTI
Cotton	T303-3	BCS-GH003-6	T7; T3	cry1Ab; bar
Cotton	T304-40	BCS-GH004-7	T7; T3	cry1Ab; bar
Cotton	CE43-67B	-	T7	cry1Ab
Cotton	CE46-02A	-	T7	cry1Ab
Cotton	CE44-69D	-	T7	cry1Ab
Cotton	1143-14A	-	T7	cry1Ab
Cotton	1143-51B	-	T7	cry1Ab
Cotton	T342-142	-	T7	cry1Ab
Cotton	PV-GHGT07 (1445)	-	T1	cp4 epsps (aroA:CP4)
Cotton	EE-GH3	-	T1	mepsps
Cotton	EE-GH5	-	T7	cry1Ab
Cotton	MON88701	MON-88701-3	T12; T3	Modified dmo; bar
Cotton	OsCr11	-	T13	Modified Cry j
Creeping Bentgrass	ASR368	SMG-36800-2	T1	cp4 epsps (aroA:CP4)
Eucalyptus	20-C	-	T14	codA
Eucalyptus	12-5C	-	T14	codA
Eucalyptus	12-5B	-	T14	codA
Eucalyptus	107-1	-	T14	codA
Eucalyptus	1/9/2001	-	T14	codA
Eucalyptus	2/1/2001	-	T14	codA
Eucalyptus		-	T15	des9
Flax	FP967	CDC-FL001-2	T11	als
Lentil	RH44	-	T16	als
Maize	3272	SYN-E3272-5	T17	amy797E
Maize	5307	SYN-05307-1	T7	ecry3.1Ab
Maize	59122	DAS-59122-7	T7; T3	cry34Ab1; cry35Ab1; pat
Maize	676	PH-000676-7	T3; T18	pat; dam
Maize	678	PH-000678-9	T3; T18	pat; dam
Maize	680	PH-000680-2	T3; T18	pat; dam
Maize	98140	DP-098140-6	T1; T11	gat4621; zm-hra
Maize	Bt10	-	T7; T3	cry1Ab; pat
Maize	Bt176 (176)	SYN-EV176-9	T7; T3	cry1Ab; bar
Maize	BVLA430101	-	T4	phyA2
Maize	CBH-351	ACS-ZM004-3	T7; T3	cry9C; bar
Maize	DAS40278-9	DAS40278-9	T19	aad-1
Maize	DBT418	DKB-89614-9	T7; T3	cry1Ac; pinII; bar
Maize	DLL25 (B16)	DKB-89790-5	T3	bar
Maize	GA21	MON-00021-9	T1	mepsps
Maize	GG25	-	T1	mepsps

Maize	GJ11	-	T1	mepsps
Maize	Fl117	-	T1	mepsps
Maize	GAT-ZM1	-	T3	pat
Maize	LY038	REN-00038-3	T20	cordapA
Maize	MIR162	SYN-IR162-4	T7	vip3Aa20
Maize	MIR604	SYN-IR604-5	T7	mcry3A
Maize	MON801 (MON80100)	MON801	T7; T1	cry1Ab; cp4 epsps (aroA:CP4); goxv247
Maize	MON802	MON-80200-7	T7; T1	cry1Ab; cp4 epsps (aroA:CP4); goxv247
Maize	MON809	PH-MON-809- 2	T7; T1	cry1Ab; cp4 epsps (aroA:CP4); goxv247
Maize	MON810	MON-00810-6	T7; T1	cry1Ab; cp4 epsps (aroA:CP4); goxv247
Maize	MON832	-	T1	cp4 epsps (aroA:CP4); goxv247
Maize	MON863	MON-00863-5	T7	cry3Bb1
Maize	MON87427	MON-87427-7	T1	cp4 epsps (aroA:CP4)
Maize	MON87460	MON-87460-4	T21	cspB
Maize	MON88017	MON-88017-3	T7; T1	cry3Bb1; cp4 epsps (aroA:CP4)
Maize	MON89034	MON-89034-3	T7	cry2Ab2; cry1A.105
Maize	MS3	ACS-ZM001-9	T3; T18	bar; bar-se
Maize	MS6	ACS-ZM005-4	T3; T18	bar; bar-se
Maize	NK603	MON-00603-6	T1	cp4 epsps (aroA:CP4)
Maize	T14	ACS-ZM002-1	T3	pat (syn)
Maize	T25	ACS-ZM003-2	T3	pat (syn)
Maize	TC1507	DAS-01507-1	T7; T3	cry1Fa2; pat
Maize	TC6275	DAS-06275-8	T7; T3	mocry1F; bar
Maize	VIP1034		T7; T3	vip3A; pat
Maize	43A47	DP-043A47-3	T7; T3	cry1F; cry34Ab1; cry35Ab1; pat
Maize	40416	DP-040416-8	T7; T3	cry1F; cry34Ab1; cry35Ab1; pat
Maize	32316	DP-032316-8	T7; T3	cry1F; cry34Ab1; cry35Ab1; pat
Maize	4114	DP-004114-3	T7; T3	cry1F; cry34Ab1; cry35Ab1; pat
Melon	Melon A	-	T22	sam-k
Melon	Melon B	-	T22	sam-k
Papaya	55-1	CUH-CP551-8	T6	prsv cp
Papaya	63-1	CUH-CP631-7	T6	prsv cp
Papaya	Huanong No. 1	-	T6	prsv rep
Papaya	X17-2	UFL-X17CP-6	T6	prsv cp
Petunia	Petunia-CHS	-	T25	CHS suppression
Plum	C-5	ARS-PLMC5-6	T6	ppv cp
Canola**	ZSR500	-	T1	cp4 epsps (aroA:CP4); goxv247
Canola**	ZSR502	-	T1	cp4 epsps (aroA:CP4); goxv247
Canola**	ZSR503	-	T1	cp4 epsps (aroA:CP4); goxv247
Poplar	Bt poplar	-	T7	cry1Ac; API

Poplar	Hybrid poplar clone 741	-	T7	cry1Ac; API
Poplar	trg300-1	-	T24	AaXEG2
Poplar	trg300-2	-	T24	AaXEG2
Potato	1210 amk	-	T7	cry3A
Potato	2904/1 kgs	-	T7	cry3A
Canola**	ZSR500	-	T1	cp4 epsps (aroA:CP4); goxv247
Canola**	ZSR502	-	T1	cp4 epsps (aroA:CP4); goxv247
Potato	ATBT04-27	NMK-89367-8	T7	cry3A
Potato	ATBT04-30	NMK-89613-2	T7	cry3A
Potato	ATBT04-31	NMK-89170-9	T7	cry3A
Potato	ATBT04-36	NMK-89279-1	T7	cry3A
Potato	ATBT04-6	NMK-89761-6	T7	cry3A
Potato	BT06	NMK-89812-3	T7	cry3A
Potato	BT10	NMK-89175-5	T7	cry3A
Potato	BT12	NMK-89601-8	T7	cry3A
Potato	BT16	NMK-89167-6	T7	cry3A
Potato	BT17	NMK-89593-9	T7	cry3A
Potato	BT18	NMK-89906-7	T7	cry3A
Potato	BT23	NMK-89675-1	T7	cry3A
Potato	EH92-527-1	BPS-25271-9	T25	gbss (antisense)
Potato	HLMT15-15	-	T7; T6	cry3A; pvy cp
Potato	HLMT15-3	-	T7; T6	cry3A; pvy cp
Potato	HLMT15-46	-	T7; T6	cry3A; pvy cp
Potato	RBMT15-101	NMK-89653-6	T7; T6	cry3A; pvy cp
Potato	RBMT21-129	NMK-89684-1	T7; T6	cry3A; plrv orf1; plrv orf2
Potato	RBMT21-152	-	T7; T6	cry3A; plrv orf1; plrv orf2
Potato	RBMT21-350	NMK-89185-6	T7; T6	cry3A; plrv orf1; plrv orf2
Potato	RBMT22-082	NMK-89896-6	T7; T6.; T1	cry3A; plrv orf1; plrv orf2; cp4 epsps (aroA:CP4)
Potato	RBMT22-186	-	T7; T6.; T1	cry3A; plrv orf1; plrv orf2; cp4 epsps (aroA:CP4)
Potato	RBMT22-238	-	T7; T6.; T1	cry3A; plrv orf1; plrv orf2; cp4 epsps (aroA:CP4)
Potato	RBMT22-262	-	T7; T6.; T1	cry3A; plrv orf1; plrv orf2; cp4 epsps (aroA:CP4)
Potato	SEMT15-02	NMK-89935-9	T7; T6	cry3A; pvy cp
Potato	SEMT15-07	-	T7; T6	cry3A; pvy cp
Potato	SEMT15-15	NMK-89930-4	T7; T6	cry3A; pvy cp
Potato	SPBT02-5	NMK-89576-1	T7	cry3A
Potato	SPBT02-7	NMK-89724-5	T7	cry3A
Rice	7Crp#242-95-7	-	T13	7crp
Rice	7Crp#10	-	T13	7crp
Rice	GM Shanyou 63	-	T7	cry1Ab; cry1Ac

Rice	Huahui-1/TT51-1	-	T7	cry1Ab; cry1Ac
Rice	LLRICE06	ACS-OS001-4	T3	bar
Rice	LLRICE601	BCS-OS003-7	T3	bar
Rice	LLRICE62	ACS-OS002-5	T3	bar
Rice	Tarom molaii + cry1Ab	-	T7	cry1Ab (truncated)
Rice	GAT-OS2	-	T3	bar
Rice	GAT-OS3	-	T3	bar
Rice	PE-7	-	T7	Cry1Ac
Rice	7Crp#10	-	T13	7crp
Rice	KPD627-8	-	T27	OASA1D
Rice	KPD722-4	-	T27	OASA1D
Rice	KA317	-	T27	OASA1D
Rice	HW5	-	T27	OASA1D
Rice	HW1	-	T27	OASA1D
Rice	B-4-1-18	-	T28	Δ OsBRI1
Rice	G-3-3-22	-	T29	OSGA2ox1
Rice	AD77	-	T6	DEF
Rice	AD51	-	T6	DEF
Rice	AD48	-	T6	DEF
Rice	AD41	-	T6	DEF
Rice	13p-s-atAprt1	-	T30	Hv-S1; Hv-AT-A; APRT
Rice	13pAprt1	-	T30	APRT
Rice	gHv-S1-gHv-AT-1	-	T30	Hv-S1; Hv-AT-A; Hv-AT-B
Rice	gHvIDS3-1	-	T30	HvIDS3
Rice	gHv-AT1	-	T30	Hv-AT-A; Hv-AT-B
Rice	gHv-S1-1	-	T30	Hv-S1
Rice	NIA-OS006-4	-	T6	WRKY45
Rice	NIA-OS005-3	-	T6	WRKY45
Rice	NIA-OS004-2	-	T6	WRKY45
Rice	NIA-OS003-1	-	T6	WRKY45
Rice	NIA-OS002-9	-	T6	WRKY45
Rice	NIA-OS001-8	-	T6	WRKY45
Rice	OsCr11	-	T13	Modified Cry j
Rice	17053	-	T1	cp4 epsps (aroA:CP4)
Rice	17314	-	T1	cp4 epsps (aroA:CP4)
Rose	WKS82 / 130-4-1	IFD-52401-4	T9	5AT; bp40 (f3'5'h)
Rose	WKS92 / 130-9-1	IFD-52901-9	T9	5AT; bp40 (f3'5'h)
Soybean	260-05 (G94-1, G94-19, G168)	-	T9	gm-fad2-1 (silencing locus)
Soybean	A2704-12	ACS-GM005-3	T3	pat
Soybean	A2704-21	ACS-GM004-2	T3	pat

Soybean	A5547-127	ACS-GM006-4	T3	pat
Soybean	A5547-35	ACS-GM008-6	T3	pat
Soybean	CV127	BPS-CV127-9	T16	csr1-2
Soybean	DAS68416-4	DAS68416-4	T3	pat
Soybean	DP305423	DP-305423-1	T31; T11	gm-fad2-1 (silencing locus); gm-hra
Soybean	DP356043	DP-356043-5	T31; T1	gm-fad2-1 (silencing locus); gat4601
Soybean	FG72	MST-FG072-3	T1; T32	2mepsps; hppdPF W336
Soybean	GTS 40-3-2 (40-3-2)	MON-04032-6	T1	cp4 epsps (aroA:CP4)
Soybean	GU262	ACS-GM003-1	T3	pat
Soybean	MON87701	MON-87701-2	T7	cry1Ac
Soybean	MON87705	MON-87705-6	T31; T1	fatb1-A (sense & antisense); fad2-1A (sense & antisense); cp4 epsps (aroA:CP4)
Soybean	MON87708	MON-87708-9	T12; T1	dmo; cp4 epsps (aroA:CP4)
Soybean	MON87769	MON-87769-7	T31; T1	Pj.D6D; Nc.Fad3; cp4 epsps (aroA:CP4)
Soybean	MON89788	MON-89788-1	T1	cp4 epsps (aroA:CP4)
Soybean	W62	ACS-GM002-9	T3	bar
Soybean	W98	ACS-GM001-8	T3	bar
Soybean	MON87754	MON-87754-1	T33	dgat2A
Soybean	DAS21606	DAS-21606	T34; T3	Modified aad-12; pat
Soybean	DAS44406	DAS-44406-6	T34; T1; T3	Modified aad-12; 2mepsps; pat
Soybean	SYHT04R	SYN-0004R-8	T35	Modified avhppd
Soybean	9582.814.19.1		T7; T3	cry1Ac; cry1F; pat
Squash	CZW3	SEM-ØCZW3-2	T6	cmv cp; zymv cp; wmv cp
Squash	ZW20	SEM-ØZW20-7	T6	zymv cp, wmv cp
Sugar Beet	GTSB77 (T9100152)	SY-GTSB77-8	T1	cp4 epsps (aroA:CP4); goxv247
Sugar Beet	H7-1	KM-000H71-4	T1	cp4 epsps (aroA:CP4)
Sugar Beet	T120-7	ACS-BV001-3	T3	pat
Sugar Beet	T227-1	-	T1	cp4 epsps (aroA:CP4)
Sugarcane	NXI-1T	-	T21	EcbetA
Sunflower	X81359	-	T16	als
Sweet Pepper	PK-SP01	-	T6	cmv cp
Tobacco	C/F/93/08-02	-	T5	bxn
Tobacco	Vector 21-41	-	T36	NtQPT1 (antisense)
Tomato	1345-4	-	T22	acc (truncated)
Tomato	35-1-N	-	T22	sam-k
Tomato	5345	-	T7	cry1Ac
Tomato	8338	CGN-89322-3	T22	accd
Tomato	B	SYN-0000B-6	T22	pg (sense or antisense)
Tomato	Da	SYN-0000DA-9	T22	pg (sense or antisense)

Sunflower	X81359	-	T16	als
Tomato	Da Dong No 9	-	T37	-
Tomato	F (1401F, h38F, 11013F,7913F)	SYN-0000F-1	T22	pg (sense or antisense)
Tomato	FLAVR SAVR™	CGN-89564-2	T22	pg (sense or antisense)
Tomato	Huafan No 1	-	T22	anti-efe
Tomato	PK-TM8805R (8805R)	-	T6	cmv cp
Wheat	MON71800	MON-71800-3	T1	cp4 epsps (aroA:CP4)

* Argentine, ** Polish, # Eggplant

Treatment of genetically modified plants and seeds with compounds of the invention may result in super-additive or synergistic effects. For example, reduction in application rates, broadening of the activity spectrum, increased tolerance to biotic/abiotic stresses or enhanced storage stability may be greater than expected from just simple additive effects of the application of compounds of the invention on genetically modified plants and seeds.

Compounds of this invention are useful in seed treatments for protecting seeds from plant diseases. In the context of the present disclosure and claims, treating a seed means contacting the seed with a biologically effective amount of a compound of this invention, which is typically formulated as a composition of the invention. This seed treatment protects the seed from soil-borne disease pathogens and generally can also protect roots and other plant parts in contact with the soil of the seedling developing from the germinating seed. The seed treatment may also provide protection of foliage by translocation of the compound of this invention or a second active ingredient within the developing plant. Seed treatments can be applied to all types of seeds, including those from which plants genetically transformed to express specialized traits will germinate. Representative examples include those expressing proteins toxic to invertebrate pests, such as *Bacillus thuringiensis* toxin or those expressing herbicide resistance such as glyphosate acetyltransferase, which provides resistance to glyphosate. Seed treatments with compounds of this invention can also increase vigor of plants growing from the seed.

Compounds of this invention and their compositions, both alone and in combination with other fungicides, nematicides and insecticides, are particularly useful in seed treatment for crops including, but not limited to, maize or corn, soybeans, cotton, cereal (e.g., wheat, oats, barley, rye and rice), potatoes, vegetables and oilseed rape.

Furthermore, the compounds of this invention are useful in treating postharvest diseases of fruits and vegetables caused by fungi and bacteria. These infections can occur before, during and after harvest. For example, infections can occur before harvest and then remain dormant until some point during ripening (e.g., host begins tissue changes in such a way that infection can progress); also infections can arise from surface wounds created by mechanical or insect injury. In this respect, the compounds of this invention can reduce losses (i.e. losses resulting from quantity and quality) due to postharvest diseases which may

occur at any time from harvest to consumption. Treatment of postharvest diseases with compounds of the invention can increase the period of time during which perishable edible plant parts (e.g, fruits, seeds, foliage, stems, bulbs, tubers) can be stored refrigerated or un-refrigerated after harvest, and remain edible and free from noticeable or harmful degradation or contamination by fungi or other microorganisms. Treatment of edible plant parts before or after harvest with compounds of the invention can also decrease the formation of toxic metabolites of fungi or other microorganisms, for example, mycotoxins such as aflatoxins.

Plant disease control is ordinarily accomplished by applying an effective amount of a compound of this invention either pre- or post-infection, to the portion of the plant to be protected such as the roots, stems, foliage, fruits, seeds, tubers or bulbs, or to the media (soil or sand) in which the plants to be protected are growing. The compounds can also be applied to seeds to protect the seeds and seedlings developing from the seeds. The compounds can also be applied through irrigation water to treat plants. Control of postharvest pathogens which infect the produce before harvest is typically accomplished by field application of a compound of this invention, and in cases where infection occurs after harvest the compounds can be applied to the harvested crop as dips, sprays, fumigants, treated wraps and box liners.

Rates of application for these compounds (i.e. a fungicidally effective amount) can be influenced by factors such as the plant diseases to be controlled, the plant species to be protected, ambient moisture and temperature and should be determined under actual use conditions. One skilled in the art can easily determine through simple experimentation the fungicidally effective amount necessary for the desired level of plant disease control. Foliage can normally be protected when treated at a rate of from less than about 1 g/ha to about 5,000 g/ha of active ingredient. Seed and seedlings can normally be protected when seed is treated at a rate of from about 0.001 g (more typically about 0.1 g) to about 10 g per kilogram of seed.

Compounds of this invention can also be mixed with one or more other biologically active compounds or agents including fungicides, insecticides, nematocides, bactericides, acaricides, herbicides, herbicide safeners, growth regulators such as insect molting inhibitors and rooting stimulants, chemosterilants, semiochemicals, repellents, attractants, pheromones, feeding stimulants, plant nutrients, other biologically active compounds or entomopathogenic bacteria, virus or fungi to form a multi-component pesticide giving an even broader spectrum of agricultural protection. Thus the present invention also pertains to a composition comprising a compound of Formula 1 (in a fungicidally effective amount) and at least one additional biologically active compound or agent (in a biologically effective amount) and can further comprise at least one of a surfactant, a solid diluent or a liquid diluent. The other biologically active compounds or agents can be formulated in compositions comprising at least one of a surfactant, solid or liquid diluent. For mixtures of

the present invention, one or more other biologically active compounds or agents can be formulated together with a compound of Formula 1, to form a premix, or one or more other biologically active compounds or agents can be formulated separately from the compound of Formula 1, and the formulations combined together before application (e.g., in a spray tank) or, alternatively, applied in succession.

As mentioned in the Summary of the Invention, one aspect of the present invention is a fungicidal composition comprising (i.e. a mixture or combination of) a compound of Formula 1, an *N*-oxide, or a salt thereof (i.e. component a), and at least one other fungicide (i.e. component b). Of note is such a combination where the other fungicidal active ingredient has different site of action from the compound of Formula 1. In certain instances, a combination with at least one other fungicidal active ingredient having a similar spectrum of control but a different site of action will be particularly advantageous for resistance management. Thus, a composition of the present invention can further comprise a fungicidally effective amount of at least one additional fungicidal active ingredient having a similar spectrum of control but a different site of action.

Of note is a composition which in addition to the Formula 1 compound of component (a), includes as component (b) at least one fungicidal compound selected from the group consisting of the FRAC-defined mode of action (MOA) classes (A) nucleic acid synthesis, (B) mitosis and cell division, (C) respiration, (D) amino acid and protein synthesis, (E) signal transduction, (F) lipid synthesis and membrane integrity, (G) sterol biosynthesis in membranes, (H) cell wall biosynthesis in membranes, (I) melanin synthesis in cell wall, (P) host plant defense induction, multi-site contact activity and unknown mode of action.

FRAC-recognized or proposed target sites of action along with their FRAC target site codes belonging to the above MOA classes are (A1) RNA polymerase I, (A2) adenosine deaminase, (A3) DNA/RNA synthesis (proposed), (A4) DNA topoisomerase, (B1-B3) β -tubulin assembly in mitosis, (B4) cell division (proposed), (B5) delocalization of spectrin-like proteins, (C1) complex I NADH oxidoreductase, (C2) complex II: succinate dehydrogenase, (C3) complex III: cytochrome bc1 (ubiquinol oxidase) at Q_o site, (C4) complex III: cytochrome bc1 (ubiquinone reductase) at Q_i site, (C5) uncouplers of oxidative phosphorylation, (C6) inhibitors of oxidative phosphorylation, ATP synthase, (C7) ATP production (proposed), (C8) complex III: cytochrome bc1 (ubiquinone reductase) at Q_x (unknown) site, (D1) methionine biosynthesis (proposed), (D2-D5) protein synthesis, (E1) signal transduction (mechanism unknown), (E2-E3) MAP/histidine kinase in osmotic signal transduction, (F2) phospholipid biosynthesis, methyl transferase, (F3) lipid peroxidation (proposed), (F4) cell membrane permeability, fatty acids (proposed), (F6) microbial disrupters of pathogen cell membranes, (F7) cell membrane disruption (proposed), (G1) C14- demethylase in sterol biosynthesis, (G2) Δ 14-reductase and Δ 8 \rightarrow Δ 7- isomerase in sterol biosynthesis, (G3) 3-keto reductase, C4-demethylation, (G4) squalene epoxidase in

sterol biosynthesis, (H3) trehalase and inositol biosynthesis, (H4) chitin synthase, (H5) cellulose synthase, (I1) reductase in melanin biosynthesis and (I2) dehydratase in melanin biosynthesis.

Of particular note is a composition which in addition to the Formula 1 compound of component (a), includes as component (b) at least one fungicidal compound selected from the group consisting of the classes (b1) methyl benzimidazole carbamate (MBC) fungicides; (b2) dicarboximide fungicides; (b3) demethylation inhibitor (DMI) fungicides; (b4) phenylamide fungicides; (b5) amine/morpholine fungicides; (b6) phospholipid biosynthesis inhibitor fungicides; (b7) succinate dehydrogenase inhibitor fungicides; (b8) hydroxy(2-amino-)pyrimidine fungicides; (b9) anilinopyrimidine fungicides; (b10) *N*-phenyl carbamate fungicides; (b11) quinone outside inhibitor (QoI) fungicides; (b12) phenylpyrrole fungicides; (b13) azanaphthalene fungicides; (b14) lipid peroxidation inhibitor fungicides; (b15) melanin biosynthesis inhibitor-reductase (MBI-R) fungicides; (b16) melanin biosynthesis inhibitor-dehydratase (MBI-D) fungicides; (b17) sterol biosynthesis inhibitor (SBI): Class III fungicides; (b18) squalene-epoxidase inhibitor fungicides; (b19) polyoxin fungicides; (b20) phenylurea fungicides; (b21) quinone inside inhibitor (QiI) fungicides; (b22) benzamide and thiazole carboxamide fungicides; (b23) enopyranuronic acid antibiotic fungicides; (b24) hexopyranosyl antibiotic fungicides; (b25) glucopyranosyl antibiotic: protein synthesis fungicides; (b26) glucopyranosyl antibiotic: trehalase and inositol biosynthesis fungicides; (b27) cyanoacetamideoxime fungicides; (b28) carbamate fungicides; (b29) oxidative phosphorylation uncoupling fungicides; (b30) organo tin fungicides; (b31) carboxylic acid fungicides; (b32) heteroaromatic fungicides; (b33) phosphonate fungicides; (b34) phthalamic acid fungicides; (b35) benzotriazine fungicides; (b36) benzene-sulfonamide fungicides; (b37) pyridazinone fungicides; (b38) thiophene-carboxamide fungicides; (b39) complex I NADH oxidoreductase inhibitor fungicides; (b40) carboxylic acid amide (CAA) fungicides; (b41) tetracycline antibiotic fungicides; (b42) thiocarbamate fungicides; (b43) benzamide fungicides; (b44) microbial fungicides; (b45) Q_xI fungicides; (b46) plant extract fungicides; (b47) host plant defense induction fungicides; (b48) multi-site contact activity fungicides; (b49) fungicides other than fungicides of classes (b1) through (b48); and salts of compounds of classes (b1) through (b48).

Further descriptions of these classes of fungicidal compounds are provided below.

(b1) "Methyl benzimidazole carbamate (MBC) fungicides" (FRAC code 1) inhibit mitosis by binding to β -tubulin during microtubule assembly. Inhibition of microtubule assembly can disrupt cell division, transport within the cell and cell structure. Methyl benzimidazole carbamate fungicides include benzimidazole and thiophanate fungicides. The benzimidazoles include benomyl, carbendazim, fuberidazole and thiabendazole. The thiophanates include thiophanate and thiophanate-methyl.

(b2) “Dicarboximide fungicides” (FRAC code 2) inhibit a MAP/histidine kinase in osmotic signal transduction. Examples include chlozolate, iprodione, procymidone and vinclozolin.

(b3) “Demethylation inhibitor (DMI) fungicides” (FRAC code 3) (Sterol Biosynthesis Inhibitors (SBI): Class I) inhibit C14-demethylase, which plays a role in sterol production. Sterols, such as ergosterol, are needed for membrane structure and function, making them essential for the development of functional cell walls. Therefore, exposure to these fungicides results in abnormal growth and eventually death of sensitive fungi. DMI fungicides are divided between several chemical classes: azoles (including triazoles and imidazoles), pyrimidines, piperazines, pyridines and triazolinthiones. The triazoles include 5 azaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole (including diniconazole-M), epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, quinconazole, simeconazole, tebuconazole, 10 tetraconazole, triadimefon, triadimenol, triticonazole, uniconazole, uniconazole-P, α -(1-chlorocyclopropyl)- α -[2-(2,2-dichlorocyclopropyl)ethyl]-1*H*-1,2,4-triazole-1-ethanol, *rel*-1-[[*(2R,3S)*-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1*H*-1,2,4-triazole, *rel*-2-[[*(2R,3S)*-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1,2-dihydro-3*H*-1,2,4-triazole-3-thione, and *rel*-1-[[*(2R,3S)*-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-5-(2-propen-1-ylthio)-1*H*-1,2,4-triazole. The imidazoles include 20 econazole, imazalil, oxpoconazole, prochloraz, pefurazoate and triflumizole. The pyrimidines include fenarimol, nuarimol and triarimol. The piperazines include triforine. The pyridines include buthiobate, pyrifenoxy, pyrisoxazole (3-[(3*R*)-5-(4-chlorophenyl)-2,3-dimethyl-3-isoxazolidinyl]pyridine, mixture of 3*R,5R*- and 3*R,5S*-isomers) and (α *S*)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-4-isoxazolyl]-3-pyridinemethanol. The triazolinthiones include prothioconazole and 2-[2-(1-chlorocyclopropyl)-4-(2,2-dichlorocyclopropyl)-2-hydroxybutyl]-1,2-dihydro-3*H*-1,2,4-triazole-3-thione. Biochemical investigations have shown that all of the above mentioned fungicides are DMI fungicides as described by K. H. Kuck et al. in *Modern Selective Fungicides - Properties, Applications and Mechanisms of Action*, H. Lyr (Ed.), Gustav Fischer Verlag: New York, 1995, 205–258. 30

(b4) “Phenylamide fungicides” (FRAC code 4) are specific inhibitors of RNA polymerase in Oomycete fungi. Sensitive fungi exposed to these fungicides show a reduced capacity to incorporate uridine into rRNA. Growth and development in sensitive fungi is prevented by exposure to this class of fungicide. Phenylamide fungicides include 35 acylalanine, oxazolidinone and butyrolactone fungicides. The acylalanines include benalaxyl, benalaxyl-M (also known as kiralaxyl), furalaxyl, metalaxyl and metalaxyl-M (also known as mefenoxam). The oxazolidinones include oxadixyl. The butyrolactones include ofurace.

(b5) "Amine/morpholine fungicides" (FRAC code 5) (SBI: Class II) inhibit two target sites within the sterol biosynthetic pathway, $\Delta^8 \rightarrow \Delta^7$ isomerase and Δ^{14} reductase. Sterols, such as ergosterol, are needed for membrane structure and function, making them essential for the development of functional cell walls. Therefore, exposure to these fungicides results in abnormal growth and eventually death of sensitive fungi. Amine/morpholine fungicides (also known as non-DMI sterol biosynthesis inhibitors) include morpholine, piperidine and spiroketal-amine fungicides. The morpholines include aldimorph, dodemorph, fenpropimorph, tridemorph and trimorphamide. The piperidines include fenpropidin and piperalin. The spiroketal-amines include spiroxamine.

(b6) "Phospholipid biosynthesis inhibitor fungicides" (FRAC code 6) inhibit growth of fungi by affecting phospholipid biosynthesis. Phospholipid biosynthesis fungicides include phosphorothiolate and dithiolane fungicides. The phosphorothiolates include edifenphos, iprobenfos and pyrazophos. The dithiolanes include isoprothiolane.

(b7) "Succinate dehydrogenase inhibitor (SDHI) fungicides" (FRAC code 7) inhibit Complex II fungal respiration by disrupting a key enzyme in the Krebs Cycle (TCA cycle) named succinate dehydrogenase. Inhibiting respiration prevents the fungus from making ATP, and thus inhibits growth and reproduction. SDHI fungicides include phenylbenzamide, furan carboxamide, oxathiin carboxamide, thiazole carboxamide, pyrazole-4-carboxamide, pyridine carboxamide, phenyl oxoethyl thiophene amides and pyridinyethyl benzamides. The benzamides include benodanil, flutolanil and mepronil. The furan carboxamides include fenfuram. The oxathiin carboxamides include carboxin and oxycarboxin. The thiazole carboxamides include thifluzamide. The pyrazole-4-carboxamides include benzovindiflupyr (*N*-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1*H*-pyrazole-4-carboxamide), bixafen, fluxapyroxad (3-(difluoromethyl)-1-methyl-*N*-(3',4',5'-trifluoro[1,1'-biphenyl]-2-yl)-1*H*-pyrazole-4-carboxamide), furametpyr, isopyrazam (3-(difluoromethyl)-1-methyl-*N*-[1,2,3,4-tetrahydro-9-(1-methylethyl)-1,4-methanonaphthalen-5-yl]-1*H*-pyrazole-4-carboxamide), penflufen (*N*-[2-(1,3-dimethylbutyl)phenyl]-5-fluoro-1,3-dimethyl-1*H*-pyrazole-4-carboxamide), penthiopyrad, sedaxane (*N*-[2-[1,1'-bicyclopropyl]-2-ylphenyl]-3-(difluoromethyl)-1-methyl-1*H*-pyrazole-4-carboxamide), *N*-[2-(1*S*,2*R*)-[1,1'-bicyclopropyl]-2-ylphenyl]-3-(difluoromethyl)-1-methyl-1*H*-pyrazole-4-carboxamide, 3-(difluoromethyl)-*N*-(2,3-dihydro-1,1,3-trimethyl-1*H*-inden-4-yl)-1-methyl-1*H*-pyrazole-4-carboxamide, *N*-[2-(2,4-dichlorophenyl)-2-methoxy-1-methylethyl]-3-(difluoromethyl)-1-methyl-1*H*-pyrazole-4-carboxamide and *N*-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-*N*-[[2-(1-methylethyl)phenyl]methyl]-1*H*-pyrazole-4-carboxamide. The pyridine carboxamides include boscalid. The phenyl oxoethyl thiophene amides include isofetamid (*N*-[1,1-dimethyl-2-[2-methyl-4-(1-methylethoxy)phenyl]-2-oxoethyl]-3-methyl-2-thiophenecarboxamide). The pyridinyethyl benzamides include fluopyram.

(b8) “Hydroxy-(2-amino-)pyrimidine fungicides” (FRAC code 8) inhibit nucleic acid synthesis by interfering with adenosine deaminase. Examples include bupirimate, dimethirimol and ethirimol.

(b9) “Anilinopyrimidine fungicides” (FRAC code 9) are proposed to inhibit biosynthesis of the amino acid methionine and to disrupt the secretion of hydrolytic enzymes that lyse plant cells during infection. Examples include cyprodinil, mepanipyrim and pyrimethanil.

(b10) “*N*-Phenyl carbamate fungicides” (FRAC code 10) inhibit mitosis by binding to β -tubulin and disrupting microtubule assembly. Inhibition of microtubule assembly can disrupt cell division, transport within the cell and cell structure. Examples include diethofencarb.

(b11) “Quinone outside inhibitor (QoI) fungicides” (FRAC code 11) inhibit Complex III mitochondrial respiration in fungi by affecting ubiquinol oxidase. Oxidation of ubiquinol is blocked at the “quinone outside” (Q_o) site of the cytochrome bc_1 complex, which is located in the inner mitochondrial membrane of fungi. Inhibiting mitochondrial respiration prevents normal fungal growth and development. Quinone outside inhibitor fungicides include methoxyacrylate, methoxycarbamate, oximinoacetate, oximinoacetamide and dihydrodioxazine fungicides (collectively also known as strobilurin fungicides), and oxazolidinedione, imidazolinone and benzylcarbamate fungicides. The methoxyacrylates include azoxystrobin, coumoxystrobin (methyl (αE)-2-[[[(3-butyl-4-methyl-2-oxo-2*H*-1-benzopyran-7-yl)oxy]methyl]- α -(methoxymethylene)benzeneacetate), enoxastrobin (methyl (αE)-2-[[[(*E*)-[(2*E*)-3-(4-chlorophenyl)-1-methyl-2-propen-1-ylidene]amino]oxy]methyl]- α -(methoxymethylene)benzeneacetate) (also known as enestroburin), flufenoxystrobin (methyl (αE)-2-[[2-chloro-4-(trifluoromethyl)phenoxy]methyl]- α -(methoxymethylene)benzeneacetate), picoxystrobin, and pyraoxystrobin (methyl (αE)-2-[[[3-(4-chlorophenyl)-1-methyl-1*H*-pyrazol-5-yl]oxy]methyl]- α -(methoxymethylene)benzeneacetate). The methoxycarbamates include pyraclostrobin, pyrametostrobin (methyl *N*-[2-[[[(1,4-dimethyl-3-phenyl-1*H*-pyrazol-5-yl)oxy]methyl]phenyl]-*N*-methoxycarbamate) and triclopyricarb (methyl *N*-methoxy-*N*-[2-[[[(3,5,6-trichloro-2-pyridinyl)oxy]methyl]phenyl]carbamate). The oximinoacetates include kresoxim-methyl, and trifloxystrobin. The oximinoacetamides include dimoxystrobin, fenaminstrobin ((αE)-2-[[[(*E*)-[(2*E*)-3-(2,6-dichlorophenyl)-1-methyl-2-propen-1-ylidene]amino]oxy]methyl]- α -(methoxyimino)-*N*-methylbenzeneacetamide), metominostrobin, oryastrobin and α -[methoxyimino]-*N*-methyl-2-[[[1-[3-(trifluoromethyl)phenyl]ethoxy]imino]methyl]benzeneacetamide. The dihydrodioxazines include fluoxastrobin. The oxazolidinediones include famoxadone. The imidazolinones include fenamidone. The benzylcarbamates include pyribencarb. Class (b11) also includes mandestrobin (2-[(2,5-dimethylphenoxy)methyl]- α -methoxy-*N*-benzeneacetamide).

(b12) "Phenylpyrrole fungicides" (FRAC code 12) inhibit a MAP/histidine kinase associated with osmotic signal transduction in fungi. Fenpiclonil and fludioxonil are examples of this fungicide class.

(b13) "Azanaphthalene fungicides" (FRAC code 13) are proposed to inhibit signal transduction by a mechanism which is as yet unknown. They have been shown to interfere with germination and/or appressorium formation in fungi that cause powdery mildew diseases. Azanaphthalene fungicides include aryloxyquinolines and quinazolinones. The aryloxyquinolines include quinoxifen. The quinazolinones include proquinazid.

(b14) "Lipid peroxidation inhibitor fungicides" (FRAC code 14) are proposed to inhibit lipid peroxidation which affects membrane synthesis in fungi. Members of this class, such as etridiazole, may also affect other biological processes such as respiration and melanin biosynthesis. Lipid peroxidation fungicides include aromatic hydrocarbon and 1,2,4-thiadiazole fungicides. The aromatic hydrocarbon fungicides include biphenyl, chloroneb, dicloran, quintozone, tecnazene and tolclofos-methyl. The 1,2,4-thiadiazoles include etridiazole.

(b15) "Melanin biosynthesis inhibitors-reductase (MBI-R) fungicides" (FRAC code 16.1) inhibit the naphthal reduction step in melanin biosynthesis. Melanin is required for host plant infection by some fungi. Melanin biosynthesis inhibitors-reductase fungicides include isobenzofuranone, pyrroloquinolinone and triazolobenzothiazole fungicides. The isobenzofuranones include fthalide. The pyrroloquinolinones include pyroquilon. The triazolobenzothiazoles include tricyclazole.

(b16) "Melanin biosynthesis inhibitors-dehydratase (MBI-D) fungicides" (FRAC code 16.2) inhibit scytalone dehydratase in melanin biosynthesis. Melanin is required for host plant infection by some fungi. Melanin biosynthesis inhibitors-dehydratase fungicides include cyclopropanecarboxamide, carboxamide and propionamide fungicides. The cyclopropanecarboxamides include carpropamid. The carboxamides include diclocymet. The propionamides include fenoxanil.

(b17) "Sterol Biosynthesis Inhibitor (SBI): Class III fungicides (FRAC code 17) inhibit 3-ketoreductase during C4-demethylation in sterol production. SBI: Class III inhibitors include hydroxyanilide fungicides and amino-pyrazolinone fungicides. Hydroxyanilides include fenhexamid. Amino-pyrazolinones include fenpyrazamine (*S*-2-propen-1-yl 5-amino-2,3-dihydro-2-(1-methylethyl)-4-(2-methylphenyl)-3-oxo-1*H*-pyrazole-1-carbothioate).

(b18) "Squalene-epoxidase inhibitor fungicides" (FRAC code 18) (SBI: Class IV) inhibit squalene-epoxidase in the sterol biosynthesis pathway. Sterols such as ergosterol are needed for membrane structure and function, making them essential for the development of functional cell walls. Therefore exposure to these fungicides results in abnormal growth and eventually death of sensitive fungi. Squalene-epoxidase inhibitor fungicides include

thiocarbamate and allylamine fungicides. The thiocarbamates include pyributicarb. The allylamines include naftifine and terbinafine.

(b19) "Polyoxin fungicides" (FRAC code 19) inhibit chitin synthase. Examples include polyoxin.

5 (b20) "Phenylurea fungicides" (FRAC code 20) are proposed to affect cell division. Examples include pencycuron.

(b21) "Quinone inside inhibitor (QiI) fungicides" (FRAC code 21) inhibit Complex III mitochondrial respiration in fungi by affecting ubiquinone reductase. Reduction of ubiquinone is blocked at the "quinone inside" (Q_i) site of the cytochrome bc_1 complex, which is located in the inner mitochondrial membrane of fungi. Inhibiting mitochondrial respiration prevents normal fungal growth and development. Quinone inside inhibitor fungicides include cyanoimidazole and sulfamoyltriazole fungicides. The cyanoimidazoles include cyazofamid. The sulfamoyltriazoles include amisulbrom.

10 (b22) "Benzamide and thiazole carboxamide fungicides" (FRAC code 22) inhibit mitosis by binding to β -tubulin and disrupting microtubule assembly. Inhibition of microtubule assembly can disrupt cell division, transport within the cell and cell structure. The benzamides include zoxamide. The thiazole carboxamides include ethaboxam.

(b23) "Enopyranuronic acid antibiotic fungicides" (FRAC code 23) inhibit growth of fungi by affecting protein biosynthesis. Examples include blasticidin-S.

20 (b24) "Hexopyranosyl antibiotic fungicides" (FRAC code 24) inhibit growth of fungi by affecting protein biosynthesis. Examples include kasugamycin.

(b25) "Glucopyranosyl antibiotic: protein synthesis fungicides" (FRAC code 25) inhibit growth of fungi by affecting protein biosynthesis. Examples include streptomycin.

25 (b26) "Glucopyranosyl antibiotic: trehalase and inositol biosynthesis fungicides" (FRAC code 26) inhibit trehalase and inositol biosynthesis. Examples include validamycin.

(b27) "Cyanoacetamidoxime fungicides (FRAC code 27) include cymoxanil.

30 (b28) "Carbamate fungicides" (FRAC code 28) are considered multi-site inhibitors of fungal growth. They are proposed to interfere with the synthesis of fatty acids in cell membranes, which then disrupts cell membrane permeability. Propamacarb, iodocarb, and prothiocarb are examples of this fungicide class.

(b29) "Oxidative phosphorylation uncoupling fungicides" (FRAC code 29) inhibit fungal respiration by uncoupling oxidative phosphorylation. Inhibiting respiration prevents normal fungal growth and development. This class includes 2,6-dinitroanilines such as fluazinam, and dinitrophenyl crotonates such as dinocap, meptyldinocap and binapacryl.

35 (b30) "Organo tin fungicides" (FRAC code 30) inhibit adenosine triphosphate (ATP) synthase in oxidative phosphorylation pathway. Examples include fentin acetate, fentin chloride and fentin hydroxide.

(b31) “Carboxylic acid fungicides” (FRAC code 31) inhibit growth of fungi by affecting deoxyribonucleic acid (DNA) topoisomerase type II (gyrase). Examples include oxolinic acid.

(b32) “Heteroaromatic fungicides” (Fungicide Resistance Action Committee (FRAC) code 32) are proposed to affect DNA/ribonucleic acid (RNA) synthesis. Heteroaromatic fungicides include isoxazoles and isothiazolones. The isoxazoles include hymexazole and the isothiazolones include othililone.

(b33) “Phosphonate fungicides” (FRAC code 33) include phosphorous acid and its various salts, including fosetyl-aluminum.

(b34) “Phthalamic acid fungicides” (FRAC code 34) include teclofthalam.

(b35) “Benzotriazine fungicides” (FRAC code 35) include triazoxide.

(b36) “Benzene-sulfonamide fungicides” (FRAC code 36) include flusulfamide.

(b37) “Pyridazinone fungicides” (FRAC code 37) include diclomezine.

(b38) “Thiophene-carboxamide fungicides” (FRAC code 38) are proposed to affect ATP production. Examples include silthiofam.

(b39) “Complex I NADH oxidoreductase inhibitor fungicides” (FRAC code 39) inhibit electron transport in mitochondria and include pyrimidinamines such as diflufenorim, and pyrazole-5-carboxamides such as tolfenpyrad.

(b40) “Carboxylic acid amide (CAA) fungicides” (FRAC code 40) inhibit cellulose synthase which prevents growth and leads to death of the target fungus. Carboxylic acid amide fungicides include cinnamic acid amide, valinamide and other carbamate, and mandelic acid amide fungicides. The cinnamic acid amides include dimethomorph, flumorph and pyrimorph (3-(2-chloro-4-pyridinyl)-3-[4-(1,1-dimethylethyl)phenyl]-1-(4-morpholinyl)-2-propene-1-one). The valinamide and other carbamates include benthiavalicarb, benthiavalicarb-isopropyl, iprovalicarb, tolprocarb (2,2,2-trifluoroethyl *N*-[(1*S*)-2-methyl-1-[[4-methylbenzoyl]amino]methyl]propyl]carbamate) and valifenalate (methyl *N*-[(1-methylethoxy)carbonyl]-L-valyl-3-(4-chlorophenyl)- β -alaninate) (also known as valiphenal). The mandelic acid amides include mandipropamid, *N*-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(methylsulfonyl)-amino]butanamide and *N*-[2-[4-[[3-(4-chlorophenyl)-2-propyn-1-yl]oxy]-3-methoxyphenyl]-ethyl]-3-methyl-2-[(ethylsulfonyl)amino]butanamide.

(b41) “Tetracycline antibiotic fungicides” (FRAC code 41) inhibit growth of fungi by affecting protein synthesis. Examples include oxytetracycline.

(b42) “Thiocarbamate fungicides” (FRAC code 42) include methasulfocarb.

(b43) “Benzamide fungicides” (FRAC code 43) inhibit growth of fungi by delocalization of spectrin-like proteins. Examples include pyridinylmethyl benzamide fungicides such as fluopicolide (now FRAC code 7, pyridinylethyl benzamides).

(b44) “Microbial fungicides” (FRAC code 44) disrupt fungal pathogen cell membranes. Microbial fungicides include *Bacillus* species such as *Bacillus amyloliquefaciens* strains QST 713, FZB24, MB1600, D747 and the fungicidal lipopeptides which they produce.

5 (b45) “Q_xI fungicides” (FRAC code 45) inhibit Complex III mitochondrial respiration in fungi by affecting ubiquinone reductase at an unknown (Q_x) site of the cytochrome *bc*₁ complex. Inhibiting mitochondrial respiration prevents normal fungal growth and development. Q_xI fungicides include triazolopyrimidylamines such as ametctradin (5-ethyl-6-octyl[1,2,4]triazolo[1,5-*a*]pyrimidin-7-amine).

10 (b46) “Plant extract fungicides” are proposed to act by cell membrane disruption. Plant extract fungicides include terpene hydrocarbons and terpene alcohols such as the extract from *Melaleuca alternifolia* (tea tree).

(b47) “Host plant defense induction fungicides” (FRAC code P) induce host plant defense mechanisms. Host plant defense induction fungicides include benzothiadiazoles, 15 benzisothiazole and thiadiazole-carboxamide fungicides. The benzothiadiazoles include acibenzolar-S-methyl. The benzisothiazoles include probenazole. The thiadiazole-carboxamides include tiadinil and isotianil.

(b48) “Multi-site contact fungicides” inhibit fungal growth through multiple sites of action and have contact/preventive activity. This class of fungicides includes: (b48.1) 20 “copper fungicides” (FRAC code M1), (b48.2) “sulfur fungicides” (FRAC code M2), (b48.3) “dithiocarbamate fungicides” (FRAC code M3), (b48.4) “phthalimide fungicides” (FRAC code M4), (b48.5) “chloronitrile fungicides” (FRAC code M5), (b48.6) “sulfamide fungicides” (FRAC code M6), (b48.7) multi-site contact “guanidine fungicides” (FRAC code M7), (b48.8) “triazine fungicides” (FRAC code M8), (b48.9) “quinone fungicides” 25 (FRAC code M9), (b48.10) “quinoxaline fungicides” (FRAC code M10) and (b48.11) “maleimide fungicides” (FRAC code M11). “Copper fungicides” are inorganic compounds containing copper, typically in the copper(II) oxidation state; examples include copper oxychloride, copper sulfate and copper hydroxide, including compositions such as Bordeaux mixture (tribasic copper sulfate). “Sulfur fungicides” are inorganic chemicals containing 30 rings or chains of sulfur atoms; examples include elemental sulfur. “Dithiocarbamate fungicides” contain a dithiocarbamate molecular moiety; examples include mancozeb, metiram, propineb, ferbam, maneb, thiram, zineb and ziram. “Phthalimide fungicides” contain a phthalimide molecular moiety; examples include folpet, captan and captafol. “Chloronitrile fungicides” contain an aromatic ring substituted with chloro and cyano; 35 examples include chlorothalonil. “Sulfamide fungicides” include dichlofluanid and tolyfluanid. Multi-site contact “guanidine fungicides” include, guazatine, iminoctadine albesilate and iminoctadine triacetate. “Triazine fungicides” include anilazine. “Quinone

fungicides” include dithianon. “Quinoxaline fungicides” include quinomethionate (also known as chinomethionate). “Maleimide fungicides” include fluoroimide.


(b49) “Fungicides other than fungicides of classes (b1) through (b48)” include certain fungicides whose mode of action may be unknown. These include: (b49.1) “phenyl-
 5 acetamide fungicides” (FRAC code U6), (b49.2) “aryl-phenyl-ketone fungicides” (FRAC code U8), (b49.3) “guanidine fungicides” (FRAC code U12), (b49.4) “thiazolidine fungicides” (FRAC code U13), (b49.5) “pyrimidinone-hydrazone fungicides” (FRAC code U14) and (b49.6) compounds that bind to oxysterol-binding protein as described in PCT Patent Publication WO 2013/009971. The phenyl-acetamides include cyflufenamid and *N*-
 10 [[(cyclopropylmethoxy)amino][6-(difluoromethoxy)-2,3-difluorophenyl]-methylene]-benzeneacetamide. The aryl-phenyl ketones include benzophenones such as metrafenone, and benzoylpyridines such as pyriofenone ((5-chloro-2-methoxy-4-methyl-3-pyridinyl)(2,3,4-trimethoxy-6-methylphenyl)methanone). The guanidines include dodine. The thiazolidines include flutianil ((2*Z*)-2-[[2-fluoro-5-(trifluoromethyl)phenyl]thio]-2-[3-(2-methoxyphenyl)-2-thiazolidinylidene]acetonitrile). The pyrimidinone-hydrazones include
 15 ferimzone. The (b49.6) class includes oxathiapiprolin (1-[4-[4-[5-(2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]ethanone) and its *R*-enantiomer which is 1-[4-[4-[5*R*-(2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1*H*-
 20 pyrazol-1-yl]ethanone (Registry Number 1003319-79-6).

The (b49) class also includes bethoxazin, flometoquin (2-ethyl-3,7-dimethyl-6-[4-(trifluoromethoxy)phenoxy]-4-quinoliny] methyl carbonate), fluoroimide, neo-asozin (ferric methanearsonate), picarbutrazox (1,1-dimethylethyl *N*-[6-[[[(*Z*)-1-methyl-1*H*-tetrazol-5-yl]phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate), pyrrolnitrin,
 25 quinomethionate, tebufloquin (6-(1,1-dimethylethyl)-8-fluoro-2,3-dimethyl-4-quinoliny] acetate), toltriflur (N-(4-chloro-2-nitrophenyl)-N-ethyl-4-methylbenzenesulfonamide), 2-butoxy-6-iodo-3-propyl-4*H*-1-benzopyran-4-one, 3-butyn-1-yl *N*-[6-[[[(1-methyl-1*H*-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate, (N-(4-chloro-2-nitrophenyl)-N-ethyl-4-methylbenzenesulfonamide), *N'*-[4-[4-chloro-3-(trifluoromethyl)-phenoxy]-2,5-dimethylphenyl]-N-ethyl-N-methylmethanimidamide, *N*-[[[(cyclopropylmethoxy)amino][6-(difluoromethoxy)-2,3-difluorophenyl]methylene]benzeneacetamide,
 30 2,6-dimethyl-1*H*,5*H*-[1,4]dithiino[2,3-*c*:5,6-*c'*]dipyrrole-1,3,5,7(2*H*,6*H*)-tetrone, 5-fluoro-2-[(4-methylphenyl)methoxy]-4-pyrimidinamine, 5-fluoro-2-[(4-fluorophenyl)methoxy]-4-pyrimidinamine and 4-fluorophenyl *N*-[1-[[[1-(4-cyanophenyl)ethyl]sulfonyl]methyl]-propyl]carbamate,
 35 pentyl *N*-[6-[[[(1-methyl-1*H*-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate, pentyl *N*-[4-[[[(1-methyl-1*H*-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-thiazolyl]carbamate and pentyl *N*-[6-[[[(*Z*)-(1-methyl-1*H*-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]-


carbamate. The (b49) class further includes mitosis- and cell division-inhibiting fungicides besides those of the particular classes described above (e.g., (b1), (b10) and (b22)).

Additional “Fungicides other than fungicides of classes (b1) through (b48)” whose mode of action may be unknown, or may not yet be classified include a fungicidal compound selected from components (b49.7) through (b49.12), as shown below.


Component (b49.7) relates to a compound of Formula b49.7



wherein R^{b1} is




or



Examples of a compound of Formula b49.7 include (b49.7a) (2-chloro-6-fluorophenyl)-methyl 2-[1-[2-[3,5-bis(difluoromethyl)-1*H*-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolecarboxylate (Registry Number 1299409-40-7) and (b49.7b) (1*R*)-1,2,3,4-tetrahydro-1-naphthalenyl 2-[1-[2-[3,5-bis(difluoromethyl)-1*H*-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolecarboxylate (Registry Number 1299409-42-9). Methods for preparing compounds of Formula b49.7 are described in PCT Patent Publications WO 2009/132785 and WO 2011/051243.

Component (b49.8) relates to a compound of Formula b49.8




wherein R^{b2} is CH₃, CF₃ or CHF₂; R^{b3} is CH₃, CF₃ or CHF₂; R^{b4} is halogen or cyano; and n is 0, 1, 2 or 3.


Examples of a compound of Formula b49.8 include (b49.8a) 1-[4-[4-[5-[(2,6-difluorophenoxy)methyl]-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]ethanone. Methods for preparing compounds of Formula b49.8 are described in PCT Patent Application PCT/US11/64324.

Component (b49.9) relates to a compound of Formula b49.9

90




wherein R^{b5} is -CH₂OC(O)CH(CH₃)₂, -C(O)CH₃, -CH₂OC(O)CH₃,



Examples of a compound of Formula b49.9 include (b49.9a) [[4-methoxy-2-
 5 [[[(3*S*,7*R*,8*R*,9*S*)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-
 dioxonan-3-yl]amino]carbonyl]-3-pyridinyl]oxy]methyl 2-methylpropanoate (Registry
 Number 517875-34-2), (b49.9b) (3*S*,6*S*,7*R*,8*R*)-3-[[[3-(acetyloxy)-4-methoxy-2-pyridinyl]-
 carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl 2-methyl-
 propanoate (Registry Number 234112-93-7), (b49.9c) (3*S*,6*S*,7*R*,8*R*)-
 3-[[[3-[(acetyloxy)methoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-
 10 8-(phenylmethyl)-1,5-dioxonan-7-yl 2-methylpropanoate (Registry Number 517875-31-9),
 (b49.9d) (3*S*,6*S*,7*R*,8*R*)-3-[[[4-methoxy-3-[(2-methylpropoxy)carbonyl]oxy]-2-pyridinyl]-
 carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl
 2-methylpropanoate (Registry Number 328256-72-0), and (b49.9e) *N*-[[3-(1,3-benzodioxol-
 5-ylmethoxy)-4-methoxy-2-pyridinyl]carbonyl]-*O*-[2,5-dideoxy-3-*O*-(2-methyl-1-
 15 oxopropyl)-2-(phenylmethyl)-*L*-arabinonoyl]-*L*-serine, (1→4')-lactone (Registry Number
 1285706-70-8). Methods for preparing compounds of Formula b49.9 are described in PCT
 Patent Publications WO 99/40081, WO 2001/014339, WO 2003/035617 and WO
 2011044213.


Component (b49.10) relates to a compound of Formula b49.10



wherein R^{b6} is H or F, and R^{b7} is -CF₂CHF₂ or -CF₂CF₂H. Examples of a compound of
 Formula b49.10 are (b49.10a) 3-(difluoromethyl)-*N*-[4-fluoro-2-(1,1,2,3,3,3-hexafluoro-
 propoxy)phenyl]-1-methyl-1*H*-pyrazole-4-carboxamide (Registry Number 1172611-40-3)

and (b49.10b) 3-(difluoromethyl)-1-methyl-*N*-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-1*H*-pyrazole-4-carboxamide (Registry Number 923953-98-4). Compounds of Formula 49.10 can be prepared by methods described in PCT Patent Publication WO 2007/017450.

Component b49.11 relates a compound of Formula b49.11



wherein

R^{b8} is halogen, C_1 - C_4 alkoxy or C_2 - C_4 alkynyl;

R^{b9} is H, halogen or C_1 - C_4 alkyl;

R^{b10} is C_1 - C_{12} alkyl, C_1 - C_{12} haloalkyl, C_1 - C_{12} alkoxy, C_2 - C_{12} alkoxyalkyl, C_2 - C_{12} alkenyl, C_2 - C_{12} alkynyl, C_4 - C_{12} alkoxyalkenyl, C_4 - C_{12} alkoxyalkynyl, C_1 - C_{12} alkylthio or C_2 - C_{12} alkylthioalkyl;

R^{b11} is methyl or $-Y^{b13}-R^{b12}$;

R^{b12} is C_1 - C_2 alkyl; and

Y^{b13} is CH_2 , O or S.

Examples of compounds of Formula b49.11 include (b49.11a) 2-[(3-bromo-6-quinolinyl)oxy]-*N*-(1,1-dimethyl-2-butyn-1-yl)-2-(methylthio)acetamide, (b49.11b) 2-[(3-ethynyl-6-quinolinyl)oxy]-*N*-[1-(hydroxymethyl)-1-methyl-2-propyn-1-yl]-2-(methylthio)acetamide, (b49.11c) *N*-(1,1-dimethyl-2-butyn-1-yl)-2-[(3-ethynyl-6-quinolinyl)oxy]-2-(methylthio)acetamide, (b49.11d) 2-[(3-bromo-8-methyl-6-quinolinyl)oxy]-*N*-(1,1-dimethyl-2-propyn-1-yl)-2-(methylthio)acetamide and (b49.11e) 2-[(3-bromo-6-quinolinyl)oxy]-*N*-(1,1-dimethylethyl)butanamide. Compounds of Formula b49.11, their use as fungicides and methods of preparation are generally known; see, for example, PCT Patent Publications WO 2004/047538, WO 2004/108663, WO 2006/058699, WO 2006/058700, WO 2008/110355, WO 2009/030469, WO 2009/049716 and WO 2009/087098.

Component (b49.12) relates to *N*'-[4-[[3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5-yl]oxy]-2,5-dimethylphenyl]-*N*-ethyl-*N*-methylmethanimidamide, which is believed to inhibit C24-methyl transferase involved in the biosynthesis of sterols.

Therefore of note is a mixture (i.e. composition) comprising a compound of Formula 1 and at least one fungicidal compound selected from the group consisting of the aforescribed classes (b1) through (b49). Also of note is a composition comprising said mixture (in fungicidally effective amount) and further comprising at least one additional component selected from the group consisting of surfactants, solid diluents and liquid

diluents. Of particular note is a mixture (i.e. composition) comprising a compound of Formula 1 and at least one fungicidal compound selected from the group of specific compounds listed above in connection with classes (b1) through (b49). Also of particular note is a composition comprising said mixture (in fungicidally effective amount) and further comprising at least one additional surfactant selected from the group consisting of surfactants, solid diluents and liquid diluents.

Examples of component (b) fungicides include acibenzolar-S-methyl, aldimorph, ametoctradin, amisulbrom, anilazine, azaconazole, azoxystrobin, benalaxyl (including benalaxyl-M), benodanil, benomyl, benthiavalicarb (including benthiavalicarb-isopropyl), benzovindiflupyr, bethoxazin, binapacryl, biphenyl, bitertanol, bixafen, blasticidin-S, boscalid, bromuconazole, bupirimate, buthiobate, captafol, captan, carbendazim, carboxin, carpropamid, chloroneb, chlorothalonil, chlozolate, clotrimazole, copper hydroxide, copper oxychloride, copper sulfate, coumoxystrobin, cyazofamid, cyflufenamid, cymoxanil, cyproconazole, cyprodinil, dichlofluanid, diclocymet, diclomezine, dicloran, diethofencarb, difenoconazole, diflumetorim, dimethirimol, dimethomorph, dimoxystrobin, diniconazole (including diniconazole-M), dinocap, dithianon, dithiolanes, dodemorph, dodine, econazole, edifenphos, enoxastrobin (also known as enestroburin), epoxiconazole, etaconazole, ethaboxam, ethirimol, etridiazole, famoxadone, fenamidone, fenarimol, fenaminostrobin, fenbuconazole, fenfuram, fenhexamid, fenoxanil, fenciclonil, fenpropidin, fenpropimorph, fenpyrazamine, fentin acetate, fentin chloride, fentin hydroxide, ferbam, ferimzone, flometoquin, fluazinam, fludioxonil, flufenoxystrobin, flumorph, fluopicolide, fluopyram, flouroimide, fluoxastrobin, fluquinconazole, flusilazole, flusulfamide, flutianil, flutolanil, flutriafol, fluxapyroxad, folpet, fthalide, fuberidazole, furalaxyl, furametpyr, guazatine, hexaconazole, hymexazole, imazalil, imibenconazole, iminoctadine albesilate, iminoctadine triacetate, iodocarb, ipconazole, iprobenfos, iprodione, iprovalicarb, isoconazole, isofetamid, isoprothiolane, isopyrazam, isotianil, kasugamycin, kresoxim-methyl, mancozeb, mandeppropamid, mandestrobin, maneb, mepanipyrim, mepronil, meptyldinocap, metalaxyl (including metalaxyl-M/mefenoxam), metconazole, methasulfocarb, metiram, metominostrobin, metrafenone, miconazole, myclobutanil, naftifine, neo-asozin, nuarimol, octhilineone, ofurace, orysastrobin, oxadixyl, oxathiapiprolin, oxolinic acid, oxpoconazole, oxycarboxin, oxytetracycline, pefurazoate, penconazole, pencycuron, penflufen, penthiopyrad, phosphorous acid (including salts thereof, e.g., fosetyl-aluminum), picarbutrazox, picoxystrobin, piperalin, polyoxin, probenazole, prochloraz, procymidone, propamacarb, propiconazole, propineb, proquinazid, prothiocarb, prothioconazole, pyraclostrobin, pyrametostrobin, pyraoxystrobin, pyrazophos, pyribencarb, pyributicarb, pyrifenoxy, pyrimethanil, pyriofenone, pyrisoxazole, pyroquilon, pyrrolnitrin, quinconazole, quinomethionate, quinoxifen, quintozone, sedaxane, silthiofam, simeconazole, spiroxamine, streptomycin, sulfur, tebuconazole, tebufloquin, teclofthalam, tecnazene, terbinafine,

tetraconazole, thiabendazole, thifluzamide, thiophanate, thiophanate-methyl, thiram, tiadinil, tolclofos-methyl, tolnifanide, tolprocarb, tolyfluanid, triadimefon, triadimenol, triarimol, triticonazole, triazoxide, tribasic copper sulfate, tricyclazole, triclopyricarb, tridemorph, trifloxystrobin, triflumizole, triforine, trimorphamide, uniconazole, uniconazole-P,

5 validamycin, valifenalate (also known as valiphenal), vinclozolin, zineb, ziram, zoxamide, (3*S*,6*S*,7*R*,8*R*)-3-[[[3-[(acetyloxy)methoxy]-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl 2-methylpropanoate, (3*S*,6*S*,7*R*,8*R*)-3-[[[3-(acetyloxy)-4-methoxy-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl 2-methylpropanoate, *N*-[[3-(1,3-benzodioxol-5-ylmethoxy)-4-methoxy-2-pyridinyl]carbonyl]-*O*-[2,5-dideoxy-3-*O*-(2-methyl-1-oxopropyl)-2-(phenylmethyl)-*L*-arabinonoyl]-*L*-serine, (1→4')-lactone, *N*-[2-(1*S*,2*R*)-[1,1'-bicyclopropyl]-2-ylphenyl]-3-(difluoromethyl)-1-methyl-1*H*-pyrazole-4-carboxamide, 2-[(3-bromo-6-quinolinyloxy)-*N*-(1,1-dimethyl-2-butyne-1-yl)-2-(methylthio)acetamide, 2-[(3-bromo-6-quinolinyloxy)-*N*-(1,1-dimethylethyl)butanamide,

10 2-[(3-bromo-8-methyl-6-quinolinyloxy)-*N*-(1,1-dimethyl-2-propyne-1-yl)-2-(methylthio)acetamide, 2-butoxy-6-iodo-3-propyl-4*H*-1-benzopyran-4-one, 3-butyne-1-yl *N*-[6-[[[(1-methyl-1*H*-tetrazol-5-yl)-phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate, α-(1-chlorocyclopropyl)-α-[2-(2,2-dichlorocyclopropyl)ethyl]-1*H*-1,2,4-triazole-1-ethanol, 2-[2-(1-chlorocyclopropyl)-4-(2,2-dichlorocyclopropyl)-2-hydroxybutyl]-1,2-dihydro-3*H*-1,2,4-triazole-3-thione, (α*S*)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-4-isoxazolyl]-3-pyridinemethanol, *rel*-1-[[[(2*R*,3*S*)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1*H*-1,2,4-triazole, *rel*-2-[[[(2*R*,3*S*)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1,2-dihydro-3*H*-1,2,4-triazole-3-thione, *rel*-1-[[[(2*R*,3*S*)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-5-(2-propen-1-ylthio)-1*H*-1,2,4-triazole,

15 3-[5-(4-chlorophenyl)-2,3-dimethyl-3-isoxazolidinyl]pyridine, (2-chloro-6-fluorophenyl)methyl 2-[1-[2-[3,5-bis(difluoromethyl)-1*H*-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolecarboxylate, *N'*-[4-[[3-[(4-chlorophenyl)methyl]-1,2,4-thiadiazol-5-yl]oxy]-2,5-dimethylphenyl]-*N*-ethyl-*N*-methylmethanimidamide, *N*-[2-[4-[[3-(4-chlorophenyl)-2-propyne-1-yl]oxy]-3-methoxyphenyl]-ethyl]-3-methyl-2-[(methylsulfonyl)amino]butanamide, *N*-[2-[4-[[3-(4-chlorophenyl)-2-propyne-1-yl]oxy]-3-methoxyphenyl]ethyl]-3-methyl-2-[(ethylsulfonyl)amino]butanamide,

20 *N'*-[4-[4-chloro-3-(trifluoromethyl)phenoxy]-2,5-dimethylphenyl]-*N*-ethyl-*N*-methylmethanimidamide, *N*-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-*N*-[[2-(1-methylethyl)phenyl]methyl]-1*H*-pyrazole-4-carboxamide, *N*-[[[(cyclopropylmethoxy)amino][6-(difluoromethoxy)-2,3-difluorophenyl]methylene]benzeneacetamide, *N*-[2-(2,4-dichlorophenyl)-2-methoxy-1-methylethyl]-3-(difluoromethyl)-1-methyl-1*H*-pyrazole-4-carboxamide,

25 *N*-(3',4'-difluoro[1,1'-biphenyl]-2-yl)-3-(trifluoromethyl)-2-pyrazinecarboxamide, 3-(difluoromethyl)-*N*-(2,3-dihydro-1,1,3-trimethyl-1*H*-inden-4-yl)-1-methyl-1*H*-pyrazole-4-carboxamide, 3-(difluoromethyl)-*N*-[4-fluoro-2-(1,1,2,3,3,3-hexa-

fluoropropoxy)phenyl]-1-methyl-1*H*-pyrazole-4-carboxamide, 5,8-difluoro-*N*-[2-[3-methoxy-4-[[4-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]ethyl]-4-quinazolinamine, 3-(difluoromethyl)-1-methyl-*N*-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-1*H*-pyrazole-4-carboxamide, 1-[4-[4-[5*R*-(2,6-difluorophenoxy)methyl]-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]ethanone, *N*-(1,1-dimethyl-2-butyn-1-yl)-2-[(3-ethynyl-6-quinolinyl)oxy]-2-(methylthio)acetamide, 2,6-dimethyl-1*H*,5*H*-[1,4]dithiino[2,3-*c*:5,6-*c'*]dipyrrole-1,3,5,7(2*H*,6*H*)-tetrone, 2-[(3-ethynyl-6-quinolinyl)oxy]-*N*-[1-(hydroxymethyl)-1-methyl-2-propyn-1-yl]-2-(methylthio)acetamide, 4-fluorophenyl *N*-[1-[[[1-(4-cyanophenyl)ethyl]sulfonyl]methyl]propyl]carbamate, 5-fluoro-2-[(4-fluorophenyl)methoxy]-4-pyrimidinamine, 5-fluoro-2-[(4-methylphenyl)methoxy]-4-pyrimidinamine, (3*S*,6*S*,7*R*,8*R*)-3-[[[4-methoxy-3-[[2-methylpropoxy]carbonyl]oxy]-2-pyridinyl]carbonyl]amino]-6-methyl-4,9-dioxo-8-(phenylmethyl)-1,5-dioxonan-7-yl 2-methylpropanoate, α -(methoxyimino)-*N*-methyl-2-[[[1-[3-(trifluoromethyl)phenyl]ethoxy]imino]methyl]benzeneacetamide, [[4-methoxy-2-[[[(3*S*,7*R*,8*R*,9*S*)-9-methyl-8-(2-methyl-1-oxopropoxy)-2,6-dioxo-7-(phenylmethyl)-1,5-dioxonan-3-yl]-amino]carbonyl]-3-pyridinyl]oxy]methyl 2-methylpropanoate, pentyl *N*-[6-[[[(1-methyl-1*H*-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate, pentyl *N*-[4-[[[(1-methyl-1*H*-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-thiazolyl]carbamate, and pentyl *N*-[6-[[[(*Z*)-(1-methyl-1*H*-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate and (1*R*)-1,2,3,4-tetrahydro-1-naphthalenyl 2-[1-[2-[3,5-bis(difluoromethyl)-1*H*-pyrazol-1-yl]acetyl]-4-piperidinyl]-4-thiazolecarboxylate. Therefore of note is a fungicidal composition comprising as component (a) a compound of Formula 1 (or an *N*-oxide or salt thereof) and as component (b) at least one fungicide selected from the preceding list.

Of particular note are combinations of compounds of Formula 1 (or an *N*-oxide or salt thereof) (i.e. Component (a) in compositions) with azoxystrobin, benzovindiflupyr, bixafen, captan, carpropamid, chlorothalonil, copper hydroxide, copper oxychloride, copper sulfate, cymoxanil, cyproconazole, cyprodinil, diethofencarb, difenoconazole, dimethomorph, epoxiconazole, ethaboxam, fenarimol, fenhexamid, fluazinam, fludioxonil, fluopyram, flusilazole, flutianil, flutriafol, fluxapyroxad, folpet, iprodione, isofetamid, isopyrazam, kresoxim-methyl, mancozeb, mandestrobin, meptyldinocap, metalaxyl (including metalaxyl-M/mefenoxam), metconazole, metrafenone, myclobutanil, oxathiapiprolin, penflufen, penthiopyrad, phosphorous acid (including salts thereof, e.g., fosetyl-aluminum), picoxystrobin, propiconazole, proquinazid, prothioconazole, pyraclostrobin, pyrimethanil, sedaxane spiroxamine, sulfur, tebuconazole, thiophanate-methyl, trifloxystrobin, zoxamide, α -(1-chlorocyclopropyl)- α -[2-(2,2-dichlorocyclopropyl)ethyl]-1*H*-1,2,4-triazole-1-ethanol, 2-[2-(1-chlorocyclopropyl)-4-(2,2-dichlorocyclopropyl)-2-hydroxybutyl]-1,2-dihydro-3*H*-1,2,4-triazole-3-thione, *N*-[2-(2,4-dichlorophenyl)-2-methoxy-1-methylethyl]-3-

(difluoromethyl)-1-methyl-1*H*-pyrazole-4-carboxamide, 3-(difluoromethyl)-*N*-(2,3-dihydro-1,1,3-trimethyl-1*H*-inden-4-yl)-1-methyl-1*H*-pyrazole-4-carboxamide, 1-[4-[4-[5*R*-(2,6-difluorophenyl)-4,5-dihydro-3-isoxazolyl]-2-thiazolyl]-1-piperidinyl]-2-[5-methyl-3-(trifluoromethyl)-1*H*-pyrazol-1-yl]ethanone, 1,1-dimethylethyl *N*-[6-[[[(1-methyl-1*H*-tetrazol-5-yl)phenylmethylene]amino]oxy]methyl]-2-pyridinyl]carbamate, 2,6-dimethyl-1*H*,5*H*-[1,4]dithiino[2,3-*c*:5,6-*c'*]dipyrrole-1,3,5,7(2*H*,6*H*)-tetrone, 5-fluoro-2-[(4-fluorophenyl)methoxy]-4-pyrimidinamine, 5-fluoro-2-[(4-methylphenyl)methoxy]-4-pyrimidinamine, (α *S*)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-4-isoxazolyl]-3-pyridinemethanol, *rel*-1-[[2*R*,3*S*)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1*H*-1,2,4-triazole, *rel*-2-[[2*R*,3*S*)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-1,2-dihydro-3*H*-1,2,4-triazole-3-thione, and *rel*-1-[[2*R*,3*S*)-3-(2-chlorophenyl)-2-(2,4-difluorophenyl)-2-oxiranyl]methyl]-5-(2-propen-1-ylthio)-1*H*-1,2,4-triazole (i.e. as Component (b) in compositions).

Preferred for better control of plant diseases caused by fungal plant pathogens (e.g., lower use rate or broader spectrum of plant pathogens controlled) or resistance management are mixtures of a compound of this invention with a fungicide selected from the group.

Examples of other biologically active compounds or agents with which compounds of this invention can be formulated are: invertebrate pest control compounds or agents such as abamectin, acephate, acetamiprid, acrinathrin, afidopyropen ([3*S*,4*R*,4*aR*,6*S*,6*aS*,12*R*,12*aS*,12*bS*)-3-[(cyclopropylcarbonyl)oxy]-1,3,4,4*a*,5,6,6*a*,12,12*a*,12*b*-decahydro-6,12-dihydroxy-4,6*a*,12*b*-trimethyl-11-oxo-9-(3-pyridinyl)-2*H*,11*H*-naphtho[2,1-*b*]pyrano[3,4-*e*]pyran-4-yl]methyl cyclopropanecarboxylate), amidoflumet (S-1955), avermectin, azadirachtin, azinphos-methyl, bifenthrin, bifentazate, buprofezin, carbofuran, cartap, chlorantraniliprole, chlorfenapyr, chlorfluazuron, chlorpyrifos, chlorpyrifos-methyl, chromafenozide, clothianidin, cyantraniliprole (3-bromo-1-(3-chloro-2-pyridinyl)-*N*-[4-cyano-2-methyl-6-[(methylamino)carbonyl]phenyl]-1*H*-pyrazole-5-carboxamide), cyclaniliprole (3-bromo-*N*-[2-bromo-4-chloro-6-[[1-cyclopropylethyl]amino]carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1*H*-pyrazole-5-carboxamide), cycloxaprid ((5*S*,8*R*)-1-[(6-chloro-3-pyridinyl)methyl]-2,3,5,6,7,8-hexahydro-9-nitro-5,8-epoxy-1*H*-imidazo[1,2-*a*]azepine), cyflumetofen, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, cypermethrin, cyromazine, deltamethrin, diafenthiuron, diazinon, dieldrin, diflubenzuron, dimefluthrin, dimethoate, dinotefuran, diofenolan, emamectin, endosulfan, esfenvalerate, ethiprole, fenothiocarb, fenoxycarb, fenpropathrin, fenvalerate, fipronil, flonicamid, flubendiamide, flucythrinate, flufenoxystrobin (methyl (α *E*)-2-[[2-chloro-4-(trifluoromethyl)phenoxy]methyl]- α -(methoxymethylene)benzeneacetate), flufensulfone (5-chloro-2-[(3,4,4-trifluoro-3-buten-1-yl)sulfonyl]thiazole), flupiprole (1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-5-[(2-methyl-2-propen-1-yl)amino]-4-[(trifluoromethyl)sulfinyl]-

1*H*-pyrazole-3-carbonitrile), flupyradifurone (4-[[[(6-chloro-3-pyridinyl)methyl](2,2-difluoroethyl)amino]-2(5*H*)-furanone), tau-fluvalinate, flufenimer (UR-50701), flufenoxuron, fonophos, halofenozide, heptafluthrin ([2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]methyl 2,2-dimethyl-3-[(1*Z*)-3,3,3-trifluoro-1-propen-1-yl]cyclopropanecarboxylate), hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, isofenphos, lufenuron, malathion, meperfluthrin ([2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]methyl (1*R*,3*S*)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate), metaflumizone, metaldehyde, methamidophos, methidathion, methomyl, methoprene, methoxychlor, methoxyfenozide, metofluthrin, milbemycin oxime, momfluorothrin ([2,3,5,6-tetrafluoro-4-(methoxymethyl)phenyl]methyl 3-(2-cyano-1-propen-1-yl)-2,2-dimethylcyclopropanecarboxylate), monocrotophos, nicotine, nitenpyram, nithiazine, novaluron, noviflumuron (XDE-007), oxamyl, pyflubumide (1,3,5-trimethyl-*N*-(2-methyl-1-oxopropyl)-*N*-[3-(2-methylpropyl)-4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]phenyl]-1*H*-pyrazole-4-carboxamide), parathion, parathion-methyl, permethrin, phorate, phosalone, phosmet, phosphamidon, pirimicarb, profenofos, profluthrin, pymetrozine, pyrafluprole, pyrethrin, pyridalyl, pyrifluquinazon, pyriminostrobin (methyl (α *E*)-2-[[[2-[(2,4-dichlorophenyl)amino]-6-(trifluoromethyl)-4-pyrimidinyl]oxy]methyl]- α -(methoxymethylene)benzeneacetate), pyriprole, pyriproxyfen, rotenone, ryanodine, spinetoram, spinosad, spirotetramat, sulfoxaflo, sulprofos, tebufenozide, teflubenzuron, tefluthrin, terbufos, tetrachlorvinphos, tetramethylfluthrin, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tolfenpyrad, tralomethrin, triazamate, trichlorfon and triflumuron; and biological agents including entomopathogenic bacteria, such as *Bacillus thuringiensis* subsp. *aizawai*, *Bacillus thuringiensis* subsp. *kurstaki*, and the encapsulated delta-endotoxins of *Bacillus thuringiensis* (e.g., Cellcap, MPV, MPVII); entomopathogenic fungi, such as green muscardine fungus; and entomopathogenic virus including baculovirus, nucleopolyhedro virus (NPV) such as HzNPV, AfNPV; and granulosis virus (GV) such as CpGV.

Compounds of this invention and compositions thereof can be applied to plants genetically transformed to express proteins toxic to invertebrate pests (such as *Bacillus thuringiensis* delta-endotoxins). The effect of the exogenously applied fungicidal compounds of this invention may be synergistic with the expressed toxin proteins.

General references for agricultural protectants (i.e. insecticides, fungicides, nematocides, acaricides, herbicides and biological agents) include *The Pesticide Manual, 13th Edition*, C. D. S. Tomlin, Ed., British Crop Protection Council, Farnham, Surrey, U.K., 2003 and *The BioPesticide Manual, 2nd Edition*, L. G. Copping, Ed., British Crop Protection Council, Farnham, Surrey, U.K., 2001.

For embodiments where one or more of these various mixing partners are used, the weight ratio of these various mixing partners (in total) to the compound of Formula 1 is

typically between about 1:3000 and about 3000:1. Of note are weight ratios between about 1:300 and about 300:1 (for example ratios between about 1:30 and about 30:1). One skilled in the art can easily determine through simple experimentation the biologically effective amounts of active ingredients necessary for the desired spectrum of biological activity. It will be evident that including these additional components may expand the spectrum of diseases controlled beyond the spectrum controlled by the compound of Formula 1 alone.

In certain instances, combinations of a compound of this invention with other biologically active (particularly fungicidal) compounds or agents (i.e. active ingredients) can result in a greater-than-additive (i.e. synergistic) effect. Reducing the quantity of active ingredients released in the environment while ensuring effective pest control is always desirable. When synergism of fungicidal active ingredients occurs at application rates giving agronomically satisfactory levels of fungal control, such combinations can be advantageous for reducing crop production cost and decreasing environmental load.

Also in certain instances, combinations of a compound of the invention with other biologically active compounds or agents can result in a less-than-additive (i.e. safening) effect on organisms beneficial to the agronomic environment. For example, a compound of the invention may safen a herbicide on crop plants or protect a beneficial insect species (e.g., insect predators, pollinators such as bees) from an insecticide.

Fungicides of note for formulation with compounds of Formula 1 to provide mixtures useful in seed treatment include but are not limited to amisulbrom, azoxystrobin, boscalid, carbendazim, carboxin, cymoxanil, cyproconazole, difenoconazole, dimethomorph, fluazinam, fludioxonil, flufenoxystrobin, fluquinconazole, fluopicolide, fluoxastrobin, flutriafol, fluxapyroxad, ipconazole, iprodione, metalaxyl, mefenoxam, metconazole, myclobutanil, paclobutrazole, penflufen, picoxystrobin, prothioconazole, pyraclostrobin, sedaxane, silthiofam, tebuconazole, thiabendazole, thiophanate-methyl, thiram, trifloxystrobin and triticonazole.

Invertebrate pest control compounds or agents with which compounds of Formula 1 can be formulated to provide mixtures useful in seed treatment include but are not limited to abamectin, acetamiprid, acrinathrin, afidopyropen, amitraz, avermectin, azadirachtin, bensultap, bifenthrin, buprofezin, cadusafos, carbaryl, carbofuran, cartap, chlorantraniliprole, chlorfenapyr, chlorpyrifos, clothianidin, cyantraniliprole, cyclaniliprole, cyfluthrin, beta-cyfluthrin, cyhalothrin, gamma-cyhalothrin, lambda-cyhalothrin, cypermethrin, alpha-cypermethrin, zeta-cypermethrin, cyromazine, deltamethrin, dieldrin, dinotefuran, diofenolan, emamectin, endosulfan, esfenvalerate, ethiprole, etofenprox, etoxazole, fenothiocarb, fenoxycarb, fenvalerate, fipronil, flonicamid, flubendiamide, fluensulfone, flufenoxuron, flupiprole, flupyradifurone, fluvalinate, formetanate, fosthiazate, heptafluthrin, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, lufenuron, meperfluthrin, metaflumizone, methiocarb, methomyl, methoprene, methoxyfenozide, momfluorothrin,

nitenpyram, nithiazine, novaluron, oxamyl, pyflubumide, pymetrozine, pyrethrin, pyridaben, pyriminostrobin, pyridalyl, pyriproxyfen, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen, spirotetramat, sulfoxaflor, tebufenozide, tetramethrin, tetramethylfluthrin, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tralomethrin, triazamate, triflumuron, *Bacillus thuringiensis* delta-endotoxins, strains of *Bacillus thuringiensis* and strains of *Nucleo polyhydrosis* viruses.

Compositions comprising compounds of Formula 1 useful for seed treatment can further comprise bacteria and fungi that have the ability to provide protection from the harmful effects of plant pathogenic fungi or bacteria and/or soil born animals such as nematodes. Bacteria exhibiting nematicidal properties may include but are not limited to *Bacillus firmus*, *Bacillus cereus*, *Bacillus subtilis* and *Pasteuria penetrans*. A suitable *Bacillus firmus* strain is strain CNCM I-1582 (GB-126) which is commercially available as BioNemTM. A suitable *Bacillus cereus* strain is strain NCMM I-1592. Both *Bacillus* strains are disclosed in US 6,406,690. Other suitable bacteria exhibiting nematicidal activity are *B. amyloliquefaciens* IN937a and *B. subtilis* strain GB03. Bacteria exhibiting fungicidal properties may include but are not limited to *B. pumilus* strain GB34. Fungal species exhibiting nematicidal properties may include but are not limited to *Myrothecium verrucaria*, *Paecilomyces lilacinus* and *Purpureocillium lilacinum*.


Seed treatments can also include one or more nematicidal agents of natural origin such as the elicitor protein called harpin which is isolated from certain bacterial plant pathogens such as *Erwinia amylovora*. An example is the Harpin-N-Tek seed treatment technology available as N-HibitTM Gold CST.

Seed treatments can also include one or more species of legume-root nodulating bacteria such as the microsymbiotic nitrogen-fixing bacteria *Bradyrhizobium japonicum*. These inoculants can optionally include one or more lipo-chitooligosaccharides (LCOs), which are nodulation (Nod) factors produced by rhizobia bacteria during the initiation of nodule formation on the roots of legumes. For example, the Optimize[®] brand seed treatment technology incorporates LCO Promoter TechnologyTM in combination with an inoculant.


Seed treatments can also include one or more isoflavones which can increase the level of root colonization by mycorrhizal fungi. Mycorrhizal fungi improve plant growth by enhancing the root uptake of nutrients such as water, sulfates, nitrates, phosphates and metals. Examples of isoflavones include, but are not limited to, genistein, biochanin A, formononetin, daidzein, glycitein, hesperetin, naringenin and pratensein. Formononetin is available as an active ingredient in mycorrhizal inoculant products such as PHC Colonize[®] AG.

Seed treatments can also include one or more plant activators that induce systemic acquired resistance in plants following contact by a pathogen. An example of a plant activator which induces such protective mechanisms is acibenzolar-*S*-methyl.


The following Tests demonstrate the control efficacy of compounds of this invention on specific pathogens. The pathogen control protection afforded by the compounds is not limited, however, to these species. See Index Tables A-H for compound descriptions. The following abbreviations are used in the Tables which follow: Me means methyl, Et means ethyl, Pr means propyl, *i*-Pr means isopropyl, *i*-Pre means isopropenyl, c-Pr means cyclopropyl, OMe means methoxy, TMS means trimethylsilyl, Ph means phenyl, MeOC(=O) means methoxycarbonyl and CN means cyano. Where $(R^3)_n$ is listed as "H", this means that *n* is 0 and the ring comprising G is not substituted with R^3 . The abbreviation "Ex." stands for "Example" and is followed by a number indicating in which example the compound is prepared. In the following Index Tables, Mass spectra are reported as the molecular weight of the highest isotopic abundance parent ion (*M*+1) formed by addition of H^+ (molecular weight of 1) to the molecule, or (*M*-1) formed by the loss of H^+ (molecular weight of 1) from the molecule, observed by using an liquid chromatography coupled to a mass spectrometer (MS) using either atmospheric pressure chemical ionization (AP^+) or electrospray ionization (ESI^+), where "amu" stands for atomic mass units. In the following Index Tables A through F, "G" is defined as the following:




G-1a




G-1b




G-2a



G-3a




G-4a



G-7a

INDEX TABLE A



Cmpd. No.	R ⁵	R ^{2a}	G	(R ³) _n	Q	m.p. (°C)	M+1	M-1
1 (Ex. 1)	H	CH ₃	G-3a	H	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	*		
2	H	H	G-3a	H	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		441	
3	F	H	G-1b	H	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		458	
4	H	H	G-4a	H	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		442	
5	H	H	G-4a	H	3-Cl-1 <i>H</i> -pyrazol-1-yl		408	
6	H	H	G-4a	H	4-Cl-1 <i>H</i> -pyrazol-1-yl		408	
7	H	H	G-4a	H	1 <i>H</i> -pyrazol-1-yl		374	
8	H	H	G-4a	H	3-phenyl-1 <i>H</i> -pyrazol-1-yl		450	
9 (Ex. 2)	H	H	G-1b	H	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	*		
10	H	H	G-1a	2-Cl	4-Br-1 <i>H</i> -pyrazol-1-yl	**	485	
11	H	H	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	112-115		
12 (Ex. 3)	F	H	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	*	492	
13	H	H	G-1b	6-NO ₂	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		485	
14	H	H	G-1b	6-OCH ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		471	
16	H	H	G-4a	3-Br	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	150-153	521	
17	H	CH ₃	G-4a	3-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		489	
18	F	CH ₃	G-4a	3-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		510	
19	H	CH ₃	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		489	
20	H	H	G-1a	2-Cl	4-Cl-1 <i>H</i> -pyrazol-1-yl		441	
21	H	CH ₃	G-1b	4-CF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			522
22	H	CH ₃	G-1b	5-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			488
23	F	H	G-1a	2-OCF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	94-96		
24	H	H	G-1a	2,6-di-Cl	1 <i>H</i> -pyrazol-1-yl	133-136		
25	F	H	G-1a	2-OMe	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	126-129		
26	H	CH ₃	G-1b	4-Me	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			468
27	H	H	G-1b	4-Me	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		454	
28	H	H	G-1b	6-Me	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		454	
29	H	H	G-1b	5-Me-6-F	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		473	
30	H	H	G-1b	6-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		474	
31	Cl	H	G-1a	2-Cl	4-Br-1 <i>H</i> -pyrazol-1-yl		520	
32	H	H	G-1b	6-Br	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		518	
33	H	H	G-1b	6- <i>c</i> -Pr	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		480	
34	F	H	G-1a	2-Cl	4-Br-1 <i>H</i> -pyrazol-1-yl		504	
36	H	H	G-1a	2,6-di-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	129-132		
37	F	H	G-1a	2-CF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	114-117		
38	H	H	G-1b	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		474	
39	H	H	G-1b	6-OCF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		525	

Cmpd. No.	R ⁵	R ^{2a}	G	(R ³) _n	Q	m.p. (°C)	M+1	M-1
40	H	H	G-1a	2,6-di-Cl	3-Br-1 <i>H</i> -pyrazol-1-yl	86-89		
41	H	H	G-1b	2-CF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		508	
42	H	CH ₃	G-1b	5-CF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			522
43	F	H	G-3a	5-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	121-124		
44	H	CH ₃	G-1b	4-OMe	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			484
45	H	CH ₃	G-1b	6-Me	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			468
46	F	H	G-1a	2-Cl	1 <i>H</i> -pyrazol-1-yl		424	
47	F	H	G-1a	2-Cl	3-Br-1 <i>H</i> -pyrazol-1-yl		504	
48	H	H	G-1a	2-Cl	1 <i>H</i> -pyrazol-1-yl		406	
49	H	H	G-1a	2-Cl	3-Br-1 <i>H</i> -pyrazol-1-yl		486	
50	H	H	G-1a	2-Cl	1 <i>H</i> -1,2,4-triazol-1-yl		407	
51	F	CH ₃	G-1b	4-CF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	96-99		
52	F	CH ₃	G-1b	6-Me	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			486
53	F	CH ₃	G-1b	6-Br	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			552
54	F	CH ₃	G-1b	5-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	119-122		
55	F	CH ₃	G-1b	4-OMe	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	96-99		
56	F	CH ₃	G-1b	5-CF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	111-115		
57	F	H	G-1b	6-CF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		527	
58	F	H	G-1b	5-CF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		527	
59	F	H	G-1b	4-CF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		527	
60	F	H	G-1b	5-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		493	
61	F	H	G-1a	2-OCH ₂ CN	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	121-124		
62	F	H	G-1a	2-OCH ₂ C≡CH	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	96-99		
63	H	H	G-4a	3- <i>i</i> -Pr	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	135-138		
64	F	H	G-1a	2-Cl	2 <i>H</i> -1,2,3-triazol-2-yl		425	
65	F	H	G-1a	2-Cl	3-CH ₃ -1 <i>H</i> -1,2,4-triazol-1-yl		439	
66	F	H	G-1a	2-Cl	1 <i>H</i> -1,2,3-triazol-1-yl		425	
67	F	H	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -1,2,4-triazol-1-yl		494	
68	F	H	G-1a	2-F	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		476	
69	H	H	G-1a	2-F	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		459	
70	F	H	G-1a	2,6-di-F	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		495	
71	H	H	G-1a	2,6-di-F	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		476	
72	F	CH ₃	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		506	
73	F	CH ₃	G-1b	4-Me	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	112-115		
74	F	CH ₃	G-1b	4-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			506
75	H	H	G-2a	5-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	160-163		
76	F	H	G-4a	3- <i>i</i> -Pr	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	124-127		


Cmpd. No.	R ⁵	R ^{2a}	G	(R ³) _n	Q	m.p. (°C)	M+1	M-1
77	H	CH ₃	G-1b	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	79-83		
78	F	CH ₃	G-4a	3-Cl	4-Br-1 <i>H</i> -pyrazol-1-yl	156-159		
79	F	CH ₃	G-1b	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			506
80	H	CH ₃	G-1b	6- <i>i</i> -Pre	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			494
81	F	H	G-4a	3-Me	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	130-133		
82	H	CH ₃	G-1b	6- <i>i</i> -Pr	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			496
84	F	H	G-1b	6-Me	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		473	
85	F	H	G-1b	5-Me-6-F	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		491	
86	F	H	G-1b	6-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		493	
87	F	H	G-1b	4-Me	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		473	
88	F	H	G-1b	6- <i>i</i> -Pr	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		499	
89	F	CH ₃	G-4a	3-Cl	3-Br-1 <i>H</i> -pyrazol-1-yl	77-81		
90	F	CH ₃	G-4a	3-Cl	3-Ph-1 <i>H</i> -pyrazol-1-yl	170-172		
91	F	H	G-4a	3-Br	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	154-158		
92	F	H	G-2a	5-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	171-174		
93	F	H	G-1a	3-Me	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	104-107		
94	F	H	G-1a	3-OCF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		543	
95	F	H	G-1a	3-CF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		526	
96	F	H	G-1a	3-OMe	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		489	
97	F	CH ₃	G-4a	3-Cl	4-Cl-1 <i>H</i> -pyrazol-1-yl	142-145		
98	F	H	G-1a	3-Br	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		536	
99	F	H	G-1a	3-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		492	
100	H	H	G-2a	3-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			474
101	F	CH ₃	G-4a	3-Cl	1 <i>H</i> -pyrazol-1-yl	112-116		
102	F	H	G-1a	3- <i>i</i> -Pre	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		498	
103	F	CH ₃	G-4a	3-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	170-173		
104	F	H	G-7a	H	1 <i>H</i> -pyrazol-1-yl	107-111		
105	F	H	G-1a	2-Me	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	97-100		
106	F	H	G-1a	2-Br	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	121-124		
107	H	H	G-1b	6-CF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		509	
108	H	H	G-1b	5-CF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		509	
109	H	H	G-1b	4-CF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		509	
110	F	H	G-4a	3-Br	1-CH ₃ -1 <i>H</i> -pyrazol-4-yl		483	
111	F	H	G-1b	6-NO ₂	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		504	
112	H	H	G-1b	5-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		475	
113	F	H	G-1b	6-OMe	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		489	
114	F	H	G-4a	3- <i>c</i> -Pr	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	123-126		

Cmpd. No.	R ⁵	R ^{2a}	G	(R ³) _n	Q	m.p. (°C)	M+1	M-1
115	H	H	G-4a	3- <i>i</i> -Pre	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	128-131		
116	F	H	G-1a	3- <i>i</i> -Pr	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		500	
117	F	H	G-4a	3-Cl	4-Cl-1 <i>H</i> -pyrazol-1-yl	300-300		
118	F	H	G-7a	H	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	125-128		
119	H	CH ₃	G-1b	6-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	87-90		
120	H	CH ₃	G-1b	6-OMe	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			484
121	F	H	G-1a	2- <i>i</i> -Pr	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	107-110		
122	F	H	G-4a	3-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	150-153		
123	F	CH ₃	G-1b	6- <i>i</i> -Pre	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			512
124	H	H	G-4a	3-CH ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		456	
125	F	H	G-1a	2,6-di-Cl	1 <i>H</i> -pyrazol-1-yl	144-148		
126	H	CH ₃	G-1b	4-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			488
127	F	H	G-1a	2,6-di-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	132-135		
128	H	CH ₃	G-1b	6-Br	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	131-134		
129	H	CH ₃	G-1b	6-NO ₂	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	172-175		
130	H	CH ₃	G-1b	6-OCF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	99-102		
131	F	H	G-4a	3- <i>i</i> -Pre	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	127-130		
132	F	H	G-1a	2,6-di-Cl	3-Br-1 <i>H</i> -pyrazol-1-yl	66-69		
133	F	CH ₃	G-1b	6-OCF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			556
134	F	CH ₃	G-1b	6-NO ₂	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	154-157		
135	F	CH ₃	G-1b	6-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	117-121		
136	F	H	G-1b	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		492	
137	F	H	G-1b	2-CF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		526	
138	F	H	G-1b	4-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		493	
139	H	H	G-1b	4-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		475	
140	F	H	G-1b	6-OCF ₃	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		543	
141	F	CH ₃	G-1b	6- <i>i</i> -Pr	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			514
142	F	CH ₃	G-1b	6-OMe	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	88-92		
143	F	H	G-1a	2-Cl	4-Cl-1 <i>H</i> -pyrazol-1-yl		458	
144	F	H	G-1a	2-Cl	4-CH ₃ -1 <i>H</i> -pyrazol-1-yl		438	
145	F	H	G-1a	2-Cl	1 <i>H</i> -1,2,4-triazol-1-yl		425	
146	F	H	G-1a	2-Cl	3-Cl-1 <i>H</i> -1,2,4-triazol-1-yl		459	
147	F	H	G-1a	2-Cl	3-Br-1 <i>H</i> -1,2,4-triazol-1-yl		505	


* See synthesis example for ¹H NMR data.

** See Index Table G for ¹H NMR data.

104


INDEX TABLE B

Cmpd. No.	R ⁵	G	(R ³) _n	Q	m.p. (°C)	M+1	M-1
35	H	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		493	
148	H	G-3a	4-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	200-203		
149	H	G-1b	H	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl			458

INDEX TABLE C

Cmpd. No.	R ⁷	R ⁸	G	(R ³) _n	Q	m.p. (°C)	M + 1
150	CF ₃	CH ₃	G-1b	H	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	99-101	
151	CF ₃	CH ₃	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		510
158	Br	H	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	129-132	
159	CH ₃	H	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	106-109	
160	F	H	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	120-124	


5

INDEX TABLE D

Cmpd. No.	R ⁹	R ^{2a}	G	(R ³) _n	Q	m.p. (°C)	M+1	M-1
152	CH ₃	H	G-1b	H	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	*		406
153	Cl	H	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	124-127		
154	I	H	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	117-119		
155	CH ₃	CH ₃	G-1b	6-Me	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		435	
156	I	CH ₃	G-1b	6-Me	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl		547	


157 CH₃ H G-1a 2-Cl 3-CF₃-1*H*-pyrazol-1-yl 89-92

INDEX TABLE E



Cmpd. No.	R ¹⁰	R ^{2a}	G	(R ³) _n	Q	m.p. (°C)
161	CH ₃	H	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	78-81

INDEX TABLE F



Cmpd. No.	R ⁵	R ⁵¹	G	(R ³) _n	Q	m.p. (°C)
162	F	CH ₂	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	134-137
163	H	CH ₂	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	131-134
164	F	O	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl	114-117

5

INDEX TABLE G

Compd. No.	¹ H NMR Data (CDCl ₃ solution unless indicated otherwise) ^a
10	δ 7.91 (s, 1H), 7.75 (d, 1H), 7.67 (m, 2H), 7.49 (dd, 1H), 7.38 (d, 1H), 7.07 (t, 1H), 4.83 (s, 2H), 3.97 (s, 3H), 2.74 (t, 1H), 0.62–0.82 (m, 4H).

^a ¹H NMR data are in ppm downfield from tetramethylsilane. Couplings are designated by (s)-singlet, (d)-doublet, (t)-triplet, (m)-multiplet, (dd)-doublet of doublets.

BIOLOGICAL EXAMPLES OF THE INVENTION

10 General protocol for preparing test suspensions for Tests A–E: the test compounds were first dissolved in acetone in an amount equal to 3 % of the final volume and then suspended at the desired concentration (in ppm) in acetone and purified water (50/50 mix by volume) containing 250 ppm of the surfactant Trem[®] 014 (polyhydric alcohol esters). The resulting test suspensions were then used in Tests A–E. Samples were applied to plants at

15 either a 10 ppm (**), 40 ppm, 50 ppm (*) or 200 ppm (#) test solution to the point of run-off

on the test plants with the equivalent of a rate of 40 g ai/ha, 160 g ai/ha, 200 g ai/ha, or 800 g ai/ha, respectively.

TEST A

5 The test suspension was sprayed to the point of run-off on tomato seedlings. The following day the seedlings were inoculated with a spore suspension of *Botrytis cinerea* (the causal agent of gray mold on many crops) and incubated in a saturated atmosphere at 20 °C for 48 h, and moved to a growth chamber at 27 °C for 2 days, after which time visual disease ratings were made.

TEST B

10 The test suspension was sprayed to the point of run-off on wheat seedlings. The following day the seedlings were inoculated with a spore suspension of *Stagonospora nodorum* (also known as *Septoria nodorum*; the causal agent of wheat glume blotch) and incubated in a saturated atmosphere at 20 °C for 48 h, and then moved to a growth chamber at 20 °C for 6 days, after which time visual disease ratings were made.

TEST C

15 The test suspension was sprayed to the point of run-off on wheat seedlings. The following day the seedlings were inoculated with a spore suspension of *Septoria tritici* (the causal agent of wheat leaf blotch) and incubated in a saturated atmosphere at 24 °C for 48 h, and then moved to a growth chamber at 20 °C for 21 days, after which time visual disease ratings were made.

TEST D

20 The test suspension was sprayed to the point of run-off on wheat seedlings. The following day the seedlings were inoculated with a spore suspension of *Puccinia recondita* f. sp. *tritici*; (the causal agent of wheat leaf rust) and incubated in a saturated atmosphere at 20 °C for 24 h, and then moved to a growth chamber at 20 °C for 6 days, after which time visual disease ratings were made.

TEST E

30 The test suspension was sprayed to the point of run-off on wheat seedlings. The following day the seedlings were inoculated with a spore dust of *Erysiphe graminis* f. sp. *tritici*, (the causal agent of wheat powdery mildew) and incubated in a growth chamber at 20 °C for 7 or 8 days, after which time visual disease ratings were made.

Results for Tests A–E are given in Table A. In the Table, a rating of 100 indicates 100% disease control and a rating of 0 indicates no disease control (relative to the controls). A dash (–) indicates no test results.

Table A

Cmpd. No	Test A	Test B	Test C	Test D	Test E
1	0	0	86	0	96
1 [#]	0	69	93	28	98
2	0	0	43	0	0
2 [#]	0	0	96	0	43
3	0	100	100	99	99
4	0	0	42	0	0
4 [#]	0	0	46	28	27
5	0	0	17	0	0
5 [#]	0	0	80	28	0
6	0	0	9	0	0
6 [#]	0	98	67	28	13
7	0	0	0	0	0
7 [#]	0	0	18	0	0
8	0	0	27	0	0
8 [#]	0	0	88	74	0
9	9	93	96	9	81
9 [#]	39	99	100	74	96
10	0	99	38	86	0
11	0	89	100	54	43
12	0	100	100	99	97
13	0	0	0	32	0
14	0	42	83	32	92
16*	-	-	100	67	56
17	0	100	99	23	92
18	0	100	99	98	98
19	0	99	75	85	64
20	32	99	94	79	40
21	0	0	-	0	64
22	0	90	-	55	81
23	0	98	-	99	98
24	0	100	-	99	90
25	0	100	-	100	98
26	0	99	-	0	81
27	0	92	38	31	21
28	11	99	45	45	59
29	0	94	83	68	48

Cmpd. No	Test A	Test B	Test C	Test D	Test E
30	0	60	87	31	64
31	0	0	42	98	0
32	0	0	-	0	97
33	0	98	-	68	94
34	23	100	94	100	95
35	0	0	89	9	0
36	0	99	-	99	90
37	0	100	-	97	99
38	14	0	-	41	69
39	0	0	-	55	72
40	-	99	99	99	89
41	0	0	94	23	40
42	-	0	39	0	0
43	-	0	6	0	0
44	-	78	87	0	0
45	-	100	96	9	90
46	-	100	99	94	98
47	-	100	99	98	99
48	-	100	98	0	73
49	-	98	99	9	69
50	-	0	28	0	0
51	-	100	88	0	84
52	-	100	99	93	99
53	-	100	97	74	96
54*	-	-	96	99	93
55	-	100	97	61	87
56	-	100	97	86	92
57	-	-	-	-	-
58	-	-	-	-	-
59	-	-	-	-	-
60	-	-	-	-	-
61	-	0	90	9	21
62	-	99	99	99	94
63	-	-	-	-	-
64	-	100	98	100	97
65	-	87	98	0	0
66	-	97	94	28	0


Cmpd. No	Test A	Test B	Test C	Test D	Test E
67	-	0	99	0	0
68	-	100	97	91	99
69	-	60	98	0	69
70	-	100	99	80	97
71	-	92	99	0	91
72	-	100	100	99	99
73	-	-	99	85	90
74	-	-	99	27	93
75**	-	-	24	45	0
76	-	-	-	-	-
77**	-	-	82	9	64
78**	-	-	100	94	92
79*	-	-	99	74	98
80*	-	-	94	98	73
81**	-	-	94	98	81
82*	-	-	88	0	87
84*	-	100	98	89	94
85*	-	100	99	-	95
86*	-	100	99	68	95
87*	-	-	98	80	92
88*	-	-	94	99	98
89**	-	-	100	99	81
90**	-	-	99	99	86
91**	-	-	100	98	73
92**	-	-	-	67	0
93**	-	-	100	99	69
94**	-	-	88	73	40
95**	-	-	87	67	27
96**	-	-	100	99	73
97**	-	100	97	94	94
98**	-	64	94	86	84
99**	-	59	96	97	89
100**	-	0	6	0	0
101**	-	-	96	82	79
102**	-	-	100	98	13
103**	-	-	98	98	94
104	-	-	-	-	-

Cmpd. No	Test A	Test B	Test C	Test D	Test E
105	-	100	98	99	98
106	-	100	96	99	97
107	-	0	31	19	89
108	-	0	66	0	40
109	-	0	75	0	40
110*	-	-	90	94	40
111*	-	-	14	9	0
112*	-	-	94	54	40
113*	-	-	100	99	97
114**	-	-	100	100	92
115**	-	-	27	93	40
116**	-	-	-	98	69
117	-	-	-	-	-
118	-	-	-	-	-
119	-	99	92	93	92
120	-	100	92	-	95
121	-	100	95	100	99
122**	-	-	96	99	87
123*	-	-	100	92	93
124	-	0	94	0	73
125	-	100	99	100	92
126	-	92	92	68	48
127	-	100	99	100	98
128	-	100	92	0	93
129	-	0	10	0	0
130	-	93	28	68	72
131*	-	-	100	100	99
132	-	100	99	100	91
133*	-	100	92	68	94
134*	-	94	43	68	0
135*	-	100	99	80	95
136*	-	-	100	99	87
137*	-	-	94	98	87
138	-	-	-	-	-
139	-	-	-	-	-
140	-	-	-	-	-
141	-	-	-	-	-

Cmpd. No	Test A	Test B	Test C	Test D	Test E
142*	-	100	97	83	98
143	-	100	99	99	99
144	-	100	99	97	99
145	-	95	95	0	0
146	-	0	94	0	0
147	-	0	93	0	0
148*	0	0	9	0	0
149	0	0	43	0	0
150	0	0	48	9	0
151	23	0	87	23	0
152	0	0	0	0	0
153	-	-	-	-	-
154	-	-	-	-	-
155	-	-	-	-	-
156	-	-	-	-	-
157	-	-	-	-	-
158	-	-	-	-	-
159	-	-	-	-	-
160	-	-	-	-	-
161	-	-	-	-	-
162**	-	0	64	0	0
163	-	-	-	-	-
164**	-	0	46	0	0


The Claims defining the invention are as follows:

1. A compound selected from Formula 1, *N*-oxides and salts thereof,



wherein

A is a radical selected from the group consisting of



Z is O or S;

R¹ is C₃–C₅ cycloalkyl; or a 4- to 6-membered ring containing carbon ring members and heteroatom ring members selected from 1 O atom and 1 S atom;

R^{2a} and R^{2b} are each independently H, halogen, C₁–C₂ alkyl or C₁–C₂ haloalkyl; or R^{2a} and R^{2b} are taken together as C₂–C₅ alkanediyl;

G is phenyl, pyridinyl, pyridazinyl or pyrazinyl substituted with Q *meta* or *para* to the -C(R^{2a})R^{2b}- radical, and optionally substituted with up to 3 substituents selected from R³;

R³ is halogen, nitro, cyano, C₁–C₅ alkyl, C₁–C₅ haloalkyl, C₁–C₅ alkoxy, C₁–C₅ haloalkoxy, C₂–C₅ alkoxyalkyl, C₃–C₅ cycloalkyl, C₂–C₅ alkoxycarbonyl or C₃–C₁₂ trialkylsilyl; or R³ is C₁–C₅ cyanoalkoxy, C₂–C₅ alkynyloxy or C₂–C₅ alkenyl;

R⁴ is halogen, C₁–C₃ alkyl or C₁–C₃ haloalkyl;

R⁵ is H, halogen, C₁–C₃ alkyl or C₁–C₃ haloalkyl;

R⁶ is C₁–C₂ alkyl;

R⁷ is halogen, C₁–C₃ alkyl or C₁–C₃ haloalkyl;

R⁸ is H, C₁–C₂ alkyl or C₁–C₂ haloalkyl;

R⁹ is halogen, C₁–C₃ alkyl or C₁–C₃ haloalkyl;


R¹⁰ is halogen, C₁–C₃ alkyl or C₁–C₃ haloalkyl;

R¹¹ is halogen, C₁–C₃ alkyl or C₁–C₃ haloalkyl;

m is 0, 1 or 2;

Q is a 5-membered unsaturated or partially unsaturated heterocyclic ring containing ring members selected from carbon atoms and up to 4 heteroatoms independently selected from up to 1 O, up to 1 S and up to 4 N atoms, wherein up to 2 carbon

- atom ring members are independently selected from C(=O), the ring optionally substituted with one substituent on a ring member distal relative to the ring member connecting the heteroaromatic ring to the remainder of Formula 1, said optional substituent selected from R^{12c} on carbon atom ring members and from R¹²ⁿ on nitrogen atom ring members, the heterocyclic ring further optionally substituted with substituents selected from R^{13c} on carbon atom ring members and R¹³ⁿ on nitrogen atom ring members;
- each R^{12c} is independently halogen, cyano, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ alkoxy, C₁-C₃ haloalkoxy or C₂-C₃ alkoxycarbonyl; or a phenyl ring optionally substituted with up to 5 substituents independently selected from R¹⁴; or a heteroaromatic ring optionally substituted with up to 4 substituents independently selected from R^{15c} on carbon atom ring members and from R¹⁵ⁿ on nitrogen atom ring members; or
- two R^{12c} bonded to adjacent carbon atoms are taken together with carbon atom ring members to form a 5- or 6-membered carbocyclic or partially aromatic ring;
- each R¹²ⁿ is independently C₁-C₃ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkoxy; or a phenyl ring optionally substituted with up to 5 substituents independently selected from R¹⁶; or a heteroaromatic ring optionally substituted with up to 4 substituents independently selected from R^{17c} on carbon atom ring members and from R¹⁷ⁿ on nitrogen atom ring members;
- each R^{13c} is independently halogen, C₁-C₃ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkoxy;
- each R¹³ⁿ is independently C₁-C₃ alkyl, C₁-C₃ haloalkyl or C₁-C₃ alkoxy;
- each R¹⁴, R^{15c}, R¹⁶ and R^{17c} is independently halogen, cyano, C₁-C₂ alkyl, C₁-C₂ haloalkyl, C₁-C₂ alkoxy or C₁-C₂ haloalkoxy;
- each R¹⁵ⁿ and R¹⁷ⁿ is independently C₁-C₂ alkyl, C₁-C₂ haloalkyl or C₁-C₂ alkoxy;
- and wherein the compound is not



wherein R⁹, R^{2a}, G, (R³)_n and Q are defined as follows:

R ⁹	R ^{2a}	G	(R ³) _n	Q
CH ₃	H	G-1b	H	3-CF ₃ -1H-pyrazol-1-yl

- A compound of Claim 1 wherein:
Z is O;
R¹ is C₃-C₄ cycloalkyl; or a 4- to 5-membered ring containing ring members selected from carbon atoms, 1 O atom and 1 S atom;

R^{2a} is H, CH₃, CF₃ or CHF₂;

R^{2b} is H or CH₃; or

R^{2a} and R^{2b} are taken together as C₂ or C₃ alkanediyl;

G is phenyl or pyridinyl substituted with Q *meta* or *para* to the -C(R^{2a})R^{2b}- radical, and optionally substituted with up to 2 substituents selected from R³;

R³ halogen, cyano, C₁-C₅ alkyl, C₁-C₅ haloalkyl, C₁-C₅ alkoxy, C₁-C₅ haloalkoxy, C₂-C₅ alkoxyalkyl, C₃-C₅ cycloalkyl;

R⁴ is halogen, C₁-C₂ alkyl or C₁-C₂ haloalkyl;

R⁵ is H, halogen, C₁-C₂ alkyl or C₁-C₂ haloalkyl;

R⁶ is CH₃;

R⁷ is halogen, C₁-C₂ alkyl or C₁-C₂ haloalkyl;


R⁸ is H or CH₃;

R⁹ is halogen, C₁-C₂ alkyl or C₁-C₂ haloalkyl;

R¹⁰ is F, Cl, Br, CH₃, CHF₂ or CF₃;

R¹¹ is F, Cl, Br, CH₃, CHF₂ or CF₃;

Q is selected from;




Q-1

Q-2

Q-3

Q-4




Q-5

Q-6

Q-7

Q-8




Q-9

Q-10

Q-11

Q-12




Q-13

Q-14

Q-15

Q-16




Q-17

Q-18

Q-19

Q-20

and



Q-21

wherein

R^{12} is bonded to a ring member distal relative to the ring member connecting the Q ring to the remainder of Formula 1, and independently selected from R^{12c} on carbon atom ring members and R^{12n} on nitrogen atom ring members;
 each R^{13} is independently selected from R^{13c} on carbon atom ring members and R^{13n} on nitrogen atom ring members;
 each x is independently 0 or 1;
 each y is independently 0, 1 or 2;
 each z is independently 0, 1, 2 or 3;
 each R^{12c} is independently halogen, cyano, C_1-C_2 alkyl, C_1-C_2 haloalkyl, C_1-C_2 alkoxy or C_1-C_2 haloalkoxy;
 each R^{12n} is independently C_1-C_2 alkyl or C_1-C_2 haloalkyl;
 each R^{13c} is independently halogen, C_1-C_2 alkyl, C_1-C_2 haloalkyl or C_1-C_2 alkoxy;
 each R^{13n} is independently C_1-C_2 alkyl or C_1-C_2 haloalkyl;
 each R^{14} , R^{15c} , R^{16} and R^{17c} is independently halogen, CH_3 or C_1 haloalkyl; and
 R^{15n} and R^{17n} is independently C_1-C_2 alkyl or C_1-C_2 haloalkyl.

3. A compound of Claim 2 wherein:

A is selected from the group consisting of A-1, A-2, A-3 and A-4;

R^1 is cyclopropyl; or a 4-membered ring containing ring members selected from carbon atoms, 1 O atom and 1 S atom;

R^{2b} is H; or

R^{2a} and R^{2b} are taken together as C_2 alkanediyl;

G is phenyl or pyridinyl substituted with Q *meta* or *para* to the $-C(R^{2a})R^{2b}$ - radical, and optionally substituted with 1 substituent selected from R^3 ;

R^3 is halogen, CH_3 , CF_3 , CHF_2 , OCH_3 , OCF_3 , $CH_2CH_2OCH_3$ or cyclopropyl;

R^4 is halogen, CH_3 or C_1 haloalkyl;

R^5 is H, F, Cl, Br, CH_3 , CHF_2 or CF_3 ;

R^7 is halogen, CH_3 or C_1 haloalkyl;

R^9 is F, Cl, Br, CHF_2 or CF_3 ;

Q is selected from Q-1 through Q-19;

R^{12c} is independently halogen, CH_3 or C_1 haloalkyl;

R^{12n} is C_1-C_2 alkyl;

each R^{13c} is independently halogen, CH_3 or C_1 haloalkyl;

each R^{13n} is C_1-C_2 alkyl;

each R^{14} , R^{15c} , R^{16} and R^{17c} is independently F, Cl, Br, CH_3 , CHF_2 or CF_3 ; and each R^{15n} and R^{17n} is independently C_1 – C_2 alkyl.

4. A compound of Claim 3 wherein:

A is selected from the group consisting of A-1, A-2 and A-3;

R^1 is cyclopropyl, 3-oxetanyl or 3-thietanyl;

G is phenyl substituted with Q *meta* or *para* to the $-C(R^{2a})R^{2b}$ - radical, and optionally substituted with 1 substituent selected from R^3 ;

R^3 is Cl, Br, CH_3 , CF_3 , CHF_2 , OCH_3 or cyclopropyl;


R^4 is F, Cl, Br, CH_3 , CHF_2 or CF_3 ;

R^5 is F or Cl;

R^7 is F, Cl, Br, CH_3 , CHF_2 or CF_3 ;

R^9 is F, Cl, Br, CHF_2 or CF_3 ;

Q is selected from



each R^{12c} is independently F, Cl, Br, CH_3 , CHF_2 or CF_3 ;

each R^{12n} is CH_3 ;

each R^{13c} is independently F, Cl, Br, CH_3 , CHF_2 or CF_3 ;

each R^{13n} is CH_3 ; and

each R^{15n} and R^{17n} is CH_3 .

5. A compound of Claim 2 wherein:


A is selected from the group consisting of A-1 and A-2;

R^1 is cyclopropyl;

G is phenyl substituted with Q *para* to the $-C(R^{2a})R^{2b}$ - radical;

R^4 is CHF_2 ;

Q is selected from



R^{12c} is CF_3 .

6. A compound of Claim 3 wherein:

A is A-1;


R^1 is cyclopropyl;

G is pyridinyl substituted with Q *meta* or *para* to the $-C(R^{2a})R^{2b}$ - radical, and optionally substituted with 1 substituent selected from R^3 ;

R^3 is Cl;

R^4 is CHF_2 ;

Q is




Q-9A

R^{12c} is CF_3 .





7. A compound of Claim 1 which is selected from the group consisting of:
N-[[2-chloro-4-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]phenyl]methyl]-*N*-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1*H*-pyrazole-4-carboxamide; and
N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-*N*-[[3-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]phenyl]methyl]-1*H*-pyrazole-4-carboxamide.

8. A compound of Formula 1A



1A

wherein R^5 , R^{2a} , G, $(R^3)_n$ and Q are defined as follows:



R^5	R^{2a}	G	$(R^3)_n$	Q
H	CH_3	G-2a	H	3- CF_3 -1 <i>H</i> -pyrazol-1-yl
H	H	G-2a	H	3- CF_3 -1 <i>H</i> -pyrazol-1-yl
F	H	G-1b	H	3- CF_3 -1 <i>H</i> -pyrazol-1-yl
H	H	G-2b	H	3- CF_3 -1 <i>H</i> -pyrazol-1-yl
H	H	G-2b	H	3-Cl-1 <i>H</i> -pyrazol-1-yl
H	H	G-2b	H	4-Cl-1 <i>H</i> -pyrazol-1-yl

R^5	R^{2a}	G	$(R^3)_n$	Q
H	H	G-2b	H	1 <i>H</i> -pyrazol-1-yl
H	H	G-2b	H	3-phenyl-1 <i>H</i> -pyrazol-1-yl
H	H	G-1b	H	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl
H	H	G-1a	2-Cl	4-Br-1 <i>H</i> -pyrazol-1-yl
H	H	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl
F	H	G-1a	2-Cl	3-CF ₃ -1 <i>H</i> -pyrazol-1-yl.

9. A fungicidal composition comprising (a) a compound of any one of Claims 1 to 8; and (b) at least one other fungicide.

10. A fungicidal composition comprising (a) a compound of any one of Claims 1 to 8; and (b) at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents.

11. A method for controlling plant diseases caused by fungal plant pathogens comprising applying to the plant or portion thereof, or to the plant seed, a fungicidally effective amount of a compound of any one of Claims 1 to 8.

12. A compound that is *N*-cyclopropyl-3-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]benzenemethanamine.

13. A compound that is 2-chloro-*N*-cyclopropyl-4-[3-(trifluoromethyl)-1*H*-pyrazol-1-yl]benzenemethanamine.